EVALUATING THE ROLE OF NF-êB SUPPRESSION IN AMELIORATING MAMMALIAN DISEASE: AN EXAMINATION OF INFLAMMATORY BOWEL DISEASE AND DISEASES ASSOCIATED WITH AGING by Tilstra, Jeremy Scott
 EVALUATING THE ROLE OF NF-κB SUPPRESSION IN AMELIORATING MAMMALIAN 
DISEASE: AN EXAMINATION OF INFLAMMATORY BOWEL DISEASE AND DISEASES 
ASSOCIATED WITH AGING  
 
 
 
 
 
 
 
 
by 
Jeremy Tilstra 
Bachelor of Science in Biochemistry, University of Maryland, 2003 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of the Department of Immunology 
[name of school] in partial fulfillment  
of the requirements for the degree of 
 ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
This thesis was presented 
 
By 
Jeremy Tilstra 
 
 
It was defended on 
August 11, 2009 
and approved by 
Olivera Finn, Distinguished Professor and Chair, Dept of Immunology 
Lawrence Kane, Assistant Professor, Dept of Immunology 
Prabir Ray, Associate Professor, Dept of Immunology 
Co Dissertation Advisor: Laura Niedernhofer, Assistant Professor, Dept. of MMG 
Dissertation Advisor: Paul Robbins, Professor , Dept of MMG 
 
 
 iii 
Copyright © by Tilstra 
2009 
 iv 
 
NF-κB is a family of transcription factors that play a pivotal role in inflammation, cell 
proliferation, cell survival, and apoptosis in response to endogenous and exogenous stress 
stimuli.  NF-κB is implicated in numerous chronic inflammatory and degenerative diseases.  In 
this thesis, the consequences of NF-κB suppression on pathologies associated with inflammatory 
bowel disease (IBD) and age-associated degeneration are explored.  To test the hypothesis that 
NF-κB plays a causal role in driving the degenerative changes associated with the diseases we 
evaluated the efficacy of a pharmacologic peptide IKK/NF-κB activation inhibitor in the IL-10-/- 
model of colitis and genetic depletion and pharmacologic inhibition of NF-κB in a mouse model 
of accelerated aging (Ercc1
-/∆
 mice).    
Pathologic and immunologic markers of IBD were reduced in the presence of systemic 
pharmacologic NF-κB suppression.  Furthermore, this study provides evidence of the efficacy of 
the NBD inhibitory peptide in vitro and in vivo experiments, and importantly provided possible 
therapeutic avenues for the treatment of IBD.  Like naturally aged mice, NF-κB is activated in 
Ercc1
-/∆
 mice compared to wild type littermates. Ercc1
-/∆
 mice haploinsufficient for the 
p65/RelA subunit of NF-κB had a modest delay in the onset of age-related symptoms. This was 
recapitulated in mice chronically treated with the peptide inhibitor of NF-κB, which exhibited a 
significant delay in overall aging score and improved histopathological alterations. These 
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 v 
implicate NF-κB as a major driver of degenerative changes associated with aging and set a 
precedent for therapeutic intervention.  
As activated macrophages are mediators of inflammatory and age-associated 
degenerative changes, we futher evaluated the role of NF-κB suppression in this cell type.  
Macropahges and monocyte derived DC cells underwent programmed cell death (PCD) in the 
presence of pharmacologic NF-κB inhibition.  Unlike previous studies which implicated TNFα 
signaling in this pathway, the mechanisms behind this PCD is induction is induction of ROS 
formation.  This observed macrophage NF-κB induced PCD may be one of the mechanisms by 
which inflammatory and age-associated disease pathologies are reduced in response to NF-κB 
suppression.   
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1.0  INTRODUCTION 
1.1 NF-ΚB/IKK SIGNALING 
1.1.1 Introduction to NF-κB 
The NF-κB transcription factor (TF) was discovered nearly 23 years ago as 
proinflammatory regulatory element which signals downstream of LPS
1, 2
.  Since its discovery, 
vast amounts of research has been undertaken to evaluated NF-κB signaling, function, and 
relevance resulting in nearly 35,000 publications.  NF-κB has traditionally been viewed as an 
immunologic TF, involved in the activation of inflammatory cells, and transcription of cytokines 
and chemokines.  Over time scientists realized the vast implications of dysregulated NF-κB 
signaling because of the plethora of pathologic conditions associated with this
3
.  Furthermore, 
the number of biologic processes known to be controlled by NF-κB continues to increase4.  Thus, 
the understanding of dysregulated NF-κB signaling is critically important to the treatment of 
many pathologic disease states. 
1.1.2 NF-κB Subunits 
The NF-κB TF is a dimer which can be formed by combinations of five distinct family 
members: p65(relA), relB, c-rel, p105/p50, and p100/p52 (for the latter NF-κB subunits the 
 2 
larger form is the non-cleaved component).  These NF-κB subunits act either as homo- or 
heterodimers and are defined by a short rel-homology domain (RHD), which is responsible for 
dimerization as well as DNA binding.  Three of the subunits, p65, relB, and c-rel, also contain 
transcription activation domains (TAD), which are regions that promote the transcription of 
DNA into RNA.  The other two subunits do not have TADs and thus act as transcriptional 
suppressors (Figure 1)
5
.  For example, the p65/p50 heterodimer is the traditional inflammatory 
NF-κB dimer and activates the transcription of a variety of genes, while the p50/p50 homodimer 
can bind also bind to the NF-κB consensus sequence (GGGRNNYYCC) and has a higher affinity 
than a p65 homodimer
6
, but results in blocked transcription.   
1.1.3 NF-κB stimulatory molecules 
As stated previously, there are a wide variety of NF-κB activators (Figure 2), which 
include numerous inflammatory stimulating factors.  The toll like receptor (TLR) ligands, which 
are part of a larger group of pattern recognition receptors (which recognize conserved attributes 
found in bacterial, viral and parasitic pathogens), are potent NF-κB activators. TLR ligands 
signal through several PRR exemplified by: lipopolysaccaride (LPS) via TLR4
7
, CPG via 
TLR9
8
, Flagellin via TLR2
9
, and muramyl dipeptides (MDP) via NOD2
10
.  Additionally, tumor 
necrosis factors (TNF) and interleukin-1 (IL-1), two major proinflammatory cytokines, are both 
activators as well as transcriptional targets of NF-κB.  Other NF-κB activators also include the 
antigen receptors found on the adaptive immune cells, specifically the T-cell receptor and B-cell 
receptor (TCR and BCR), as well as varying receptors found on antigen presenting cells 
including the already mentioned TLRs and CD40R.  Additionally growth factors such as: 
hepatocyte growth factor (HGF), follicle stimulating hormone (FSH), granulocyte macrophage- 
 3 
including the already mentioned TLRs and CD40R.  Additionally growth factors such as: 
  
Figure 1: NF-κB, IκB, and IKK family members.  Postranslational modifications are indicated with P, U, Ac, 
for phosphorylation, ubiquitination, and acetylation respectively.  These modifications in white indicate 
activators while  those in red describe either inhibitory or proteosmal degredation mediators.  Amino acid in 
human proteins are shown at the right, and NF-κB1 and NF-κB2 are shown in their uncleaved (inhibitory) 
form.  Other abbreviations include; GRR, glycine-rich region; HLH, helix-loop-helix domain; Z, zinc 
fingerdomain; CC1/2, coiled-coil domains; NBD, NEMO-binding domain; MOD/UBD, minimal 
oligomerization domain and ubiquitin-binding domain; and DD, death domain.  (Reprinted from Cell press, 
Vol 132, Hayden MS and Ghosh S., Shared Principles in NF-κB Signaling, 344-362, 20085) 
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colony stimulating factor (GM-CSF), and nerve growth factor (NGF) can also activate NF-κB 
vai their associated receptors
4
 
Interestingly, the NF-κB signaling pathway can be activated secondary to DNA damage 
via the  DNA response protein ataxia telangiectasia mutated (ATM), which acts directly at the 
level of the Inhibitor of Kappa B Kinase (IKK) complex
11, 12
.  There is also abundant amounts of 
data which suggest that ROS can activate and/or suppress NF-κB as reviewed in13, and these 
variations may depend on cell types and specific conditions.  Thus, the NF-κB response is a 
ubiquitous signaling pathway which is activated in response to stimuli, the majority of which are 
mediators or markers of stress.   
There are hundreds of genes defined as NF-κB transcriptionally regulated genes; 
however, they are preferentially activated in response to certain stimuli but not others likely due 
to the role of other signaling pathways and transcription factors activated by NF-κB activating 
receptors.  Therefore, it is likely that other pathways activated in concert with NF-κB are integral 
in determining the exact cellular response to any one stimuli.  Exploration of these differential 
responses is beyond the scope of this manuscript, but is important to take into account when 
evaluating the effects of specific NF-κB suppression in models of disease.   
1.1.4 Activation of NF-κB through the IKK complex 
The canonical or activated NF-κB signaling cascade is initiated by numerous membrane 
and intracellular receptors as described above
4
.  Of the numerous signaling cascade which 
activate NF-κB, many share a small number of signaling molecules upstream of the IKK 
complex.   For example LPS activates the Tollip which activates MyD88 and IRAK, these 
components the signaling through TRAF6, which leads to subsequent activation of the IKK 
 5 
complex.  Other common signaling proteins involved in TLR, IL-1, TNF, and TCR signaling 
pathways  include MyD88, RIP, NIK and TRAF proteins which act upstream of the IKK 
complex
5
.  The IKK complex lies at the confluence of the many different NF-κB signaling 
cascades, whether activated by TLRs, TCR, or ATM.  It is composed of two catalytic subunits, 
IKKα and IKKβ, as well as a regulatory subunit IKKγ also known as the NF-κB essential 
modulator (NEMO)
14
.   
IKKγ interacts with the upstream RIP, NIK, or TRAF proteins which results in the 
oligomerization of NEMO.  IKKγ then induces phosphorylation or possible auto-
phosphorylation of the IKKα and β subunits.  After phosphorylation, the catalytic subunits are 
released from the IKKγ; the free catalytic subunits can then act to phosphorylate IκB at Ser32 
and Ser36.  After phosphorylation, IκBα is then poly-ubiquitinated at Lys22 and degraded by the 
26S proteosome.  This degradation leads to the loss of the nuclear export signal provided by IκB 
as well as the revealing of a nuclear localization signal on the NF-κB subunits.  This cascade 
results in the migration of NF-κB to the nucleas15.  Once in the nucleus NF-κB acts to promote 
gene expression or suppress various pro-inflammatory, cell growth, and other regulated genes 
(Figure 2). 
1.1.5 Non-canonical NF-κB signaling 
The non-canonical NF-κB signaling pathway is largely involved in lymphoid organ 
development, which is required for B and T-cell development via activation of the p52/RelB 
 6 
development, which is required for B and T-cell development via activation of the p52/RelB  
Figure 2: Signaling via the IKK/NF-κB Classical Pathway.  The IKK complex (NEMO, IKK1 (IKKα), and 
IKK2 (IKKβ) can be activated by numerous stimuli and via shared signaling components. Extracellular 
receptors bind to their ligands and signaling via TRAF/RIP/NIK molecules leading to phosphorylation of 
IKK subunits, which subsequently phosphorylate IκBα and lead to its ubiquitination and proteosomal 
degredation.  This then releases NF-κB into the nucleus where it acts as a transcription factor.  In addition, 
ATM responds to DNA damage and can also activate the IKK complex.  (Figure adapted from 
5, 16, 17
) 
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homodimer.  This signaling pathway is activated by a limited number of receptors (Lymphotoxin 
B, B-cell activating factor, and CD40), which subsequently stimulate an IKKα homodimer.  This 
complex then phosphorylates p100 and leads to processing of  p100 to p52, allowing for 
translocation of the p52/RelB complex to the nucleus where it acts as a transcription factor
18
.  In 
addition to lymphoid organ development, studies evaluating IKKα-/- mice suggest a role of the 
non-canonical pathway in epidermal and skeletal development
19
.  While the role of the non-
canonical pathway seems most important during development, it is the canonical pathway that 
seems to be the most relevant in the treatments of mammalian disease described in this 
manuscript. 
1.1.6 IKK and IκB signaling components 
The IκB and IKK proteins are the central regulators of activated NF-κB signaling.  It is 
thought that the IKK complex is solely a trimerization of IKKα/β/γ and in fact in vivo may be 
found as a higher order complex with numerous IKK trimers interacting.  However, some studies 
suggest that IKKα is less important than IKKβ with regards to canonical signaling; and within 
certain cell types the IKK complex may be composed of IKKβ/β/γ trimer rather than the 
traditional IKKα/β/γ20.  The IKK kinases α and β share a 52% sequence homology21 with a 
greater homology in their catalytic or kinase domains, however, genetic knockout (ko) studies 
suggest differential and non-redundant roles for these two proteins.  While IKKα is more 
important in non-canonical signaling, IKKβ ko mice show a high level of similarity to p65-/- 
cells.  Interestingly there is some evidence that IKKα contributes to canonical signaling22.   As 
the IKKβ-/- mouse does not have all of the defects seen in the IKKγ-/- mouse23, there is likely 
some differential roles for α and β in the canonical signaling pathways.   
 8 
The major ligands of the IKK proteins are the IκB cytoplasmic inhibitors.  The common 
component of the IκB-like proteins is the ankyrin repeats which are found on IκBα,β,γ,δ,ε, bcl-3 
and the uncleaved p50 and p52 subunits p100 and p105 proteins.  These ankyrin repeats act to 
bind to the Rel portion of NF-κB blocking the NLS.  Of the typical IκBs (α/β/ε), the most studied 
IκB protein is IκBα, the main inhibitor of the canonically activated p65/p50 NF-κB heterodimer, 
which act as described above.  The non-typical IκBs, bcl-3 and IκBδ are thought to inhibit NF-
κB transcription by binding to NF-κB in the nucleus.  For instance, Bcl-3 stabilizes p50 
homodimers on DNA, blocking the NF-κB promoter regions from other NF-κB  subunits and 
preventing transactivation domain (TAD) positive NF-κB subunits from binding the consensus 
sequence
24
.  
1.1.7 Genes under NF-κB transcriptional control 
Since the discovery of NF-κB1, hundreds of genes have been shown to be directly 
transcriptionally regulated by NF-κB4.  These genes fall under the following categories: 
cytokines and chemokines, immunoreceptors, antigen presentation, cell adhesion, acute phase 
response, stress response, cell surface receptors, growth factors and ligands, early response 
genes, and other transcription factors as defined by Gilmore (nf-kb.org)
4
 and summarized below 
and in Figure 3.   
It is clear that the vast numbers of these categories transcriptionally controlled by NF-κB 
are involved in immune signaling and inflammatory responses.  NF-κB transcriptional control of 
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cytokines is likely one of the most important factors when evaluating the role of NF-κB in 
 
Figure 3: NF-κB is a central regulator in stress response.  The NF-κB signaling pathway can be 
activated by numerous stimuli as listed in the blue boxes.  In response to these different stimuli NF-κB 
transcriptionally regulate hundereds of genes which are listed in the red and purple circles.  Of particular 
importance to chapters 2 are the cytokine and bacterial activators which alter cytokine, chemokine and 
immune receptor reponse.  In chapter 3 of importance are again the cytokine and bacterial activators, but 
NF-κB regulation of apoptosis and antioxidant production is of note.  While in Chapter 4 cell stressors such 
as DNA damage, oxidative stress, and physical stress are the important inducers of NF-κB while cell cycle, 
growth factor and immune gene regulation is of interest.   
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pathologic states.  Some of these cytokines include but are not limited to TNFα, IL-1α/β, IL-
2,3,6,12, GM-CSF, M-CSF, and G-CSF.  NF-κB also regulates chemokines (MCP-1, KC, MIP-1 
and several CCLs) and adhesion molecules (ICAM-1, E-selectin, and VCAM-1) which allow for 
the recruitment and attachment of immune cells to sites of inflammation.  In addition to 
recruitment and activation of immune cells NF-κB also upregulates receptors (CD80/81, IL-2Rα 
chain, TLR-2) and antigen presenting architecture (MHC class I and β2 microglobulin) on 
immune cells to allow for the proper innate and adaptive immune responses.  
In addition to immune response genes, which are integral to the control of pathogen 
induced inflammatory response and likely a major contributor to pathology in human diseases 
there are several other processes which are controlled by NF-κB.  Interestingly, NF-κB 
transcriptionally regulates both pro-apoptotic (Bim, Bax, Fas and Fas-ligand, and caspase 11) 
and anti-apoptotic genes (XIAP, bcl-2, A1/bfl-1, and c-Flip).  It has been shown that NF-κB 
blocks apoptosis in a number of inflammatory cells including macrophages, dendritic cells, T-
cells, B-cells, and neutrophils,  as well as being a pro-survival factor in several types of 
malignancies especially lymphomas (as described below).   On the other hand, the inflammatory 
response often induces apoptotic cell death in infected cells.  This inflammatory cell death 
response is initiated by the production of cell death receptors ie. Fas/FasL and intracellular 
apoptosis inducing proteins.  This apoptotic death is further assisted by activated immune cells 
which secrete granzyme, perforirin and nitric oxide, all apoptosis inducing factors.   
The other major NF-κB transcriptionally regulated genes include growth factors such as: 
nerve growth factor (NGF), vascular endothelial growth factor (VEGF), insulin-like growth 
factor binding protein (IGFBP), bone morphogenic protein (BMP), fibroblast growth factor 
(FGF) and numerous others.  Many of these receptors are involved in the expansion and 
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maturation of immune cells.  Thus, the majority NF-κB controlled genes are considered cell 
stress responders to create inflammation, block apoptosis, and increase cellular growth.  
Unfortunately many of these processes can be co-opted by cancerous cells to promote their 
survival and growth.   
1.1.8 Other substrates of IKK complex:  
While it is likely that the actions of the IKK inhibitors used in these studies exert the 
majority of their effects due to suppression of the NF-κB canonical signaling pathway, there are 
also a number of other IKK substrates and interacting proteins separate from this pathway which 
may also be altered by inhibiting the IKK complex.  Proteins known to be phosphorylated by 
IKK include Bcl-10, β-catenin, cyclinD1, FOXO3a , and ERα.  Interestingly, these genes are 
known to control cell growth and proliferation and many of these have been implicated in 
cancers
25-27
.  NEMO has also been shown to interact with HIF1α and HIF2α to promote 
transcriptional activity of these two factors, which are known to play a role in anti-oxidant 
function
25, 28
.  Thus, while the majority of the effects observed after IKK inhibition are likely 
mediated by NF-κB suppression, there may be other pathways affected by IKK suppression, 
specifically those regarding cell growth and proliferation. 
1.1.9 NF-κB in human disease 
Dysregulation of NF-κB is implicated in a vast number of human diseases, through 
inherited genetic mutations, somatic mutations, indirect mutations, or non-epigenetic 
dysregulation of NF-κB signaling (described below).  Only a few diseases, however, result from 
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genetic mutations in specific NF-κB signaling components, including Incontinentia pigmenti 
(ID), anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), osteopetrosis and 
lymphedema (OL)-EDA-ID, Immunodeficiency without EDA, EDA-ID(with impaired T-cell 
proliferation) most of which are due to mutations in NEMO or IκBα29. Each of these diseases is 
defined by severe skin inflammation, but this can progress with ocular and hair defects and in 
severe cases even central nervous system disfunction
29
. 
REL, or human c-rel, amplification is seen mainly in cancers and is more common than 
inherited mutations of NF-κB components.  Interestingly, REL amplification is likely due to the 
pro-survival (growth factor, proliferation induction, and anti-apoptotic regulation) transcriptional 
activity of NF-κB.  Rel amplification has been reported in Hodgkins lymphoma, and a variety of 
non-Hodgkin’s lymphoma including diffuse large B-cell lymphoma, follicular, primary 
mediastinal, natural killer T-cell and others.  In these lymphomas REL amplification was present 
in varying percentages of patients: specifically amplification of REL was observed in upwards of 
54% in Hodgkin’s, 75% in Cutaneous CD30+ anaplastic large cell, but only 5% in aggressive B-
cell lymphoma.  Additionally there is a retroviral oncoprotein homologue to REL, v-Rel of the 
avian Rev-T retrovirus.  Recent studies demonstrate efficacy of treating cancers with 
chemotherapeutics containing adjunct NF-κB inhibitory compounds30-32, suggesting that the 
over-active NF-κB is not a marker but rather a contributing factor to tumorgenesis and/or tumor 
cell survival
29, 33
. 
The vast majority of diseases in which NF-κB has been implicated are those with single 
nucleotide polymorphisms (SNPs), alterations in enhancer or promoter regions of NF-κB 
regulated genes or mutations in genes implicated in the NF-κB signaling pathways.  These 
mutations and associated diseases are described in detail by Courtois et al.
29
  Not suprisingly, 
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many of the diseases associated with increased NF-κB signaling are inflammatory diseases 
including familial mediterranean fever, Blau’s disease, inflammatory bowel disease, cold 
induced autoinflammatory syndrome, or conditions wich incresase susceptibility to asthma and 
sepsis. 
In addition to the diseases with known genetic alteration dysregulating NF-κB signaling, 
a vast number of diseases states exhibit upregulated NF-κB signaling despite having no 
mutations in the NF-κB sigaling pathway.  Suggesting that NF-κB may be upregulated in 
response to altered proteins or stress responses generated by these disease states.  This list of 
indirect NF-κB implicated diseases includes an ever growing number of diseases from 
Parkinson’s to Padget’s, glaucoma, cystic fibrosis, systemic lupus erytematous, COPD, pain 
disorders, osteoporosis, and metobolic disorders
4
. Thus, the implications of NF-κB dysregulation 
in human disease are vast and a greater understanding of its physiologic role and the effects of 
altering this signaling pathway is of criticial importance in understanding and treating human 
pathology.  The use of animal models is an important tool to allow for us to complete these 
goals.   
1.1.10 NF-κB inhibition/Nemo Binding Domain (NBD) Peptide:   
Many methods to inhibit NF-κB signaling in vitro and in vivo have been evaluated.  Some 
mechanisms previously used in inflammatory diseases include NF-κB decoy oligoneuclodides34, 
proteosome or ubiquitin inhibitors which block the degradation of IκBα, or systemic anti-
inflammatory agents which block NF-κB non-specifically (PTDC35, dexamethasone36, aspirin37 
and others).  However, the problems associated with these therapeutics results from their lack of 
specificity, or in the case of the NF-κB decoy peptides or p65 translocation inhibitors, they block 
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both activated and basal NF-κB signaling, thereby increases potential side effects.  A more 
appropriate therapeutically target to suppress NF-κB activation is the IKK complex.  While many 
of the major pharmaceutical companies and various laboratories are generating compounds 
which have great in vitro potential, many of these compounds have less than optimal efficacy in 
vivo.  One exception to this low in vivo bioavailability is the NEMO binding domain (NBD) 
peptide.  NBD is an 11 amino acid sequence within IKKß that binds to IKKγ14.  The addition of 
exogenous NBD peptide blocks the interaction of both IKKα and β with the regulatory subunit 
IKKγ.  While there are numerous small molecule inhibitors of NF-κB, there are some distinct 
advantages of the NBD peptide.  The site of action is highly defined, and due to this specific IKK 
targeting, only activated, but not basal levels of NF-κB is inhibited.  Also, because of the high 
specificity of the NBD peptide sequence it is unlikely to affect other essential kinases, which is 
not the case for other more general NF-κB inhibitors38.  Furthermore, the in vivo bioavailability 
of peptides linked to protein transduction domains is very high
39
.   
1.1.11 Protein Transduction as method of delivering therapeutics 
Protein transduction domains (PTDs) are small peptides which are able to transport much 
larger molecules such as oligonucleotides, peptides,
 
full-length proteins, 40nm iron 
nanoparticles, bacteriophages,
 
and even 200 nm liposomes across cellular membranes
40-44
. They 
have proven useful in delivering
 
biologically active cargoes in vivo, and, remarkably, they have
 
the ability to transduce nearly all tissues, including the brain,
 
following intraperitoneal 
administration of fusion proteins
14, 45, 46
. 
There are at least three classes of PTDs, which include positively charged (cationic), 
protein leader sequence derived domains (hydrophobic) and peptides identified by phage display 
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able to transduce cells in a cell type specific manner (tissue specific) (Table 1).  I will focus on 
the positively charged, cationic transduction domains since they are the most efficient and the 
best characterized and will be used in the studies outlined in this manuscript.     
In 1988 and 1994 respectively, two proteins were observed to cross biologic 
membranes, TAT (derived from HIV, RQIKIWFQNRRMKWKK)
47, 48
 and Antp (derived from 
within the Drosophila antenepedia protein, YGRKKRRQRRR)
49
.  Both Antp and TAT 
transduction domains are comprised of numerous cationic amino acids, or basic residues, which 
play a crucial role in their transduction properties.  These positively charged residues interact 
with the negatively charged cell membrane which mediates uptake.  Studies have suggested that 
the transduction potential of these peptides is due to their amphipathic helical 3 dimensional 
structure
50
.  However, the fact that peptides containing a minimum number of arginine or lysine 
residues works as efficiently as TAT PTD suggests that the charge of the peptide is the most 
important feature of transduction domains.  
 
Initial binding of the cationic PTDs to cells is mediated through glycosaminoglycans.
51
. It 
is generally accepted that PTDs bind glycosaminoglycans, specifically heparin sulfate, and then 
transduce cells through a mechanism of receptor-independent, but possibly energy dependent 
endocytosis.   Several mechanisms have been suggested to explain the second phase of 
transduction of PTDs, and it is still unknown whether all peptides transduce cells via the same 
mechanism. The fact that transduction can occur in an energy independent manner, albeit at a 
reduced level suggests that there may be at least two independent mechanisms.  
Studies evaluating TAT protein transduction suggest a mechanism of receptor 
independent macropinocytosis associated with lipid rafts
52
.  However, other studies suggest a 
caveolae-dependent mechanism of PTD uptake since two caveolae endocytosis inhibitors  
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Table 1: Protein Transduction domains or Cell Penetrating Peptides  
Cationic Peptides 
Name Peptide Sequence Reference 
Antp RQIKIWFQNRRMKW 
49
 
TAT YGRKKRRQRRR 
47, 48
 
8K KKKKKKKK 
53
 
6R RRRRRR 
53
 
PTD-5 RRQRRTSKLMKR 
54
 
Amphipathic Peptides 
Name Peptide Sequence Reference 
MAP KLALKLALKALKAALKLA  
55
 
KALA WEAKLAKALAKALAKHLAKALAKALKACEA 
56
 
ppTG20 GLFRALLRLLRSLWRLLLRA 
57
 
Trimer (VRLPPP)3 
58
 
P1 MGLGLHLLVLAAALQGAWSQPKKKRKV 
59
 
K-FGF AAVALLPAVLLALLAP 
60
 
Cell Targeting Peptides: 
Peptide Sequence Target Tissue Cellular Target Reference 
TSPLNIHNGQKL Human head and neck solid tumors Unknown 
61
 
CGKRK Tumour neovasculature Heparan sulfate 
62
 
RGD Integrin receptor αVβ3 63 
VHSPNKK Endothelial VCAM-1 expressing cells VCAM-1 
64
 
LTVSPWY Breast carcinoma erbB2 
65
 
ATWLPPR Tumour neovasculature VEGF receptor 
55
 
 Modified from Vivés et al.
66
, Tilstra et al.
67
, and Deshayes et al.
68
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nystatin, and fillipin reduced transduction
69
. Thus, the exact mechanism of uptake may not only 
be dependent on the PTD itself but also its cargo
70
. 
 
1.1.12 Characterization of Transduction Efficiency 
Previosuly, our lab characterized a panel of positively charged PTDs for ability to 
transduce different cell types in culture.  Peptides containing 6-8 arginines, lysines or ornithines 
are highly effective for delivery of fluorescent markers or a ß-gal fusion protein through a 
receptor independent mechanism
53
.  Lysine (8K) was the most effective for transduction of 
fibroblasts and epithelial cell lines in culture.   However, these studies as well as the majority of 
other studies evaluating PTD sequences examine cellular uptake, bio-distribution, and endosomal 
escape have used PTDs carrying fluorescent cargos.  While this approach offers insight into the 
mechanism of PTD action and allows for examination of transduction efficiency, it provides very 
little information about the potential for therapeutic application of this technology.  Therefore, 
we recently chose to evaluate various PTD sequences linked to a biologically relevant peptide 
cargo which, when present intracellularly, can inhibit the NF-κB signaling pathway (Figure 4).     
We initially tested a panel of PTD-NBD fusion peptides for their ability to inhibit IL-1ß 
induced NF-κB transcriptional activity, measured using an NF-κB luciferase reporter in HELA 
cells.  In culture, delivery of NBD with TAT, Antp and PTD-5 resulted in the most effective 
inhibition of IL-1ß induced NF-κB activity.  This result is in contrast to in vivo analysis in a 
murine footpad delayed-type hypersensitivity (DTH) model where 8K, and six arginine (6R), 
worked far more efficiently in blocking footpad swelling following local injection.  In the DTH 
model, injection of TAT-NBD and Antp-NBD were significantly less effective in model, 
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injection of TAT-NBD and Antp-NBD were significantly less effective in 
 
Figure 4: NBD inhibits NF-κB (A) PTD-NBD enters the cell due to its positive charge interacting with the 
negative charge on the cell surface mediating receptor independent endocytosis (B) NBD escapes the 
endosome via retrograde transport or Golgi/ER (endoplasmic reticulum) endosome fusion. (C) NBD interacts 
by binding to IKKγ and preventing the association with the α and β subunits. (D) This prevents the activation 
of NF-κB stimulated by the pro-inflammatory signals (E) which leads to the phosphorylation of IκB and its 
subsequent degradation. (F) Finally NF-κB dimer p65p50 is released and then translocates to the nucleus 
whereby it transcribes pro-inflammatory genes.  Reproduced with permission, J. Tilstra, K.K. Rehman, T. 
Hennon, S.E. Plevy, P. Clemens, and P.D. Robbins, 2007, Biochemical Society Transactions, Vol 35, 811-
815(http://www.biochemsoctrans.org/) 
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inhibiting footpad swelling (paper in preparation). Although the reasons for the difference in 
activity observed in cell culture and in vivo is unclear, we speculate it is due to the ability of 8K 
and 6R PTDs to persist in vivo or to efficiently transduce the appropriate target cells, most likely 
antigen presenting cells in vivo.  
1.1.13 Treatment of murine disease models with 8K-NBD 
Prior to and during the preparation of this dissertation numerous groups have evaluated 
the use of the NBD peptide.  Chronic administration of PTD-NBD is efficacious in the treatment 
of numerous murine models of degenerative disease including arthritis
71
, diabetes
67, Parkinson’s 
disease
72
, muscular dystrophy (MD)
73
, pancreatitis
74
, and multiple sclerosis
75
 (Table 2).  Many 
groups have used either the TAT or Antp PTDs linked to NEMO while we have consistently 
used 8K-NBD.  However, in each case the peptides have had efficacious results in ameliorating 
disease states.  The syndromes evaluated by our laboratory or in collaboration with others 
include type I diabetes, collagen-induced arthritis (CIA)
67
, and Duchene muscular dystrophy 
(DMD) 
67, 73
. 
1.1.14 Use of PTD-NBD in this manuscript: 
As NBD has proven to have efficacy in numerous models of inflammatory disease, as 
well as, improved bioavailability over other NF-κB inhibitors, this peptide was used to evaluate 
the effects of NF-κB suppression in two murine models of disease in this manuscript.  Not only 
will NBD have the potential to be a possible therapeutic, but it is also an appropriate tool to 
evaluate contribution of NF-κB to disease pathogenesis.  Here I will assess the effects of NF-κB  
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Table 2: Use of NBD peptide in mammalian models of human disease 
Disease PTD  Length of Trt Result of NBD treatment Pub. 
Acute Inflammation 
(PMA ear edema, 
Zymosan -induced 
peritonitis) 
Antp 100μM Single dose Reduced ear thickness, 
and decreased exudate 
14
 
Multiple Sclerosis 
(EAE model) 
Antp 1.0mg/kg q24 hrs for 
31 days 
Reduced clinical score, 
Th2 phenotype skewing, 
Decreased inflammatory 
cytokines 
75
 
Inflammatory Arthritis 
(arthritogenic serum 
addition) 
TAT 3.0 & 6.0 mg/kg at d0 
and d3 of 7 day 
experiment 
Reduced osteoclast 
formation and bone 
destruction 
71
 
Arthritis (Collagen 
induced arthritis) 
Antp Daily injections for 30 
day 
Reduced inflammation 
and bone destruction, 
reduced inflammatory 
cytokine, 
76
 
Colitis (DSS and 
TNBS) 
Antp DSS 0.1mg/kg for 10 
day, 1.0mg/kg 3 doses 
over 48 hrs 
Improved histology and 
decreased cytokine 
production 
77
 
Parkinson’s (MPTP) Antp 0.75 mg/kg given at 1d 
prior to or 2d after 
MPTP daily until 7d 
after MPTP injection 
Increased dopaminergic 
neurons, reduced CD11b 
infiltration  
72
 
Duchene Muscular 
Dystrophy (MDX 
mice) 
? Prevention: daily 
injection 10mg/kg 
from d6 to d22 
Treatment: 200μg q3d 
from d23 to d50 
Decreased macrophage 
and inflammatory 
infiltrate, improved 
muscle regeneration and 
function 
73
 
Acute Pancreatitis 
(cerulein-induced) 
? 
(Antp) 
600μg injection prior 
to cerulein injection 
Reduced inflammation, 
and MPO activation 
74
 
Colitis (IL-10-/- mice) 8K 2 and 10mg/kg 10 of 
14 days 
Reduced macroscopic 
and microscopic 
histologic inflammatory 
changes, reduced 
cytokine secretion 
78
 
Pancreatitis (Sodium 
taurocholate (5%) 
(RAT) 
TAT 13mg/kg Significant reduction in 
tissue necrosis and 
improved histology 
79
 
Acute respiratory 
distress syndrome 
(surfactant induced) 
(PIG) 
Antp 1.25 mg per piglet improved gas exchange, 
lung function and reduced 
pulmonary inflammation 
80
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signaling in both a model of inflammatory bowel disease (IBD) and a model of accelerated 
aging.   
1.2 INFLAMMATORY BOWEL DISEASE (IBD) 
Inflammatory Bowel Disease (IBD) affects nearly 1 million people in the United States 
and includes two diseases, ulcerative colitis and Crohn’s disease.  The patho-physiology of 
ulcerative colitis and Crohn’s disease are similar in that both are inflammatory in nature and 
involve dysregulation of cytokines and inflammatory cell infiltrates.  Genetic factors, 
immunological factors, and environmental triggers all play a role in the pathogenesis
81
.  There is 
continuing research on understanding of the pathogenesis of IBD and evaluating new treatment 
possibilities. Unfortunately, current therapies often do not control symptoms and are associated 
with significant side effects.  A recent study evaluated IBD disease outcome comparing 1998-
1999 with 2004-2005
82
.  From 2004-2005, one in every 12.5 patients with Crohn’s disease and 
one in every 20 patients with ulcerative colitis were hospitalized secondary to complications 
from their disease.  In addition, 1 in 28.5 patients with Crohn’s disease required surgery a ration 
not significantly decreased from 1998-1999
82
.  A much lower number of patients with ulcerative 
colitis underwent surgery
82
 however, often times these surgeries are more invasive and result in 
colonic resection (colectomy).  Nearly 8% of patients with ulcerative colitis will undergo 
colectomy within five years of diagnosis and 28% by 10 years.
83
  The most successful current 
treatment for Crohn’s disease is infliximab, an artificial/chimeric antibody that blocks TNFα.  
Infliximab is successful in reducing disease severity and fistula formation, but approximately one 
third of patients do not respond to this therapy
84
. In addition to nonresponders, some patients 
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develop anti-chimeric antibodies which block the infliximab
85
.  Furthermore, infliximab 
treatment has been linked with increased susceptibility to infections, most importantly 
tuberculosis, as well as a small, but increased risk of lymphoma.  Thus, there is still a great need 
for improved understanding of IBD physiology and other targeted therapeutics which can reduce 
symptoms associated with disease.    
1.2.1 Pathology of IBD 
The two IBD variants are differentiated and distinguished by their localization in the 
bowel as well as their pathophysiology.  Crohn’s disease is usually defined as a transmural 
disease affecting all the layers of the colon including epithelium, mucosa, submucosa, muscle, 
and serosal layers.  Crohn’s disease is also defined by skip lesions, small regions of 
inflammation affecting various areas of the intestine from the esophagus to the anus; however, is 
most common focused at the ileo-colic junction (Figure 5).  Microscopically Crohn’s disease is 
defined by crypt abscesses, villus atrophy, mononuclear infiltrate, which contributes to mucosal 
thickening and non-caseating granuloma formation. Ulceration, fissures, and thickening of all 
layers of the intestine (Figure 6) are macroscopic components of Crohn’s disease, as well as 
secondary formation of fistulas and abscesses.   
In contrast, in ulcerative colitis occurs only in the colon and is limited to the epithelial, 
mucosal and occasionally submuscosal layers.  Inflammation in ulcerative colitis leads to a loss 
of the mucosal layer and formation of pseudopolys (intact tissue amongst loss of mucosal tissue) 
(Figure 5).  Microscopically, ulcerative colitis is defined by numerous inflammatory cellular 
infiltrates associated with abnormal crypt and villus formation, ulceration, and mucosal 
thickening (Figure 6)
86-88
.  
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Figure 5: The distribution patterns of the two variants of IBD.  The top panels describe the location and 
generalized pattern of disease within the small intestine and colon of both Crohn’s disease and ulcerative 
colitis.  The bottom two panels describe the macropathologic changes in the two variants.  (Courtesy of 
Elsevier originally published in Kumar: Robbins and Cotran: Pathologic Basis of Disease, 7th ed.
89
) 
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Figure 6:  Histopathology of IBD.  (A) Normal small intestine/colon with crypt and villus formation. (B) 
Crohn’s disease micrographs, Left image, intestine is exhibiting inflammatory (mononuclear cell) infiltrate 
with non-caseating granuloma formation and loss of normal villus structure. Right image, transmural fissure 
(center) which extends through epithelium, submucosa, mucosa and into the muscle layer, with large 
inflammatory infiltrate exhibited between the mucosa and submucosa (blue patches), and shallow ulcer 
(right). (C) Ulcerative colitis micrographs. Left image, crypt abcess formation Right image, loss of villus 
structure inflammatory infiltrate into mucosal layer (Courtesy of Elsevier originally published in Kumar: 
Robbins and Cotran: Pathologic Basis of Disease, 7th ed.
89
) 
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1.2.2 Extra-intestinal Manifestation of IBD 
IBD pathology is normally localized to the intestine, but is in fact a systemic disease 
which has numerous extraintestinal manifestations that can affect several organ systems as  
reviewed in 
88, 90, 91
 and summarized below.  Arthritis is the most common extaintestinal 
manifestation of IBD.  Manifestations of arthritis are varied, but three major forms include 
ankylosing spondilitis, sacroilitis, and migratory monoarthritis. Ankylosing spondilitis is a 
chronic inflammatory arthritis which effects the spine and sacroilium causing severe back pain 
and stiffness. The spine eventually fuses and causes rigidity and debilitation. Sacroiliitis is 
inflammation localized to the sacroiliac joint and causes low back pain. Patients with IBD can 
also experience migratory monoarthritis which affects large joints usually one at a time and runs 
a course unrelated to that of the intestinal disease.  Other extraintestinal manifestations include: 
dermatologic changes including erythema nodosum (inflammation of the fatty layer of the skin 
also seen in sarcoidosis and infectious mononucleosis), pyoderma gangrenosum (a cutaneous 
ulcerative lesion thought to do with neutrophil dysregulation, and is also seen in seropostive 
arthritis and less commonly systemic lupus erythema (SLE) and Sjogren’s syndrome)92, and 
aphthous ulcers (well circumscribed ulcers of the buccal mucosa in the mouth also seen in 
SLE)
93
. Interestingly, these signs and symptoms are characteristics of other inflammatory 
disorders as well, underlying the systemic inflammatory nature of IBD.     
1.2.3 Inflammation and role in IBD: 
It is likely that an exaggerated immune response to enteric bacteria plays a significant 
role in the development of disease.  The intestine is normally considered a suppressive 
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environment from an immunologic perspective, and dysregulation of this suppressive 
environment is thought to be a major contributor to the pathogenesis of IBD.  In numerous 
mouse models of IBD, mice do not generate disease under germ free conditions
94
, and further 
both ulcerative colitis and Crohn’s disease are localized to the ileal-colic junction and colon, the 
two areas of intestine with the highest bacteria burden
87
.   
Features of the intestine closely resemble other lymphoid organs.  Macrophages, 
dendritic cells, monocytes, and lymphocytes reside in the lamina propria and submucosal layers 
of the gut.   In addition, the intestine has intrinsic lymph tissue known as gut-associated-
lymphoid tissue (GALT) also described as Peyer’s patches (in the small intestine) and follicles 
(in the colon). GALT contains a high percentage of T and B-cells.  In contrast to other lymph 
organs, GALT has many suppressive elements.   
The gut secretes numerous molecules to prevent invasion of bacteria, however these 
molecules do not activate a gross inflammatory response.  For example, the major antibody 
secreted by the intestine is immunoglobulin A (IgA), which acts as a dimers and is linked 
together by the J-chain, allowing for its secretion into the intestinal lumen.  Importantly, IgA is 
unable to activate complement or bind Fc receptors.   Thus IgA acting as a neutralizing agent 
binding to bacteria and preventing invasion, but not as an inflammatory activator
95, 96
.  The 
intestinal epithelial layer includes the villus or surface epithelium (intestinal epithelial cells 
(IECs), goblet cells, neuroendocrine cells, and paneth cells. Each of these cells in the epithelial 
layer provides microbial protection without overt stimulation of the immune system
87
.  Goblet 
cells secrete mucin and glycoproteins, creating the glycocalyx. which overlays the epithelium 
and helps prevent bacterial invasion.  Paneth cells are responsible for secreting defensins and 
anti-microbial peptides.  Deficiencies in the defensins secreted by the paneth cells can exacerbate 
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or increase the risk of IBD development
97
.  Further, IECs express CD1d which leades to T 
regulatory cells (T-reg) or suppressive T-cells, and the IECs are one of the few non-professional 
antigen presenting cells (APC) to express MHC class II molecules
98
.  APC from the intestine 
have suppressive qualities. Mucosal macrophages in the intestine are also more suppressive than 
there general counterparts.  These mucosal macrophages do not express CD14, a co-receptor for 
TLR4
99
, and produce less inflammatory cytokines (TNFα and IL-1β) than other macrophages.  
There is also a special population of intestinal dendritic cells which sample apoptotic IECs and 
tolerize naïve T-cells against self antigens
100
.  In addition to DC tolerization of T-cells, lamina 
propria T-cells do not proliferate due to TCR engagement, but seem to activate alternative 
pathways via CD2 and CD28.  These findings exemplify the role of intestinal immune response 
as a protective yet suppressive environment. 
 Unfortunately, in IBD the normally suppressive environment in the intestine becomes an 
activated environment.  Immune dysregulation and activation appears to be a common factor in 
both ulcerative colitis and Crohn’s disease although the immune activation differs between them. 
While ulcerative colitis and Crohn’s disease are distinctive diseases, the clinical picture can vary 
from patient to patient even with the same pathology and often colonic Crohn’s disease is 
confused with ulcerative colitis.  It is traditionally thought that ulcerative colitis is a T-helper 2 
(Th2) skewed disease marked by increased IL-5, IL-6 and IL-13 secretion whereas Crohn’s 
disease is a Th1 skewed disease which is associated with increased IL-12, Il-23, and tumor 
necrosis factor alpha (TNFα) secretion101.  There are numerous reports of an over active NF-κB 
pathway in patients with Crohn’s disease102. In ulcerative colitis it is thought that the relative 
deficiency of interleukin 10 (IL-10), which has anti-inflammatory and NF-κB inhibitory effects, 
may contribute to persistent inflammatory changes
14, 103
.   
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1.2.4 NF-κB and IBD 
Evidence suggests that the pathophysiology of IBD is secondary to intestinal immune 
dysregulation.  It is thought that NF-κB is a master switch for inflammatory gene expression 
including cytokines, chemokines, adhesion molecules, and cellular defense molecules
22, 104
.  
Furthermore, activation of NF-κB has been shown to be important in a wide variety of 
inflammatory and non-inflammatory diseases
15
.  The role of NF-κB in IBD disease pathology 
has been defined by studies of patients with IBD and examination of numerous mouse models of 
intestinal inflammation.  Activated NF-κB is found Interestingly, numerous studies have shown 
that IL-10
-/-
 mice develop colitis only in the presence of bacteria
105
.   in inflamed mucosa and 
macrophages of patients with IBD 
102, 106
.  RelA/p65 was shown to be overexpressed in the 
intestines of patients with ulcerative colitis and Crohn’s disease.  Further analysis of lamina 
propria macrophages derived from the IBD patients showed increase DNA binding of NF-κB 
subunits, which were responsible for inflammatory cytokine production, IL-1β, IL-6, and 
TNF
106
.   
Initial studies focusing on the role of NF-κB in development of IBD was completed in 
animal models of colitis.  The most commonly used genetic model of colisi is the IL-10
-/-
 mouse.  
This mouse developes normally in utero, however, at approximately 4 weeks of age these mice 
exhibit weight loss and anemia, which coincides with the colonization of their intestines with 
bacteria, which is necessary for the development of colitis in  this model
105
.  Interestingly, when 
either IL-10
-/-
 or wild-type mice were exposed to intestinal bacteria, they exhibited increased NF-
κB signaling in the enterocytes of the intestine, however, as the IL-10-/- mice alone develop 
intestinal inflammation by seven weeks of age, which is defined by inflammatory infiltrations, 
villus atrophy, and ulceration.  It was origiannly observed that IL-10
-/-
 mice exhibit increased 
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NF-κB signal in the lamina propria as well as inflammatory cell populations including 
macrophages, dendritic cells, T-cells, and B-cells
107
. Thus, NF-κB inhibitors were evaluated in 
this model, specifically after it was observed that NF-κB DNA binding was increased in lamina 
propria macrophages derived from IL-10
-/-
 mice
108
.  In vivo administration of the NF-κB 
antisense oligonucleotide successfully treated established colitis in both chemical-induced and 
spontaneous occurring colitis of IL-10
-/-
 mice
109
, as shown by reduction in macroscopic and 
histological pathology of colitis 
108, 110, 111
.     
NF-κB is clearly implicated in the pathogenesis of IBD, but NF-κB activation is not 
entirely detrimental.  NF-κB is necessary to block invasion of pathogens; conditional deletion of 
NEMO or IKKα and β to the intestinal epithelium led to massive intestinal inflammation 
subsequent a loss of the eptheliums protective function 
112
 suggesting that NF-κB is protective 
and can prevent the onset of intestinal inflammation.  However, NF-κB activation in 
inflammatory cells can have a negative role by propagating inflammation once initiation of 
disease occurs.  
In addition to these murine studies, numerous IBD therapeutics used to treat human 
disease have been shown to inhibit NF-κB signaling.  Sulfasalazine, which is frequently used for 
treatment of Crohn’s disease and is currently used for ulcerative colitis. Sulfasalazine inhibits 
NF-κB by blocking IκBα degradation and inhibiting RelA phosphorylation113.  The former 
mainstay of IBD therapy, corticosteroids, have inhibitory effects on NF-κB by suppressing 
transcription through activation of histone deacetlyases
114
.  Even the most notable current IBD 
therapy, the TNFα antibodies, infliximab and adalimumab, referred to as disease modifying 
biologic therapies, target the NF-κB pathway by blocking one of its activating factors TNFα101.   
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It appears that increased NF-κB signaling, specifically in the immune compartment, 
myeloid and lymphoid cells, is a major component of the pathophysiology of IBD.  Furthermore, 
the majority of therapeutics used to treat IBD suppress NF-κB signaling.  Interestingly, genetic 
studies (discussed below) evaluating common gene variants associated with IBD, implicate 
genes involved in inflammatory signaling and specifically with NF-κB.  Overall, while NF-κB 
may have differential roles in disease development depending on cell type it appears that 
suppression of NF-κB may have beneficial effects in treating IBD. 
1.2.5 Genetics of IBD 
Crohn’s disease has been shown to have a higher concordance of disease in monozygotic 
twins than ulcerative colitis, suggesting a greater genetic component
115
.  Interestingly, in familial 
studies 80% of patients have the same disease type (Crohn’s disease or ulcerative colitis). 
However, in 20% of cases disease affecting multiple family members is mixed, suggesting that 
there is a combined genetic susceptibility for all IBD diseases
115
.   There are three major gene 
SNPs which are associated with Crohn’s disease including NOD2 (CARD15), TNFSF15, and 
IL23R.
115
  It has been shown that while NOD2 SNPs are associated with Crohn’s disease alone, 
SNPs of IL23R, IL12B, and STAT3 are associated with both ulcerative colitis and Crohn’s 
disease.  Importantly, the above genes are all involved in immune regulation suggesting a genetic 
component contributing to the dysregulation of the immune system.  There are also other genetic 
components associated with IBD that are not specifically inflammatory related genes including 
ATG16L1, IRGM, NKX2-3.  However, each has been shown to play a role in immunologic 
control of bacterial invasion or inflammatory signaling
87
.  These genes that are associated with 
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immune signaling are not only genetic predisposing factors, but may also contribute to 
pathology.   
NOD2 is a pattern recognition protein which leads to NF-κB activation.  A loss of 
function mutation in NOD2 appears to lead to overactive NF-κB signaling over time116.  IL-23 
and IL-12 are inflammatory cytokines from the same family, both of which lead to the activation 
of lymphocytes.  Using specific genetic models, IL-12 and IL-23 have been shown to contribute 
to IBD pathogenesis.  More recent evidence suggests IL-23 signaling is highly important in IBD, 
both in its role as a innate immune signaling factor as well as its role in differentiation and 
activation of the pro-inflammatory Th17 population
117
.  Furthermore, Stat3 is a downstream 
signaling component of the IL-23 pathway thus suggesting another important role for this 
inflammatory signaling pathway in pathogenesis of Crohn’s disease.  Interestingly, IL-23/Il-12 
production is transcriptionally regulated by NF-κB, specifically RelA, C-rel, and p50118. IL-23 
signaling can also activate NF-κB transcription via degradation of IκBα and allowing for IL-1 
production
119
.  Each component of genetic susceptibility, with regards to IBD, implicates the NF-
κB signaling pathway, further confirming that the NF-κB pathway is an appropriate target for 
therapeutic intervention. 
1.2.6 Evaluation of NF-κB in IBD 
The above data suggests that overactive NF-κB signaling has a causal role in IBD 
pathology, whether it is through initiation and or progression.  Current therapies for IBD are 
improving with the advent of biologics. Other therapies need to be developed due to the lack of 
efficacy of current therapies in a large fraction of patients as well their significant side effects. It 
will be imperative to further address the specific roles of NF-κB signaling in this disease to help 
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with the development of new therapies.  Additionally, the evaluation of NF-κB suppression in 
IBD will have potential therapeutic and mechanistic consequences to help tailor a more direct, 
targeted treatment for IBD patients.   
1.3 INFLAMMATION AND AGING 
Aging is usually defined as the advancement in chronologic age; however, aging is often 
characterized by the presence of aging-associated diseases, such as kyphosis, cachexia, 
sarcopenia, frailty and neurodegeneration.  Interestingly, the greatest risk factor for a wide 
variety of diseases is an increase in chronologic age.  The risk of cancer increases 10 fold for 
patients over 65 compared to those under 65
120
.  In fact the trend for many age-associated 
diseases including cardiovascular disease, neurodegeneration, diabetes, arthritis and osteoporosis 
is similar
121
.  Furthermore, there is to be an exponential increase in disease with a linear increase 
in chronologic age
120
 suggesting specific mechanisms are contributing to this change.  By 
determining what these mechanisms are and how they contribute to aging; in the future scientists 
and clinicians may be able to use systemic therapies to reduce several age-associated pathologies 
simultaneously.  The number of individuals over the age of 65 will double over the next 25 
years
122
, and the average age of our population is increasing.  In fact 27% of the 327 billion 
dollar Medicare budget in 2008 was spent on care in a patients last year of life
123
.  This reveals 
the tremendous burden that age-related diseases can have on our health care system and our 
national economy.  Therefore, understanding the mechanisms of aging and defining therapies to 
reduce this burden is of critical importance.     
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1.3.1 Stochastic Theory of Aging 
There are two predominant theories to explain why aging occurs, either through genetic 
contributions and/or time dependent damage events which lead to altered cellular function.  The 
theory of programmed genetic aging has recently fallen out of favor, but may have potential 
implications with regards to the aging process.  While aging is not likely the result of genetic 
programming, it may be in part attributed to a evolved trait that leads to a reduction in somatic 
maintenance after an animal reaches sexual maturation
121
.   
There may be some evolutionarily based gene and protein functions which contribute to 
the aging process.  For instance, the maximum age of mice bred in captivity is approximately 
three years of age; while in the wild, mice live an average of one year.  Thus an investment in 
gene expression that would block age-related changes at three years would not be selected for in 
the wild as compared to a gene that would allow mice to survive a cold harsh winter (the most 
common cause of death in wild-type mice)
121
.  For example, mice likely have evolved gene 
expression which allows for increased storage of fat deposits to allow them to surivive a cold 
winter, however, this same evolved fat storage trait may lead to an increase in fat storage which 
leads to increased cytokine secretion, reduced insulin.  Furthmore, if energy is diverted to energy 
and fat storage, then maintence of other cellular material and organelles such as mitochondira 
and DNA may suffer, thus leading to increased cellular damage and age-associated changes.  In 
whole this suggests that genes which promote young mouse survival but not aged survival are 
selected for during the evolutionary process.  Therefore it is likely that aging is not an evolved 
trait but possibly a byproduct the shortened lifespan and the perils of survival for animals in the 
wild.   
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The stochastic theory of aging, the foremost accepted theory of aging, states that 
endogenous and exogenous damage lead to breakdown of macromolecules and organelles, 
ultimately resulting in cellular and organismal senescence and aging
124
.  There are numerous 
hypotheses regarding the source of damage events which contribute to aging including, somatic 
mutations, mitochondrial/ROS, telomere shortening, and accumulation of waste, all of which 
likely contribute to stochastic aging as described by Kirkwood
121
, and are discussed in greater 
detail below. 
1.3.1.1 Somatic Theory of Aging 
The somatic theory of aging centers on damage to DNA.  Several lines of evidence 
support the hypothesis that DNA damage is the most important type of molecular damage that 
contributes to aging.  First, DNA lesions and genetic mutations caused by DNA damage 
accumulate in tissues of aged organisms 
125, 126
. Second, mice harboring germ-line mutations that 
confer resistance to genotoxic stress are long-lived
127,128
.  Third, the majority of human progerias 
(or syndromes of accelerated aging) are caused by inherited mutations in genes required for 
genome maintenance (described in 1.3.5)
129
. For example, deficiency of the DNA repair 
endonuclease ERCC1-XPF causes progeria
130
. Additionally, members within mammalian species 
with increased Poly(ADP-Ribose) polymerase levels, an integral member in stress response to 
DNA damage, have increased lifespans
131
.  Comparison of the transcriptome of DNA repair 
deficient mice and old wt mice revealed a highly significant correlation that was recapitulated in 
young wt mice exposed to genotoxic stress
130
.  Also mice exposed to long term low doses of 
irradiation develop phenotypes and gene expression profiles similar to that of normative aging 
animals.  These data suggest that accumulation of DNA damage is a major contributing factor to 
mammalian aging. 
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1.3.1.2 Mitochondrial Damage/ Reactive Oxygen Species (ROS) contribuation to Aging 
Mitochondrial damage and subsequent ROS production is thought to be the other major 
contributing factor to stochastic aging along with DNA damage.  Mitochondria, often defined as 
the energy center of the cell, are responsible for producing ATP using oxidative 
phosphorylation
132
.  Aged mitochondria in old and postmitotic cells, showed uncoupling 
demonstrated by a loss in mitochondrial membrane potential and accumulated damage of 
mitochondrial DNA (mtDNA)
133
.   Damage to mitochondria results in increased ROS 
production.  This increased ROS in the cytoplam negatively impacts the cellular environment by 
causing further damage mitochondria, other organelles, and resulting in DNA damage.  Depite 
numerous sources of ROS within the cell, nearly 90% of these can be traced to the 
mitochondria
132
.  Additionally, transgenic mouse with increased susceptibility to mtDNA 
damage, developed a shortened lifespan and symptoms of premature aging
134
.  In addition to 
mtDNA damage, loss of mitochondrial function induced aging is in part carried out by increased 
ROS production.  A murine model with reduced capability to degrade of H2O2 resuled in disease 
mimicing age-associated neural degeneration
135
.  Furthermore, cells with p21 and Ras mutations 
resulting in premature senescence, exhibited increased ROS production
136
, and mouse embryonic 
fibroblast (MEF) replicative senesecnce can be induced using 20% oxygen compared to 3% O2 
growth conditions
130, 137
.  Thus, damaged mitochondrial due to mtDNA damage and increased 
oxidative stress can advance the onset cellular senescence, and likely contribute to pathologies 
associated with aging.   
1.3.1.3 Shortening Telomeres Contribution to Aging 
Telomeres are evolutionarily conserved repeating DNA sequences meant to protect the 
ends of linear chromosomes from DNA damage responses
138
.  There is a loss of nearly 100-200 
 36 
base pairs per replication cycle
139, 140
, and this shortening may result in recognition of telomere 
ends as sites of damage by DNA repair machinery.  This DNA repair response to the 
chromosome ends can result in cell death or senescence.
138
  Additionally, exogenous expression 
of the catalytic subunit of telomerase in primary human cells led to their immortalization
141
; 
suggesting that telomerase plays an integral part in cellular senescence and aging.  However, 
there is no evidence that increased telomere length leads to reduced aging in vivo, in fact, 
nematodes with altered telomere length had no change in lifespans
142
.  Additionally, animals 
with significantly increased telomere length still undergo the aging process.  One prime example 
is mice which have longer telomeres than humans but live only for a maximum of 3 years.  
Therefore the length of telomers alone does not confer resistance to aging, but perhaps the 
maintenance is integral to reduce cellular senesense.  In support of this theory, recent studies 
suggest that oxidative and damage events may have a greater role in telomere shortening than 
replication
121, 143
.  Von Zglinicki et al. observed that fibroblasts have significantly increased rates 
of telomere shortening under conditions of oxidative stress and suggests that alkylation, UV 
exposure, and irradiation induced damage has the same effects
143
.  Thus, shortened telomeres, 
which may be responsible for replicative senescence, may contribute to aging secondary to 
stochastic damage. 
1.3.1.4 Altered Protiens and Waste Accumulation Theory of Aging 
The final contributer to the stochastic theory of aging is the accumulated waste and 
altered protein hypothesis.  Numerous diseases of aging are associated with accumulation of 
damaged proteins namely Parkinson’s, cataracts, and Alzheimer’s.  With aging there is a decline 
in the function of proteosomes and chaperones which alters waste removal and causes a build-up 
of proteins within cells
121
.  Related findings suggest that numerous deficiencies in cellular waste 
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disposal including proteases, DNA repair enzymes, autophagy, and lysosome activity increase 
with age
144
, likely secondary to damage events.  Therefore, as damaged macromolecules 
accumulate within a cell, a loss of cellular homeostasis can occur.  For example, an accumulation 
of mutated proteins or altered proteins such as amyloid in Alzheimer’s can contribute to cellular 
dysfunction or generating immune response leading to associated pathology.  Furthermore, when 
mitochondria age they become dysfunctional losing their membrane potential and increasing 
ROS production.  Due to decreased autophagy within the cells, these mitochondria persist and 
contribute to the increased intracellular damage
145
, leading to an increased loss of cellular 
homeostasis.   
1.3.1.5 Accumulated Damage and Composite Stochastic Theory of Aging 
While evidence supports each of the components of the stochastic theory of aging 
described above (somatic mutations, mitochondrial damage, telomere shortening, and altered 
waste disposal), it is likely they are inter-related components in the aging process.  Each 
stochastic event reinforces and contributes to the changes described by each of the damage 
hypotheses.  For example, damage to the mitochondria causes an increase in ROS production.  
As ROS levels increases inside the cell, this leads to a loss of homeostasis with increased 
damage to mitochondria other cellular components including DNA as well as contributing to 
more rapid telomere shortening.  Because the aging cell has reduced autophagic response these 
defective mitochondria cannot be degraded, and continue to produce the ROS.  Simultaneously, 
damaged mitochondria produce less ATP contributing to reduced protein production (possibly 
less proteosome, autophagic proteins, or DNA repair proteins), which subsequently results in  
reduced cellular repair and promotes further dysfunction within the cell.   
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A second example is endogenous DNA damage which passes to the daughter cells 
following cell division.  Dysfunctional proteins are created as a byproduct of this damage leading 
to an increased need for degradative processing.  This results in reduced capacity to repair 
additional cellular damage resulting in loss of homeostasis.  In each case, damage to individual 
cellular compartments triggers a cascade event contributing to the aging-cell phenotype. The 
stochastic theory of aging encompasses several theories of aging, each of which likely 
contributes to the overall aging phenotype.  In each case, damage is the root cause of aging seen 
at the cellular and organismal level.  In addition to the damage itself, it appears that the way the 
cell manages this damage response is integral to the aging process as a whole.   
1.3.2 Damage Response and Aging 
The most common cellular response to damage is repair, which results in normal cell 
function.  In the event that cellular damage remains unrepaired, cells either apoptose, senescence, 
or in rare instances transform into tumor cells.  The damage responses not including repair all 
results in alterations which affect cellular function and interaction with the surrounding 
environment.  Recent evidence suggests that the apoptosis and senescence response to damage is 
a mechanism by which cells reduce tumorigeneity; however these changes then contribute to the 
aging process
146
.  Replicative senescence is defined permanent cell growth arrest which results in 
altered cellular function.  Senescence is often described as aging at the cellular level and is 
characterized by an altered morphology such as, increased nuclear to cytoplasmic ratio, altered 
actin structure and a flattened sprawled appearance.  Senescent cells are distinguished by 
increased p16
ink4a 
and SA-β-galactosidase expression147.  Cellular senescence cab be accelerated 
by damage events such as DNA damage
130, 148
 or oxidative stress
149
.  Thus, previous studies on 
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the pathogenesis of aging have focused on damage and its contribution to the aging process.  
However, a growing area of interest is now examining not only these damage events but also the 
damage response and their subsequent effects on aging and age-related diseases.   
1.3.3 NF-κB as a component of stress response and aging 
Stress response pathways implicated in aging include IGF-1, mTOR, SIRT1, p53, and 
NF-κB150.  Of these, NF-κB, is of considerable interest, as it is a transcription factor has been 
implicated in both oxidative stress and DNA damage response pathways.  Additionally, Adler et 
al. defined  NF-κB as the transcription factor most associated with aging151.  NF-κB is 
traditionally thought of as a mediator of immune and inflammatory responses, but is also 
activated in response to many stress stimuli including genotoxic, oxidative, mechanical and other 
environmental insults that cause cell damage
4
. Specifically, DNA damaging resulting from UV 
rays, γ-irradiation, topoisomerase poisons and ROS activate NF-κB152, 153.  While NF-κB 
signaling is activated in conditions associated with aging, senescence, and age-associated 
changes, it is not known whether it plays a protectice or degenerative role. 
Overexpression of two NF-κB subunits, c-rel and RelA/p65, induced a senescent 
phenotype in cells
154-156
. In concert with these findings, evaluation of skin-derived human 
fibroblasts from aged individuals (aged 72-93), and HGPS progeria patients (8-14) showed 
increased levels of NF-κB activation when compared with cells derived from young individuals 
(aged 22-33 and 8-14 respectively)
151, 157
.  These cellular findings are further supported by 
studies that observed NF-κB upregulation with age in several tissues including skin, liver, 
kidney, cerebellum, cardiac muscle and gastric mucosa
158-163
.  Adler et al. first observed that 
genetice depletion of NF-κB in aged mouse skin reversed age-related pathology and gene 
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expression changes, suggesting a beneficial role for NF-κB inhibition in reversing age-related 
degeneration
151
.  Kawahara et al. then evaluated NF-κB in aging using the sirt6-/- mouse, which 
exhibits degenerative changes.  Experiments using haploinsufficient p65 (NF-κB subunit) 
background resulted in 40% of the sirt6
-/-
p65
+/-
 mice exhibit improved growth and longer 
lifespan than their sirt6
-/-
 littermates
164
.  While this provides some evidence of the role of NF-κB 
activation in aging, the sirt6
-/-
 mouse model exhibits a severe colitis phenotype, suggesting that 
these mice may have chronic colonic infection leading to NF-κB activation and more of a illness 
induced degeration rather than a true aging phenotype
165
.  Thus, further exploratory studies are 
necessary to elucidate the role of NF-κB inaging.  
One compentent contributing to increased NF-κB activity which occurs with aging is the 
altered transcriptional phenotype which occurs in senescent cells.  A recent article by Coppé et 
al. defined a specific senescent-associate secretory phenotype (SASP) in senescent cells.  SASP 
is a highly pro-inflammatory phenotype consisting of increased expression of IL-6, IL-8, IL-7, 
MCP-2, MIP-3, ICAM, Il-1α, and Il-β, and was observed in numerous senescent cell types 
induced by varying methods.  While senescence is initially a tumor-suppressive mechanism
166
 
there is likely numerous deleterious side effects of this anti-growth, pro-inflammatory senescent 
phenotype.  It is important to note that the vast majority of these SASP profile cytokines and 
chemokines are transcriptionally regulated by NF-κB167, again implicating this signaling 
pathway in aging on a cellular level. 
1.3.4 NF-κB in Age-Associated Disease 
Aging is widely considered a physiologic condition; however the majority of aging 
research focuses on age-associated diseases which are treated as pathologic conditions.  These 
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age-associated diseases include Alzheimer’s, Parkinson’s, type II diabetes, atherosclerosis, 
sarcopenia, and osteoporosis.  Therefore, aging which is defined by these diseases should be 
considered a treatable condition.  One features that these diseases share is an increased 
inflammatory state; specifically NF-κB signaling and cytokine secretion are upregulated in  
atherosclerosis
168
, osteoarthritis
169, neurodegeneration (Alzheimer’s and Parkinson’s)170, 
osteoporosis
171
, and cardiovascular disease
172
 as discussed below.   
1.3.4.1 Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common cause of age-associated dementia, and  is 
characterized by fibrillary tangles and β-amyloid plaques.173  AD affects only 0.6% of patients 
65-69 years of age, but increases with age to 8.4% of 85+ aged patients.  While the causes of AD 
remain poorly defined one common characteristic is the increased inflammatory state observed in 
patients suffering from AD.  While an overt inflammatory infiltration is not evident in AD, IL-1β 
and TNFα are present at increased levels in the brains of AD patients, both of which are NF-κB 
transcriptionally regulated cytokines.
173
   Murine studies have begun to confirm the role of 
cytokines including IL-6 an IL-1β in AD174, for example mice which underwent brain injections 
of IL-1α or β exhibited increased AD associated plaque formation175.   
A possible mechanism for this increase in cytokines seen in AD is via Aβ stimulation of 
NF-κB activity in microglia (brain monocytes)176.  Suppression of NF-κB in these microglia 
results in decreased neurotoxicity
177
, and evidence suggests that NF-κB regulatory elements lie 
upstream of the APP protein, which is necessary for plaque formation
178
.  The hypothesis that 
inflammation and NF-κB activation is the underlying cause of AD is further supported by 
observations that chronic LPS injections accelerate AD progression
179
 and patients with systemic 
infection exhibit increased rates of cognitive decline
180, 181
. Additional studies evaluating links 
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between inflammation and AD is reviewed in 
179
 and 
182. On the whole, the evidence suggesting 
that NF-κB plays a role in plaque formation is strong, but likely more important is the role of 
NF-κB, inflammation, and cytokine signaling in AD progression.   
1.3.4.2 Parkinson’s Disease 
Parkinson’s disease (PD) is a neurodegenerative disease that results in a movement 
disorder that is observed in patients over the age of 55 years
183
.  As with neurodegeneration seen 
in AD patients, there is a similar increase in inflammatory and cytokine signaling in Parkinson’s 
patients.  There is a 70 fold increase in p65 activation in dopaminergic neurons, the neurons 
which are central to disease pathology, from PD patients compared with age-matched controls
184
.  
TNFα a is increased in both brain tissue and CSF185 and further IL-1β, IL-2, IL-6 and other 
cytokines were shown to be increased in the CSF of Parkinson’s patients186.  Furthermore, 
microglia, the innate immune cells of the brain are highly active in PD and suppression of these 
cells in mouse models of PD result in reduced disease
183
.  Using MPP, a chemical compound 
known to induce a Parkinson like disease, neurons show upregulation of NF-κB signaling, which 
was necessary for cell death
187
.  The true role of NF-κB in causing neuronal cell death is still 
unknown, however it is likely that in both PD and AD, the chronic NF-κB activated 
inflammatory state act through primary or secondary mechanisms to contribute to neuronal cell 
death and progression of disease state
182, 188
. 
1.3.4.3 Type II Diabetes  
Type II Diabetes (T2D) or non insulin-dependent diabetes results is defined by insulin 
resistance, and is normally accompanied by numerous sequela or co-morbidities, dyslipidemia, 
hypertension, atherosclerosis, and central obesity, blindness, end-stage renal disease, and non-
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traumatic loss of limb
189
.  NF-κB/IKK has been implicated in obesity-induced insulin resistance 
and glucose metabolism via pharmacologic and genetic suppression
190
.  Upregulation of NF-κB 
signaling in hepatocytes results in a type II diabetes phenotype
191
.  It is further thought that 
innate immune activation and inflammatory response underlie Type II Diabetes (T2D) and its 
associated features
189
.  Macrophages or dendritic cells (DC) that reside in adipose tissue and 
secrete cytokines can contribute to insulin resistance and mediate disases progression
192
.  Novel 
data suggests that mice deficient in DC have reduced body mass and are not susceptible to Type 
II diabetes when placed on a high fat diet (private communication). As with AD, systemic 
inflammation and cytokine secretion likely play a significant role in the onset and progression of 
T2D.  IL-1β can induce β-cell cytotoxicity and inhibit β-cell function193.  Mice deficient in TNFα 
signaling have been shown to be resistant to obesity induced insulin resistance
194
.  Additionally, 
IL-6 as well as MCP-1, IL-1β and TNFα levels are found to be increased in T2D patients, 
however, the role of IL6 remains ill-defined
189
. Thus abherent NF-κB activation in numerous 
tissues including adipose, pancreas, and liver contribute to disease pathology observed in patients 
with T2D. 
1.3.4.4 Atherosclerosis 
Atherosclerosis is a disease of arterial wall thickening and plaque formation associated 
with increased age and is the leading cause of coronary artery disease.  Atherosclerosis is a 
disease resulting from a combination of endothelial, hematopoietic, T-cell and macrophage 
dysfunction. Atherosclerotic lesions have increased levels of NF-κB activity, specifically in 
unstable coronary plaques
195
.  In an LPS induced model of atherosclerosis, using apoE
-/-
 mice, 
genetic suppression of NF-κB signaling led to a reduction in the size of atherosclerotic lesions196.  
As with other diseases associated with aging, this NF-κB upregulation is accompanied by an 
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increase in cytokine release and inflammatory signaling.  A comprehensive review on the subject 
by Kleeman et al characterizes both the pro-atherogenic cytokines, IL-1, IL-12, IL-18, IFN-
gamma, TNF-alpha, and M-CSF as well as the anti-atherogenic cytokine, IL-10
197.  TNFα, both 
an inducer and target of NF-κB, was shown to increase ROS formation, increase apoptosis, and 
subsequently increase endothelial dysfunction in rat carotid arteries, mimicking changes seen in 
aging arteries
198
.  TNF blockade was further shown to have vasculoprotective effects
198
; thus 
adding addition support for the role of NF-κB activation as a negative regulator of aging 
associated atherosclerosis.   
1.3.4.5 Sarcopenia 
Sarcopenia, defined as the loss of skeletal muscle mass and strength, is highly correlated 
with advancing age
199
.  In hospitalized geriatric patients, those patients with increased 
inflammation, indicated by elevated CRP and IL-6, had a correlative decreased in grip strength, 
shoulder extension strength, and exhibited increased muscle fatigue
200
.  Furthermore, TNFα and 
IL-6 are inversely related to muscle mass and strength in elderly patients
201
.  While there is little 
research evaluating NF-κB activation in sarcopenia, numerous studies show a significant causal 
role for NF-κB activation in muscle atrophy.  Mice transgenic for active IKKβ, exhibit a muscle 
wasting phenotype
202
.  Muscle unloading, or loss of muscle innervation, led to an 8-fold increase 
in NF-κB signaling suggesting an integral role of NF-κB in muscle atrophy203, 204.  Additionally 
NF-κB was implicated in the pathology associated with muscular dystrophy (MDX model), a 
disease of muscle degeneration,   Specific suppression of NF-κB activity in macrophages 
reduced muscle degeneration, and systemic treatment of NBD, an NF-κB inhibitor, reduced 
pathologies associated with musclar dystrophy
73
.  As with T2D and other aging pathologies, NF-
κB acts in numerous cell types to contribute to disease pathology.   
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1.3.4.6 Osteoporosis 
Osteoporosis another age-associated pathology is defined by decreased bone density and 
increased fragility leading to bone breaks
205
.  It is known that inflammatory cytokines IL-6, 
TNFα, and IL-1205 signaling via NF-κB are activators of osteoclastogenesis and osteoclast 
function
206
.  As ostoclasts are responsible for bone resorbtion, the role of NF-κB in these cells 
cannot be underestimated.  Additionally, IL-6 levels are shown to be a positive predictor for 
decreased bone density, and TNFα levels were shown to be increased in patients with decreased 
vertebral bone density.  While it unknown whether these cytokines are markers or mediators of 
osteoporosic changes they implicate NF-κB and inflammation in this disease process207.  
Interestingly, patients with overactive inflammatory and NF-κB signaling exhibit increased risk 
of developing osteoporosis when suffering from diseases, including HIV infection, hyper-IgE 
syndrome, rheumatoid arthritis, myeloma, and inflammatory bowel disease
208
.  Recent findings 
also identified an important role for NF-κB in osteoblast function, mice transgenic for a DN-IKK 
expressed in osetoblasts had reduced bone loss after ovariectomy (12%) compared with wild-
type mice which exhibited 40% bone loss.  Thus it is likely, that as with many of these age-
associated disease, NF-κB acts through numerous mechanisms to promote osteoporotic 
degeneration
209
.   
 
1.3.5 Progeria and evaluating NF-κB in Age-Associated disease 
NF-κB is a main mediator or component in the majority of age-associated disease (as 
discussed above).  In each pathology described previously there are likely additional and 
possibly more important mediators of disease; however, NF-κB is one of the few factors which 
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have been implicated of the full spectrum of these age-associated diseases.  In some pathologies, 
NF-κB and inflammation may be the initiator of diseases, while in others NF-κB activation may 
promote disease progression secondary to events such as DNA damage, altered protein 
production, or oxidative stress.  While numerous groups have shown that specific NF-κB 
inhibition blocks disease pathology, what remains unknown is the effects of NF-κB suppression 
on cumulative aging seen in mammalian species, which will be explore in this disseration.   
While there are many studies which evaluate aging-related disease, aging in its own right 
is difficult to study.  Most of the current research in aging biology focuses on cellular aging by 
way of primary mouse embryonic fibroblasts (MEFs) or lower organism model systems such as 
C. elegans or Drosophilla which have lifespans of 2-3 weeks and 4-5 weeks respectively.  While 
these animals have an abundance of genes that have mammalian homologues, the systems have 
vast differences.  When evaluating mammalian models, the shortest lived, the mouse has a 
maximum lifespan of nearly 3 years, with variation dependent on strain. However, scientifically, 
this is still a lengthy period to evaluate specific gene involvement or therapeutic intervention 
associated with aging.  Using a natural phenomenon, known as progeria, or diseases of 
accelerated aging, one can study aging pathology over a compressed period of time.   
Progerias are often caused by single gene mutations, some of which will be discussed 
here, but result in children who appear normal at birth, but in early childhood begin to develop 
symptoms of accelerated aging.  Symptoms associated with progeria, as well as normative aging, 
include; visual and hearing impairment, liver and kidney dysfunction, impaired hematopoiesis, 
neurodegenerative changes, osteoporosis, cachexia, and sarcopenia.  There are numerous types 
of progeriod diseases defined in human populations including Hutchinson-Gilford Progeria 
syndrome (HGPS), Werner’s syndrome, Cockayne syndrome, Bloom syndrome, and Rothmund–
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Thomson syndrome.  All of these diseases have defects in DNA-repair pathways or deficiency in 
Lamin A/C
210
.  Werner’s, Bloom, and Rothmund-Thomas syndrome patients all have defects in 
the RecQ helicases which maintain genome stability
210
.  Werner’s syndrome, the most studied of 
these disorders, is developed secondary to a deficiency in RECQL2, which is involved in several 
DNA repair pathways including NER
211
 and double strand breaks
212
.  Patients with Werner’s 
syndrome have a mean lifespan of 47 years and normally succumb to cancer or heart disease.  
The only progerias thought to occur due to defects not specifically associated with DNA repair 
are those induced secondary to defective lamin such as HGPS.  Lamin A deficiency leads to 
abnormalities in the integrity and shape of the nuclear envelope, regulation of transcription, 
DNA replication, cell-cycle control and cellular differentiation
213
, However, recent studies 
observed that Lamin deficiency induced progeria exhibit a defective DNA damage response 
secondary to reduced recruitment of DNA-repair proteins
214
.  Accordingly, the majority of 
progerias and progeroid like diseases support the role of somatic damage in contributing to the 
aging process..   
As one would expect, the vast majority of murine models of progeria are based on human 
disease and thus have defects in DNA repair.   Some examples of progeria models include 
Werner’s like mice, HGPS like mice, and CS mice.  Interestingly, the wrn-/- mice, which 
recapitulate the human defect, do not have an aging phenotype unless crossed with a deletion in 
the telomerase gene.  These mice then develop numerous features associated with aging 
including, loss of hair, osteoporosis, diabetes mellitus and cataracts
213
.  Several murine models 
mimics HGPS, most with mutations in the lamin A gene, and thus exhibit several aging-
associated features including alopecia, skin defects, growth retardation, and osteoporosis
213
.  
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There are also several progeriod like models which result from direct defects in DNA repair, 
indcluding the Ercc1
-/-
 and Ercc1
-/∆ 
 mouse models.   
ERCC1 deficient mice have reduced expression of the DNA repair endonuclease, 
excision repair cross-complementing rodent repair deficiency, complementation group 1 
(ERCC1), which is the obligate binding partner of xeroderma pigmentosa group F (XPF).  Ercc1-
XPF is responsible for nucleotide excision repair of helix distorting lesions and is also 
responsible for double strand break, and interstrand crosslink-repair
215
 (Figure 7A).  Ercc1
-/- 
mice, which have undetectable levels of ERCC1-XPF, have a maximum lifespan of 1 month and 
pathologic and genome-wide transcriptional changes associated with natural or normative 
aging
130
. Ercc1
-/∆
 mice express 10% of the normal level of the ERCC1/XPF endonuclease and 
live for approximately 7 months. These mice age rapidly as a consequence of their DNA repair 
defect. Like the previously published Ercc1
-/-
 mice
130
, Ercc1
-/∆
 mice prematurely develop 
numerous signs and symptoms associated with old age, including trembling, ataxia, cerebral 
atrophy, renal acidosis, decreased liver function, hypoalbuminemia, bone marrow degeneration, 
osteoporosis, kyphosis, dystonia, muscle wasting, growth retardation, cachexia and loss of 
vision.  However, Ercc1
-/
 mice are asymptomatic until 8 weeks of age, offering a window of 
opportunity for therapeutic intervention. The phenotype is remarkably homogenous with all mice 
displaying an identical spectrum of symptoms in a highly predictable order. Ercc1
-/
 mice 
presenting with progressive signs associated with aging are shown in Figure 7B.  The Ercc1
-/∆
 
strain is an accurate and rapid model system for studying mammalian aging and the debilitating 
symptoms associated with human aging
216
 and will be used to evaluate the role of NF-κB 
transcriptional activity in aging. 
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Figure 7: Accelerated aging phenotype of the Ercc1
-/∆
 over its lifespan and associated phenotypic changes. (A) 
ERCC1-XPF is an endonucleas responsible for intrastrand crosslink, double strand break, and bulky adduct 
repair.  (B) These mice have a normal phenotype during the first 8 weeks of age.  At 14 weeks there is the 
beginning of reduced subcutaneous fat and early stages of sacropenia and kyphosis.  At 22 weeks these 
symptoms become more pronounced, with the addition, of urinary incontinence and abnormal posturing, 
indicative of ataxia.  At 25 weeks this mouse is exhibiting worsening symptoms in addition to matted fur, 
vision loss, and increasingly abnormal posturing.   
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1.3.6 Therapies Associated with Aging Pathology 
Recent studies have begun to evaluate the efficacy of novel pharmacologic or therapeutic 
strategies to ameliorate pathologies and phenotypic changes associated with aging.  Of these, 
caloric restriction (CR) as well as three therapeutics, SIRT1 activators, p38 inhibitors, and NF-
κB inhibition that have been evaluated for their effects on aging, will be examined here.  While 
these compounds have varying and often multiple mechanisms of action, one common feature is 
their regulation of inflammation and cytokine secretion.reFurthermore, inhibition of this pro-
inflammatory phenotype, mediated by stochastic damage and the SASP phenotype, may result in 
amelioration of age-associated degeneration. 
1.3.6.1 Caloric Restriction 
Caloric restriction (CR) is the most widely recognized and first reproducible mechanism 
by which life extension was mediated
217, 218
.  CR has been shown to not only extend longevity, 
but also ameliorate age-associated pathology including diabetes, cardiovascular disease, 
sarcopenia, as well as autoimmune diseases
218
.  While CR is efficacious in numerous mouse 
models and more recently in primates
219
, the beneficial effects have be attributed to numerous 
mechanisms, include activation of SIRT1 and PGC-1α, inhibition of Jnk, 
improvemedmmetabolism, alterationed IGF/GH axis
218, 220
, and suppression of the immune 
response
221
.  As stated previously, NF-κB is upregulated in aging, and CR inhibits this activity at 
the level of the IKK complex, possibly through a ROS dependent manner
221
.  Additionally, CR 
was shown to downregulate expression of 56 inflammatory genes many of which are 
transcriptionally regulated by NF-κB222. Even short term, 10 day CR, resulted in decreased NF-
κB activity in kidneys of aged mice223.  Therefore, CR a known mediator of improved life and 
 51 
healthspan acts, at least partially, via NF-κB and inflammatory suppression to impart its 
beneficial effects. 
1.3.6.2 SIRT Activators 
SIRT1 activators, such as resveratrol are considered cutting edge therapies for treating 
age-associated diseases.  Resveratrol has been shown to increase healthspan (delay the onset of 
age-associated diseases)
224
, protect against neurodegeneration in models of AD and amyotrophic 
lateral sclerosis (ALS)
225
, improve osteoporotic changes
226
, and reduce health defects occurring 
secondary to high fat diets
227
.   SIRT1 potentially acts via numerous mechanisms to alter age-
associated changes including increased mitocondriogenesis via PGC1α deacetylation, improved 
oxidative stress survival response via FOXO1/4, altered apoptosis and proliferation via p53 
deacetylation, and decreased inflammatory response via NF-κB suppression228.  Of specific 
interest to this disseration, is the mechanism by which SIRT promotes its anti-aging effects via 
inhibition of NF-κB.  SIRT1 directly interacts with p65, leading to deacetylation at lysine 310, 
culminating in decreased NF-κB associated transcription229.  While it is difficult to distinguish 
which beneficial effects of SIRT1 therapy are due to which specific mechanism of action, it is 
interesting to note the SIRT1 activators and NF-κB inhibitory therapies have been efficacious in 
the same disease pathologies as described above including diabetes, osteoporosis, 
neurodegeneration, and inflammatory diseases.   
1.3.6.3 p38/MAPK inhibitors 
Another therapeutic alternative for preventing progeria currently being examined is a 
p38/MAPK inhibitor.  Using cells derived from Werner’s syndrome progeria patients, p38 was 
observed to control activation of p21 and HSP27, two factors shown to be elevated in WS.  
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Furthermore, treatment with the p38 inhibitor allowed for a increased doubling speed in WS 
cells, which are inherently slow growing, as well as improved cellular morphology
148
.  In 
addition to NF-κB, p38 is a well known mediator of cytokine production, including IL-1, IL-6, 
IL-8, and TNFα, at both the transcriptional and post-transcriptional level.  Additionally, p38 
inhibition blocks cytokine production in T-cells, monocytes, and macrophages
230
.  P38/MAPK 
was shown to be up-regulated in a model of Alzheimer’s disease231, and inhibition of p38 in 
endothelial cells led to improved insulin sensitivity suggesting a role for p38 in Type II diabetes 
and cardiovascular disease
232
.  Thus, while the evidence of therapeutic relevance of p38 
suppression in ameliorating age-associated disease is less compelling that SIRT1, it contributes 
to the vast data which implicates inflammation and inflammatory signaling pathways in aging 
and age-associated disease. 
The overwhelming data suggests that there is a real and important link between 
inflammatory signaling pathways and age-associated disease onset and progression.  There are 
numerous correlative links between up-regulated of NF-κB signaling ing aged tissue and cells, as 
well as and age-associated disease.  Furthermore, evidence of the efficacy of anti-inflammatory 
agents as viable therapies for treatment of age-associated disease, suggests that NF-κB may have 
a causal role in overall aging.  In chapter 3 of this document, I intend to further explore the role 
of NF-κB signaling in a murine model of accelerated aging, to determine if this pathway has a 
causative role in age-associated disease and to further provide evidence of a common pathway by 
which age-associated diseases are manifested.  
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1.4 ANTIGEN PRESENTING CELLS AS MEDIATORS AND THERAPEUTIC 
TARGETS OF HUMAN DISEASE 
1.4.1 Professional Antigen presenting cells (APC) 
APC are central mediators of the innate and adaptive immune response.  APC directly 
recognize pathogens and generate a rapid immune response through the secretion of cytokines 
and chemokines.  They also act as the central communicators between the innate and adaptive 
immune system, by presenting antigen via MHC class II and co-stimulatory signals to T-cells, 
allowing for specific antigen responses.  Thus, APC, defined here as macrophages and dendritic 
cells (DC), are vastly important mediators of the innate and adaptive immune response.  B-cells 
are also recognized as APC due to their primary function in generate antigen specific and 
antibody responses will not be evaluated in this document.   
Macrophages are generated from monocytes, while DC are generated from monocytes, 
(Langerhans, dermal and inflammatory DC), as well as from specific pro-DC progenitor cells 
(plasmacytoid DC, interstitial DC and Resident CD8
+
 DC)
233
.    In general, monocytes arise from 
myeloid precursor cells and after differentiation they circulate through the blood stream for 
several days (constituting 5-10% of peripheral blood cells).  Monocytes then enter tissues where 
they further differentiate into DC or macrophage.   This process can be accelerated by the 
addition of pro-inflammatory or metabolic stimuli
234
.  In this study, we focus on monocyte 
derived macrophages and DC populations including: the FSDC cell line (which is a Langerhans 
like cell line
235
 and thus monocyte derived
233
), RAW264.7 (macrophage cell line), and  primary 
bone marrow derived macrophages and DC (BMDM, BMDC).  As these cells are the focus of 
this manuscript the DC described here will be the monocyte derived DC (MoDC) population.    
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1.4.2 Characterization of APC populations (inflammatory, regulatory, repair) 
Monocyte derived APC can be classified in many ways such as function. Three main 
APC functional groups exist, the classically activated APC, regulatory APC, and the wound 
healing macrophages.  APC are primarily thought of in terms of the classically activated APC, in 
macrophages these are referred to as M1 cells.  These activated APC are highly immunogenic 
and are induced by IFNγ, TNFα, TLR or other endogenous or exogenous stimuli, After 
activation these APC secrete TNFα, IL-1, IL-12/23, ROS 236, chemokines and upregulate MHC 
class II presentation and costimulatory molecules, all of which are integral in infection control
95
.   
The second APC subclass are may also be immunoregulatory or suppressive cells.  Often 
DC are regarded for their suppressive phenotypes, however, macrophages can also be induced to 
have immunoregulatory phenotype
237, 238
. Regulatory APC are induced by a variety of stimuli 
including apoptotic cells, prostaglandins, IL-10, and tumor cells
237, 239, 240
.  In addition myeloid 
DC and plasmacytoid DC have tolerogenic properties in their immature state
237
.  It is likely that 
these regulatory APC contribute to tolerance, such as oral tolerance
241
, and also protect against 
auto-immunity.  However, this regulatory phenotype can be exploited by pathogens as well as 
tumor cells
242
.  Important mechanisms of suppressor APC include: induction of T-cell anergy or 
Treg phenotype switches, expression of indolamine 2,3, dioxygenase and heme ogenase-1, or 
secretion of the anti-inflammatory cytokines IL-10 and TGF-β237.   
The third APC/macrophage type is the wound healing class, or alternatively activated 
macrophages, which are activated by IL-4. These macrophages secrete numerous components of 
the extracellular matrix and express chitenase, which likely contributes to their role in wound 
healing
236
. However, it is important to remember that due to the high degree of plasticity of APC, 
a single macrophage can change classes depending on the exogenous and endogenous stimuli
243
.   
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MoDC and Macrophages act as innate immune phagocytes, secrete cytokines, and are the 
major source of interaction between the innate and adaptive immune system.  Macrophages are 
defined by their phagocytic and cytokine secretion properties, and their ability to present antigen 
to effector T cells
238, 244-246
.  On the other hand, DC are the only antigen presenting cell capable 
of priming native T cells as well as cross presenting antigen to CD8 T-cells
247
.  Like 
macrophages, DC secrete cytokines such as TNFα, IL-1, IL-12 and IL-6 and generate 
inflammatory responses
248
.  Interestingly, recent studies observed that under specific conditions 
macrophages can prime naïve T-cells.
249, 250
  Overall, there is a high degree of similarity in the 
functions and signaling mechanisms of MoDC and macrophages.   
MoDC and macrophages can be further characterized by their tissue specificity, and 
secondarily these APC have varying attributes which are dependent on the necessity of that 
tissue.  These APC are defined as follows: alveolar (lung macrophage), Langerhans and dermal 
(epidermis/skin MoDC), osteoclasts (bone monocyte), microglial (central nervous system 
macrophage), Kuppfer cells (Liver macrophage), splenic macrophage, and inflammatory-induced 
macrophages (derived from peripheral monocytes at the site of infection)
234
.  As discussed 
previously, intestinal macrophage and DC are highly immunosuppressive, with limited ability to 
activate T-cells.  Furthermore, they contribute to oral tolerance, whereby antigens consumed 
orally will have a muted response when injected systemically
241
.  Osteoclasts are less 
inflammatory in nature and are responsible for bone breakdown and turnover to maintain bone 
strength and fidelity
251
.  On the other hand, inflammatory-induced macrophages, which are 
activated secondary to stimuli, quickly become central to the inflammatory process, secreting 
cytokines and chemokines and presenting antigen to adaptive immune cells.   Therefore while 
 56 
APC are highly heterogenous, these cells are highly plastic and thus each macrophage subclass 
has the potential to prevent disease and infection or contribute to disease pathology. 
1.4.3 Activation Receptors on APC 
APC express numerous receptors which facilitate phagocytosis, and lead to activation, 
and proliferation.  Scavenger receptors, complement receptors, and Fc Receptors allow for 
phagocytosis of pathogens, cellular debris, and apoptotic cells.  In addition, macrophages express 
pattern recognition receptors (PRR) such as Toll like receptors (TLR) which contribute to 
phagocytosis as well as promote activation and cytokine signaling.  APC also express cytokine 
receptors such as TNF, IL-1β, IFN, and IL-4 which can lead to activation, contribute to immune 
deviation, as well as lead to the production of cytokines
95
.  Many of these processes are regulated 
by NF-κB and described in more detail in Sections 1.1.3 and 1.1.7.   
1.4.4 Role of NF-κB Signaling in Macrophages 
1.4.4.1 NF-κB and APC Differentiation: 
Numerous transcription factors which play a significant role in APC activation and 
differentiation.  In vitro derivation of BMDM requires GM-CSF for differentiation, while BMDC 
require GM-CSF with the addition of IL-4.  GM-CSF activates Akt, Erk, and Jnk via the Ras 
pathway
252
 downstream of the common β chain of the GM-CSF receptor, however, the α chain 
activates the NF-κB pathway via direct interaction with IKKβ253.  IL-4 is thought to act mainly 
via Stat6 signaling but reports have shown IL-4 also activates via NF-κB254.  When examining 
the highly differentiated bone macrophage or osteoclasts; NF-κB has a definitive role in terminal 
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differentiation of osteoclasts from monocyte precursors via activation by RANK, without which 
mice do not develop osteoclasts, and TNFSF11
251
.  Thus, NF-κB plays an integral role in 
differentiation.  
1.4.4.2 Role of NF-κB in APC Function 
There is vast evidence that NF-κB plays a role in activation and the functions of 
inflammatory APC, in addition to its role in differentiation.  The activation signals for 
macrophages included IFNγ, which signals via Stat, as well as TLR, IL-1, TNFα, and CD40255 
all of which signal via NF-κB (as described in section 1.1.3 -1.1.6).  Furthermore, the two major 
roles of APC are antigen presentation/co-stimulation and cytokine/chemokine secretion, both of 
which are regulated by NF-κB.   
The antigen presentation functions of APC center on the MHC class II complex as is 
described in Janeway
95
.  Briefly, antigen is phagocytosed by the APC and processed in the 
endosome, and after proteosomal degradation antigen is loaded onto the MHC class II molecule 
which is then presented on the cell surface.  For proper APC:T-cell interaction, the interaction 
requires signal I (the MHCII:TCR interaction), signal II (interaction of costimulatory molecules, 
on the APC such as CD80/CD81, CD40, and 4-IBBL)
95
, and signal 3, (cytokine signaling).  
Recent evidence suggests that MHC class II surface expression is NF-κB dependent, and NF-κB 
transcriptionally regules the invariant chain, which has a role in MHC class II antigen loading
256
.  
Furthermore, NF-κB regulates the expression of CD80 and CD40, two costimulatory ligands 
required for T-cell/B-cell activation.  NF-κB transcription is necessary for the production of 
many pro-inflammatory cytokines secreted by APC including TNF, IL-1, IL-12 (Th1 promoting 
cytokines), IL-1, IL-6, and IL-23 (Th17 promoting cytokines)
4, 257
.  Thus NF-κB controls 
APC:T-cell interaction by regulating elements of signal 1, 2, and 3. 
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Additionally, inflammatory APC secrete a multitude of chemokines to attract immune 
cells.  CCL15 attracts monocytes as well as lymphocytes and eosinophils, CCL20 attracts DC 
and T-cells, and CXCL10 and 11 attracts NK and T-cells via CXCR3 signaling
236
.  Each of these 
chemokines is transcriptionally regulated by NF-κB. Thus, NF-κB is a central mediator of APC 
development, maturation, and function, that defines NF-κB as an important therapeutic target to 
explore when evaluating diseases with dysregulated immune and APC responses.     
1.4.5 APC role in Human Disease and Aging 
Macrophage over-activation has been noted in number of diseases including rheumatoid 
arthritis
251
, atherosclerosis
190, neurodegeneration (Alzheimer’s and Parkinson’s)176, 183, liver 
disease
258
, metabolic syndrome (including obesity, hypercholesterolemia, and diabetes)
259
 and 
osteoporosis
260
.  Many of these diseases have inflammatory and NF-κB components and are 
associated with aging (described in detail in section 1.3.4).  Each disease shares components of 
APC activation, cytokine upregulation, and NF-κB dysregulation.   
One specific example of APC involvement in disease pathogenesis is in the 
manifestations associated with IBD.  As expected, patients with untreated ulcerative colitis and 
Crohn’s disease have increased number of activated CD40+ macrophages isolated from their 
intesteines
261,262
.  Intestinal macrophages derived from IBD patients differ from those derived 
from control patients in that they express higher levels of CD14 (a component of LPS receptor 
TLR4), and a portion of these macrophages are RFD9+ and are more likely to form 
granulomas
263
.  Further, macrophages and myeloid derived DC are integral in granuloma 
formation
264
.  Interestingly, mice with macrophages and neutrophils deficient for Stat3, a 
signlaing mechanism for IL-10, develop a colitis phenotype
265
, suggesting an important role for 
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APC in disease. IL-12 and Il-23, pro-inflammatory cytokines, have been shown to be an 
important player in the development of IBD
117, 266
.  While IL-23 is often thought of as an inducer 
of Th17 T-cells, IL-23 it has been shown to mediate IBD in the absence of T-cells
117
.  
Additionally, the most efficacious therapy for IBD is currently anti-TNF biologic therapy.  Thus, 
as the cytokines produced by APC, TNF, IL-12, and IL-23, are major mediators of IBD, this 
suggests that APC are appropriate therapeutic targets for the treatment of IBD.   Furthermore, it 
is likely that the other diseases with implicated APC and NF-κB dysregulation would respond to 
these targeted therapies as well. 
1.5 HOW NF-KB SUPPRESSION TO CONTROL MAMMALIAN DISEASE WILL 
BE EVALUATED IN THIS MANUSCRIPT 
In the case of numerous human diseases the role of dysregulated NF-κB signaling is well 
defined.  In this work, I will evaluate the role of NF-κB signaling in two different pathologic 
human conditions.  The first disease investigated is IBD.  While the role of NF-κB has been 
defined in this disease over a number of years, there are still numerous questions to answer 
regarding inhibition of NF-κB as a therapeutic strategy to ameliorate disease.  In this study, we 
will examine NF-κB regulation in IL-10-/- murine model of colitis78.  Recently, there have been 
reports that loss of NF-κB and specifically IKK in IEC results in a barrier dysfunction induced 
colitis.  Thus, it likely that IKK/NF-κB signaling plays both protective and facilitative role in the 
pathology of IBD.   Despite these possible differences in the role of IKK/NF-κB in colitis 
pathogenesis, we have chosen to use the NBD peptide to evaluate its affects on disease in the IL-
10
-/-
 model.  In this study, the transduction and functional efficacy of the NBD peptide was 
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examined in vitro as well as in vivo.  Furthermore, the role of NF-κB in potentiation of disease 
was explored by suppressing this pathway after the onset of disease by treating diseased mice at 
10-12 weeks of age.  Mice were evaluated for histopathologic changes, as well as cytokine 
secretion profiles of gut extracts.  This study allows for testing the proof-of-concept, that NF-κB 
inhibition secondary to NBD treatment is a viable in vivo mechanism for treating inflammatory 
disease states. 
In the second chapter of this thesis, I will explore the role of NF-κB signaling in diseases 
associated with accelerated aging using the Ercc1
-/-
 and Ercc1
-/∆
 progeroid like models (discussed 
1.3.5).  While NF-κB dysregulation is associated with many age-associated diseases, there has 
been only one group to examine treatment with NF-κB inhibitors/suppressors with regards to 
overall age-associated changes.  Here we explore the role of NF-κB in overall aging as a possible 
central mediator in the aging process which contributes to the pathology of a number of age-
associated diseases.  Furthermore, the transcriptional changes associated with this NF-κB 
suppression in this accelerated aging model were evaluated.  Interestingly NF-κB suppression via 
pharmacologic (NBD) and genetic means (p65 allelic deletion) slowed the progression of 
numerous phenotypic changes; these alterations in phenotype were further supported by 
amelioration of histologic degeneration and transcriptional changes associated with normative 
and ERCC1 defcient aging. 
It is likely that there are many mechanisms by which NF-κB dysregulation could 
potentially play a role in inflammatory and age-related diseases.  This includes alterations in 
hormone responses, altered action and survival of stem and progenitor cells, as well as alterations 
of immune responses such as T-cell suppression, reduced cytokine and anti-body production and 
APC suppression.  Due to the documented role of APC in inflammatory and age-associated 
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diseases as described 1.4.5, as well as the fact that these diseases have increased levels of 
inflammatory cytokines (TNFα, IL-1β, IL-6, IL-12, and IL-23) which are known to be produced 
by APC, I wanted to explore the effects of NF-κB suppression in this cell type.  We hypothesized 
that suppression of NF-κB signaling in APC would lead to a reduced inflammatory state with a 
decrease in inflammatory cytokines production, decreased co-stimulatory molecule presentation, 
and lack of T-cell stimulation or possible T-regulatory cell differentiation.  However, in vitro we 
observed that in response to NF-κB suppression APC, both macrophage and DC underwent 
apoptotic cell death.  While a surprising finding, it is a possible mechanism which can explain 
the amelioration of inflammatory and age-associated disease states and could further explain how 
inhibitors which have limited half-lives in vivo can have such long-lasting effects in murine 
models of disease.   
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2.0  AMELIORATION OF CHRONIC MURINE COLITIS BY PEPTIDE MEDIATED 
TRANSDUCTION OF THE IΚB KINASE (IKK) INHIBITOR NEMO BINDING 
DOMAIN (NBD) PEPTIDE 
2.1 ABSTRACT 
The NF-κB family of transcription factors is a central regulator of chronic inflammation.  
The phosphorylation of IκB proteins by the IκB kinase (IKK) complex (IKKα, IKKβ, and NF-κB 
essential modulator, or NEMO) is a key step in NF-κB activation.  Peptides corresponding to 
IKK’s NEMO binding domain (NBD) block NF-κB activation without inhibiting basal NF-κB 
activity.  In this report, we determined the effects of the IKK inhibitor peptide (NBD) in a model 
of spontaneously occurring, chronic murine colitis, the IL-10-deficient (IL-10
-/-
) mouse.  
Utilizing a novel cationic peptide transduction domain (PTD) consisting of eight lysine residues 
(8K), we were able to transduce the NBD peptide into cells and tissues.  In a NF-κB reporter 
system, 8K-NBD dose-dependently inhibits TNF-induced NF-κB activation.  Furthermore, 8K-
NBD inhibited nuclear translocation of NF-κB family members.  In NF-κBEGFP knock-in mice, 
8K-NBD inhibited LPS-activated NF-κB in the ileum, but did not inhibit basal NF-κB in Peyer’s 
patches. IL-10
-/-
 mice treated systemically with 8K-NBD demonstrate amelioration of established 
colitis, decreased NF-κB activation in the lamina propria, and a reduction in spontaneous 
intestinal IL-12 p40, TNF, interferon-γ, and IL-17 production.  These results demonstrate that 
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inhibitors of IKK, in particular a PTD-NBD peptide, may be therapeutic in the treatment of 
inflammatory bowel disease (IBD) 
 
2.2 INTRODUCTION 
While the etiology of the human chronic inflammatory bowel diseases (IBD), Crohn’s 
disease (CD) and ulcerative colitis (UC), remains unknown, research has identified contributing 
factors that include defects in the barrier mechanism of the lining intestinal epithelial cells 
(IECs), and a poorly regulated immune response against the normal enteric microbial flora.   
NF-κB represents a group of structurally related proteins that includes five members in 
mammals (p65, c-Rel, Rel-B, p50, and p52). NF-κB is a central regulator of chronic 
inflammation in IBD 
102, 106, 267
.  Many of the standard agents used to treat human IBD, including 
sulfasalazine, 5-aminosalicylates, and corticosteroids, have been postulated to exert some of their 
anti-inflammatory effects through NF-κB inhibition268-270.   In unstimulated cells, NF-κB 
proteins are localized in the cytoplasm through their association with members of a family of 
inhibitory proteins known as IκB proteins.  Pro-inflammatory cytokines such as TNF and IL-1, 
and bacterial products such as lipopolysaccharide (LPS) induce phosphorylation of IκB proteins 
at specific N-terminal serine residues. Phosphorylation of IκB is mediated by the IκB kinase 
(IKK) complex. IκB phosphorylation leads to IκB degradation, release of NF-κB subunits, and 
their subsequent translocation to the nucleus.  Nuclear NF-κB regulates transcription of 
proinflammatory genes including cytokines (IL-1β, TNF, IL-12/23), chemokines (IL-8, MIP-1α, 
MCP-1), and adhesion molecules (ICAM-1, VCAM, E-selectin). Cytokines that are stimulated 
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by NF-κB such as IL-1β and TNF, also directly activate NF-κB, thus establishing an auto-
regulatory loop that may be essential in the perpetuation of chronic inflammation 
15
.  
IKK is made up of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit 
named “NF-κB essential modulator” (NEMO; also named IKKγ) 271.  An N-terminal region of 
NEMO associates with a hexapeptide sequence within the C-terminus of both IKKα and IKKβ, 
named the NEMO binding domain (NBD).  A short peptide derived from the 735-745 amino acid 
NBD region of IKKβ disrupts the association of NEMO with IKKs in vitro and blocks TNF 
induced NF-κB activation in vivo when delivered to cells using a cationic protein transduction 
domain (PTD).  Because of the importance of the IKK complex in inflammation, the 
identification of such a selective IKK inhibitor as a potential therapeutic agent is of considerable 
interest.  
PTDs have been shown to deliver a wide variety of therapeutic agents into cells including 
peptides, proteins, nucleic acids, antibodies and small drugs.  The first protein reported with 
transductional properties was the HIV transactivator protein, TAT, in which the 11 amino acid 
PTD was identified by virtue of its cationic content 
44
.  Recently, PTDs have been characterized 
that mediate efficient and rapid receptor-independent internalization of peptide-protein 
conjugates 
272
.  These cationic transduction peptides transduce a wide variety of cells similar to 
the HIV TAT, mediating highly efficient transduction in vitro and in vivo 
45, 54
.  Screening of a 
panel of cationic peptides has demonstrated that peptides of 8 or 10 lysines are highly efficient 
transduction domains, working as, or more, effectively than other cationic PTDs for delivery of 
peptides to numerous cell types, including mucosal cells and antigen presenting cells 
54
. 
PTD-mediated NBD delivery is efficacious therapeutic in models of autoimmunity and 
inflammation including models of multiple sclerosis 
75
, islet transplantation
273
 and rheumatoid 
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arthritis 
71
.  Accordingly, we postulated that a novel cell permeable peptide IKK inhibitor, 8K-
NBD may efficiently target cells involved in the intestinal inflammatory response.  In this report, 
we show that 8K-NBD dose-dependently inhibits TNF-induced NF-κB activation and 
translocation in cells. Furthermore, in vivo, 8K-NBD inhibits activated but not basal NF-κB in 
the intestine.  Moreover, we demonstrate that treatment of IL-10-deficient (IL-10
-/-
) mice with 
8K-NBD ameliorates chronic colitis in vivo. 
2.3 MATERIALS AND METHODS 
2.3.1 Peptide  synthesis 
Peptides 8K-NBD (acetyl-KKKKKKKKGGTALDWSWLQTE-amide), inactive mutant, 
8K-mNBD (acetyl-KKKKKKKKGGTALDASALQTE-amide), random-NBD 
(ARPLEHGSDKAT-GGTALDWSWLQTE), 8K-biotin (KKKKKKKK-biotin), and random 
peptide-biotin (ARPLEHGSDKAT-biotin) were synthesized by the peptide synthesis facility at 
the University of Pittsburgh.  The random-NBD and 8K-NBD peptides N-terminal ends were 
conjugated to 6-carboxyfluorescein (6CF, Molecular Probes) for localization experiments.  
Peptides were purified and characterized by reversed-phase
 
high performance liquid 
chromatography and mass spectrometry.  
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2.3.2 Murine macrophages   
The murine macrophage cell line, RAW264.7, was maintained in DMEM/10% FBS/1% 
Pen/Strep.  Bone marrow (BM)-derived murine macrophages were isolated from femurs of 
C57BL/6 mice.  BM was flushed with washing medium (RPMI1640 with 1% Pen/Strep), passed 
through a 70 μm nylon cell strainer into a 50 ml conical tube, and spun down at 1500 rpm for 5 
minutes.  RBCs were lysed using sterile-filtered 0.8% ammonium chloride, washed twice with 
washing medium, and resuspended in complete medium (washing medium with 10% FBS).  BM 
cells were seeded in complete medium in a 150 mm dish and differentiated using recombinant 
murine GM-CSF (20 ng/ml) (R&D Systems).  At day three, another 25 ml fresh culture medium 
containing GM-CSF was added to the culture plates.  At day seven, the cells, representing the 
BM-derived macrophage population, were harvested for experiments. 
2.3.3 NF-κB Luciferase assay   
HEK293 cells stably transfected with a multimerized NF-κB DNA binding element-
luciferase reporter (DMEM/10% FBS/1% Pen/Strep) were pretreated for one hour with 8K-NBD 
dissolved in OptiMEM media (Invitrogen) and activated for two hours with 10 ng/ml TNF (R&D 
Systems).  The cells were lysed in reporter lysis buffer and luciferase activity was measured with 
a luciferase assay system (Promega) using a Turner Designs Luminometer TD20/20. 
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2.3.4 Nuclear extracts and Western blotting   
HEK293 cells were pretreated for one hour with media, 8K-NBD, or 8K-mNBD 
dissolved in OptiMEM media (Invitrogen) and activated for 15 minutes with 10 ng/ml TNF 
(R&D Systems).  Nuclear extracts from treated HEK293 cells were isolated following 
manufacturer’s protocol (NE/PER Reagents, Pierce).  Protein concentration was determined 
using the Bradford assay (Pierce).  Western blot analyses were performed on nuclear extracts as 
described previously 
274
.  Anti-p65 and anti-c-Rel antibodies were obtained from Santa Cruz 
Biotechnology, Inc., and anti-PARP and anti-phospho-p65 (p-p65) antibodies were obtained 
from Cell Signaling. 
2.3.5 Mice   
Male C57BL/6 (10-12 weeks old) and female BALB/c (12-13 weeks old) mice were 
obtained from The Jackson Laboratory.  An IL-10
-/-
 colony on a C57BL/6 background (breeder 
pairs from The Jackson Laboratory) was maintained in accordance with guidelines from the 
American Association for Laboratory Animal Care and Research Protocols and was approved by 
the Institutional Animal Care and Use Committee at the University of Pittsburgh School of 
Medicine. The NF-κBEGFP knock-in mice (129/SvEv/C57BL6 background) were described 
previously
107, 275
. Expression of enhanced GFP (EGFP) is controlled by a chimeric promoter 
containing three HIV NF-κB cis elements in these mice. Mice were maintained in specific 
pathogen free conditions. Research Protocols were approved by the Institutional Animal Care 
and Use Committee at the University of North Carolina School of Medicine. 
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2.3.6 In vivo PTD transduction   
C57BL/6 or BALB/c mice were grouped randomly and treated intraperitoneally with 
biotinylated peptides (random or 8K) linked to streptavidin-Cy3.  After 30 minutes of treatment, 
organs were harvested, fixed in 2% paraformaldehyde, and then incubated in 30% sucrose in 
PBS at 4°C overnight.  Samples were snap-frozen in isopentane and cut into 6 μm-thick frozen 
sections and placed on microscope slides.  
2.3.7 Immunohistochemistry 
After transduced macrophages or cut tissue sections were placed on coverslips, slides 
were blocked in BSA and stained for nuclei with either Draq5 (Biostatus Limited, Leicestershire, 
United Kingdom) or Propidium Iodide (PI, Molecular Probes), for 30 min.  Phalloidin was used 
to visualize F-actin (Molecular Probes).  After extensive washing, slides were mounted and 
viewed on an Olympus Flowview 1000 confocal microscope (Olympus America, Melville, NY). 
Colonic tissue was collected from control and treated animals, fixed overnight in 
paraformaldehyde, embedded in paraffin and sectioned at 4 mm.  Serial sections were stained for 
phosphorylated NF-κB p65 (phospho-p65).  Following deparaffinization and rehydration, 
antigen unmasking was performed using Citra Plus Antigen Retrieval (Biogenex Laboratories) 
per manufacturer’s protocol. Slides were cooled, washed and endogenous peroxidase was 
blocked using 0.3% hydrogen peroxide.  Sections were next blocked with 1.5% goat serum 
(Vector Laboratories, Burlingame, CA) in PBS for 1 hour, incubated with rabbit anti-phospho-
NF-κB p65 polycolonal antibody at a 1:50 dilution (Cell Signaling) in PBS at 4oC overnight in a 
humidified chamber.  Slides were washed with PBS, and incubated with biotinylated goat anti-
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rabbit secondary antibody (Vector laboratories) for 45 minutes, slides were washed with PBS 
and Vectastain Elite ABC reagent was applied for 30 minutes. Slides were washed with PBS and 
diaminobenzene (Vector Laboratories) was utilized as a substrate.  Sections were counterstained 
hematoxylin, dehydrated and mounted on coverslips.  Stained sections were evaluated by an 
observer blinded to treatment group for phospho-p65.  Phospho-p65-positive cells were counted 
from 20 randomly selected high power fields in coded colonic sections to that the observers were 
blinded to treatment group. Cells were enumerated from 6 mice/group (mutant NBD, 2 mg/kg 
NBD, 10 mg/kg NBD treated) and results are expressed as number of positive cells per field.       
2.3.8 In vivo NBD peptide treatment   
10-week old IL-10
-/-
 mice were grouped randomly and treated with either mutant (10 
mg/kg) or wild-type (2 or 10 mg/kg) NBD peptide linked to 8K.  Treatment was administered in 
PBS in a total volume of 500 μl intraperitoneally for 10 out of 14 days.  At the end of the study 
period, animals were euthanized using excess CO2 inhalation and intestinal tissue was harvested. 
NF-κBEGFP knock-in mice were pretreated with 8K-NBD or 8K-mutant NBD peptide (10 mg/kg) 
one hour prior to LPS injection. LPS (5 mg/kg) or PBS was administered intraperitoneally to the 
mice (2 mice per treatment group). Sixteen hours later, the mice were sacrificed by excess CO2 
inhalation and dissected. 
2.3.9 Intestinal tissue explant cultures   
Colons were isolated from individual mice, cut open longitudinally, and cleaned of fecal 
matter.  The intestinal tissue was washed with PBS to remove residual fecal content.  Intestinal 
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sections were cut in half longitudinally, and one half was shaken at 250 rpm at room temperature 
for 30 min in RPMI 1640 supplemented with 1% antibiotic/antimycotic.  Tissue fragments (0.05 
g dry weight) were incubated in 1 ml RPMI supplemented with 1% antibiotic/antimycotic and 
10% FBS.  Supernatants were collected after 24 hours, assayed for spontaneous cytokine 
production via sandwich ELISAs, and normalized to dry gut weight. 
2.3.10 Histology   
Colons were isolated from individual mice, cut open longitudinally, and cleaned of fecal 
matter.  Intestinal sections were cut in half longitudinally, and one half was fixed in 10% 
buffered formalin and embedded in paraffin.  5 μm thick sections were stained with hematoxylin 
and eosin.  Colitis scores (0-4) were determined by a staff pathologist using the criteria reported 
by Berg et al. 
276
.  At least 20 separate microscopic fields (10×) were evaluated for each mouse 
by a pathologist (Dr. Antonia R. Sepulveda, University of Pittsburgh) blinded to the treatment 
groups. 
2.3.11 EGFP imaging  
Intestines removed from NF-κBEGFP knock-in mice were immediately imaged after 
dissection using a charge-coupled device camera in a light-tight imaging box with a dual filtered 
light source and emission filters specific for EGFP (LT-99D2 Illumatools; Lightools Research). 
For confocal microscopy on intestinal tissue, terminal ileums were cut open longitudinally and 
placed on the stage of a Leica SP2 Upright Laser Scanning Confocal Microscope (Leica) lumen 
side facing the lens without further processing or fixation. EGFP was excited at 495 nm 
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wavelength, and images were acquired using detection filters specific for the EGFP emission 
spectrum. Images were analyzed with the Leica SP2 Laser Scanning Confocal Imaging Software 
(Leica). 
2.3.12 Cytokine ELISAs   
Murine IL-12 p40, TNF, interferon (IFN-γ) -17 (R and D 
Systems) immunoassay kits were used according to the manufacturer’s instructions.  Values 
were measured using a plate reader and the SOFTMax Pro v4.8 software (Molecular Devices). 
2.3.13 Statistical Analysis   
Statistical significance in cell based experiments (Figure 9) was assessed by the two-
tailed Student’s t test.  Statistical significance from in vivo intervention experiments (Figures 13, 
14 and 15) was assessed by the Mann-Whitney U Test (SPSS).  A p-value equal or less than 0.05 
was considered to be statistically significant. 
2.4 RESULTS 
2.4.1 Transduction of 8K PTD peptide into macrophages   
As previously reported 
54
, a panel of cationic protein transduction domains were screened 
for their ability to efficiently transduce a variety of cell types.  Eight to 10 amino acid polylysine 
tracts have been shown to efficiently transduce a wide array of cell lines and primary cells, 
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including islet β-cells, synovial cells, polarized airway epithelial cells, tumor cells, and dendritic 
cells (DC) 
54
.  To assess transduction of the 8K PTD into a relevant immunologic target cell, 
murine BM-derived macrophages were incubated with biotinylated 8K PTD linked to 
streptavidin-Cy3 and the murine macrophage cell line RAW264.7 was incubated with 8K PTD 
conjugated to the fluorescent label 6-carboxyfluorescein (6CF).  Murine macrophages were 
efficiently transduced with the 8K PTD (>90% of cells demonstrate fluorescence) compared to a 
negative control peptide containing a random peptide sequence in place of the PTD (Figure 8).  
This result demonstrates that in vitro macrophages are efficiently transduced with the 8K PTD. 
2.4.2 8K-NBD inhibits TNF-stimulated NF-κB activation and nuclear 
translocation in cells   
To evaluate the functionality of the transduced peptide, the 8K PTD linked to the NBD 
peptide (8K-NBD) was preincubated with HEK293 cells expressing a stably transfected 
multimerized NF-κB DNA binding element-luciferase reporter gene.  Cells were subsequently 
stimulated with TNF.  Pretreatment with 8K-NBD demonstrated a dose-dependent inhibition in 
TNF-stimulated NF-κB activity (Figure 9A).  Moreover, 8K-NBD pretreatment without TNF 
stimulation did not alter basal levels of NF-κB activity, indicating that the peptide specifically 
targets activated NF-κB.  To verify the mechanism by which 8K-NBD inhibited activity, nuclear 
translocation of NF-κB family members in activated cells was assessed.  Western immunoblot 
analysis on nuclear extracts demonstrated decreased nuclear quantities of the NF-κB family 
members p65 (and its phosphorylated form, p-p65), and c-Rel (Figure 9B) in 8K-NBD 
pretreated, TNF-activated, HEK293 cells. 
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Figure 8: 8K efficiently transduces murine macrophages. A, Biotinylated random peptide linked to 
streptavidin-Cy3 or 8K PTD linked to streptavidin-Cy3 was added to BM-derived macrophages. B, The 
fluorescently labeled random (ran) peptide-NBD-6CF or 8K-NBD-6CF was added to RAW264.7 
macrophages. Following incubation for 1 h, cells were fixed, stained for nuclei (Draq5 in A, propidium iodide 
(PI) in B), and placed on a microscope slide. Localization of peptide was visualized by a confocal microscope 
system. Results were repeated three times and representative images are shown. (Reprinted with permission 
from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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Figure 9:TNF-induced NF-κB activation is inhibited by 8K-NBD transduction in cells. A, HEK293 cells stably 
transfected with a multimerized NF-κB DNA binding element-luciferase reporter were preincubated for 1 h 
with an increasing dose of 8K-NBD peptide in medium. Cells were subsequently stimulated for 2 h with 10 
ng/ml recombinant human TNF. Cells were harvested and lysates were analyzed for luciferase activity. 
Results are expressed as fold induction of luciferase compared with unstimulated plus 0 μM peptide lysates (= 
1). Experiments were performed in triplicate and repeated three times. A representative result is shown 
(mean ± SD). *, p < 0.05; **, p < 0.01; ***, p < 0.001 compared with unstimulated sample. B, Nuclear extracts 
of HEK293 cells stimulated with or without 10 ng/ml recombinant human TNF in the presence of medium, 
8K-mNBD, or 8K-NBD were isolated and run out for Western blotting. Blots were probed with phospho-p65 
(p-p65), p65, and c-Rel. Blots were probed with poly(ADP-ribose) polymerase to assess equal loading. 
Experiments were repeated three times and a representative blot is shown. (Reprinted with permission from 
Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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2.4.3 Transduction of 8K-PTD in vivo    
8K PTD efficiently transduces and inhibits NF-κB activity in cells.  We next investigated 
whether 8K PTD transduces cells in vivo in mice.  Mice were injected with biotinylated peptides 
(random sequence or 8K PTD) linked to streptavidin-Cy3.  In vivo uptake of peptide is observed 
as early as 30 minutes after administration.  Intraperitoneal administration of 8K PTD revealed 
uptake in the spleen (Figure 10A-B) and mesenteric lymph nodes (Figure 10C-D). These results 
demonstrate that systemic and intestinal immune compartments are targeted by 8K peptide-
mediated transduction in vivo. 
2.4.4 8K-NBD inhibits LPS-stimulated intestinal NF-κB but does not inhibit basal 
NF-κB in vivo   
To determine whether 8K-NBD inhibits activated, but not basal, NF-κB in the intestine in 
vivo, we utilized NF-κBEGFP knock-in mice107, 275 where expression of enhanced GFP (EGFP) is 
controlled by a chimeric promoter containing three HIV NF-κB cis elements. Strong induction of 
in vivo NF-κB activity has been described in jejunal and ileal lamina propria T cells and 
monocytes following LPS injection
275
. Furthermore, gross analysis of whole organs from cis- 
NF-κBEGFP mice demonstrated basal levels of EGFP expression in Peyer’s patches, known to 
exhibit high basal levels of NF-κB activation275. 
NF-κBEGFP knock-in mice were pretreated with 8K-NBD (10 mg/kg) or 8K-mNBD 
peptide (10 mg/kg) one hour prior to intraperitoneal LPS (5 mg/kg) or PBS administration. After 
16 hours, mice were sacrificed and intestines analyzed for GFP expression  indicative of NF-κB 
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activity. EGFP expression in lamina propria cells of the terminal ileum was visualized by 
 
Figure 10  The 8K PTD transduces lymphoid tissue in vivo. Biotinylated (A and C) random (RAN) peptide 
linked to streptavidin (SA)-Cy3 or(B and D) the 8K PTD linked to streptavidin-Cy3 was injected i.p. for 30 
min. Paraformaldehyde-fixed (A and B) spleens and (C and D) mesenteric lymph nodes (MLN) were stained 
for actin (green) and nuclei (blue; Draq5) and viewed by confocal microscopy. Insets represent the threecolor 
image for each sample. To specifically visualize the location of the peptide (Cy3; red), the signal from the red 
channel was given a false white color while the other channels were turned off. This is represented in the 
larger black and white image. Background threshold levels were adjusted to random peptide samples for 
each organ. (Reprinted with permission from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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activity. EGFP expression in lamina propria cells of the terminal ileum was visualized by 
confocal microscopy (Figure 11A). Mice injected with PBS demonstrate few EGFP positive cells 
in the lamina propria whether pretreated with 8K-NBD or 8K-mNBD (Figure 11A, left). In 
contrast, mice injected with LPS pretreated with 8K-mNBD demonstrate strong NF-κB 
activation in the ileal lamina propria. Mice pretreated with 8K-NBD prior to LPS show markedly 
fewer EGFP positive cells in the lamina propria, similar to the number observed in PBS treated 
mice (Figure 11A, right). To study NF-κBEGFP transgene expression in whole organs, a specific 
EGFP imaging camera was used to visualize EGFP expression in the intestine following 
challenge with LPS.  Strong basal NF-κB activity is observed in Peyer’s patches (visualized 
macroscopically as nodules on the serosal surface of the small intestine) of PBS. This activity is 
not inhibited by administration of 8K-NBD (Figure 11B, left). Taken together, these experiments 
demonstrate that intraperitoneal administration of 8K-NBD inhibits activated but not basal NF-
κB in the intestinal immune compartment in vivo. 
2.4.5 8K-NBD treatment ameliorates colitis in IL-10-/- mice   
Next, we tested the hypothesis that 8K-NBD may ameliorate active chronic colitis in vivo 
in IL-10
-/-
 mice.  IL-10
-/-
 mice were treated from 10 to 12 weeks of age with either 8K-NBD at 2 
or 10 mg/kg or 8K-mutant NBD (mNBD) at 10 mg/kg by intraperitoneal injection for 10 of 14 
days.  Gross inspection of the intestines revealed increased colonic lengths, decreased colonic 
wall thickening, and formed fecal pellets in the 8K-NBD treatment groups (Figure 12B-C) 
compared to the mNBD controls (Figure 12A).  Histologic severity of colitis was graded over the 
entire length of the colon for each mouse by a single pathologist blinded to treatment groups.  the 
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entire length of the colon for each mouse by a single pathologist blinded to treatment groups.  
 
Figure 11: 8K-NBD inhibits LPS-stimulated NF- B but not basal NF-κB in vivo. NF-κBEGFP knock-in mice 
were pretreated with 8K-NBD (10 mg/kg) or 8K-mNBD (mutNBD) (10 mg/kg) 1 h before LPS injection. LPS 
(25 mg/kg) or PBS was administered i.p to the mice (two mice per treatment group). After 16 h, mice were 
sacrificed and the guts were collected. A, EGFP expression in the ileal lamina propria was visualized by 
confocal microscopy. B, EGFP fluorescence of whole intestines was macroscopically assessed using the 
Lightools Research macroimaging system. Fluorescent (right) and white light imaging (left) are 
depicted.(Reprinted with permission from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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Figure 12: 8K-NBD-treated mice demonstrate improvement in gross colonic appearance. Representative 
photographs of colons from the control group 10 mg/kg 8K-mNBD (A) and the treatment groups 2 mg/kg 8K-
NBD (B) and 10 mg/kg 8K-NBD (C). Colons from mice treated with 8K-NBD peptide demonstrated increased 
length, decreased tissue thickening, and formed stool pellets compared with the control group. (Reprinted 
with permission from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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Due to the incomplete penetrance and the segmental, patchy pattern of colitis in IL-10
-/-
 
mice, colitis scores are depicted in two different ways.  First, composite scores are represented 
using a modified standard scoring system described by Berg et al. 
276
 (Figure 13A).  Mice treated 
with 8K-NBD at 2 mg/kg and 10 mg/kg demonstrated a 50% reduction in colitis scores 
compared to the control treated group (mNBD).  To illustrate the spectrum of disease 
encountered over the entire length of the colon, scores are presented as the percentage of fields 
that demonstrate no histological inflammation (colitis score of 0), mild to moderate 
inflammatory changes (colitis score of 1 and 2), and severe inflammation (colitis score of 3 and 
4).  Compared to the 8K-mNBD group (Figure 13B, red bars), 2 mg/kg and 10 mg/kg 8K-NBD 
treated mice (Figure 13B, blue and green bars, respectively) displayed more fields demonstrating 
no evidence of histologic inflammation and consequently fewer fields with significant 
inflammatory changes.  
Activated NF-κB was determined by immunohistochemistry for phosphorylated NF-κB 
p65 in colonic sections from 8K-mNBD and 8K-NBD (2 mg/kg) treated IL-10
-/-
 mice (n=6 per 
group). Significantly fewer phospho-p65 positive cells were found in the lamina propria from 
8K-NBD compared to 8K-mNBD treated mice (Figure 14), suggesting that 8K-NBD inhibits 
activated NF-κB in the colon of IL-10-/- mice, correlating with histological improvement. 
Finally, the effect of 8K-NBD treatment on mucosal inflammatory cytokine production in 
IL-10
-/-
 mice was investigated.  Spontaneous release of the NF-κB regulated proinflammatory 
cytokines IL-12(p40) (Figure 15A) and TNF (Figure 15B) were determined in cell free 
supernatants from colonic mucosal tissue explants.  Explants from 8K-NBD-treated mice 
secreted significantly less IL-12(p40) and TNF compared to 8K-mNBD-treated control mice. 
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The IL-12 p40 subunit is a component of the bioactive cytokines IL-12 and IL-23. To assess 
downstream p40 subunit is a component to the bioactive cytokines IL-12 and IL-23. To assess 
downstream 
 
Figure 13: 8K-NBD treatment ameliorates histologic colitis. Colons were isolated from individual mice (black, 
10 mg/kg mNBD; gray, 2 mg/kg NBD; white, 10 mg/kg NBD), cleaned, fixed in formalin, and embedded in 
paraffin. Sections were stained with H&E and colitis scores were determined using a modified scoring system 
(0–4) as described in Materials and Methods. At least 20 separate microscopic fields (magnification x10) were 
evaluated for each mouse by a pathologist blinded to the treatment groups. Colitis scores were significantly 
lower in the 8K-NBD-treated mice. Histologic improvement in colitis is presented as a composite score (the 
average colitis score sum of five fields) (A) and as the percentage of histologic fields that demonstrate scores 
of 0 (no inflammation), 1 and 2 (mild inflammation), or 3 and 4 (severe inflammation) (B). (Reprinted with 
permission from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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Figure 14: 8K-NBD inhibits the phosphorylation of intestinal NF-κB p65 in IL-10–/– mice. IL-10–/– mice were 
treated with 8K-NBD (2 mg/kg; n = 6) or 8K-mNBD (10 mg/kg; n = 6) for 14 days. Colonic sections were 
immunohistochemically stained for phospho-p65. (A) Phospho-p65-positive lamina propria cells were 
quantitated in stained colon sections of treated mice. Twenty high power fields were counted from each 
mouse and the results are expressed as the mean number of positive cells per high power field. (Reprinted 
with permission from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
 
 
downstream consequences of attenuated mucosal IL-12 p40 production, the prominent T cell 
targets of IL-12 and IL-23 signaling, IFN-γ and IL-17, respectively, were measured. Intestinal 
explants from 8K-NBD-treated mice secreted less spontaneous IFN-γ (Figure 15C) and IL-17 
(Figure 15D) compared to 8K-mNBD-treated control mice. Therefore, decreased mucosal innate 
and T cell inflammatory cytokine expression correlates with the histological findings, suggesting 
that specific targeting of the IKK complex with cell permeable NBD peptides may be effective in 
treating chronic IBD. 
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Figure 15: 8K-NBD inhibits NF-κB-dependent cytokine production in intestinal explants. Colons were 
isolated from individual mice (black, 10 mg/kg mNBD; gray, 2 mg/kg NBD; white, 10 mg/kg NBD), cleaned, 
and processed for intestinal tissue explant cultures as described in Materials and Methods. Tissue fragments 
(0.05 g dry weight) were incubated in 1 ml of RPMI 1640 supplemented with 1% antibiotic/antimycotic and 
10% FBS. Supernatants were collected after 24 h and spontaneous secretion of IL-12 p40 (A), TNF (B), IFN-γ 
(C), and IL-17 (D) were measured by ELISA. Values were normalized to dry weight of the intestinal explant. 
Asterisk (*) denotes comparisons where p < 0.05 compared with the mNBD control group. (Reprinted with 
permission from Journal of Immunolgy, vol 179, Dave et al., 2007
78
) 
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2.5 DISCUSSION 
In this study, effects of the IKK inhibitor peptide, NBD, employing a novel PTD (8K) 
was investigated in vitro and in vivo.  This peptide efficiently transduces cells in culture, and 
transduces intestinal lymphoid tissue following intraperitoneal administration in vivo.  In cells, 
8K-NBD inhibits TNF-induced NF-κB transcriptional activity and nuclear translocation.  In vivo, 
8K-NBD inhibited LPS-activated NF-κB in the lamina propria, but did not affect basal NF-κB in 
Peyer’s patches. Moreover, we demonstrate that 8K-NBD ameliorates chronic colitis in IL-10-/- 
mice, and histological improvement correlated with reduction in mucosal levels of the 
inflammatory cytokines IL-12(p40) and TNF. 
The critical role of NF-κB in chronic intestinal inflammation is best illustrated the effects 
of NF-κB blockade in animal models of IBD 108, 110, 111.  In spontaneously occurring colitis in IL-
10
-/-
 mice, increased NF-κB DNA binding activity and p65 protein expression were found in 
lamina propria macrophages.  The essential role of p65 in maintaining chronic intestinal 
inflammation was demonstrated by successful treatment of established colitis in these mice with 
p65 antisense oligonucleotides 
111
.  Other therapeutic interventions targeting NF-κB, including a 
dominant negative IκB mutant and NF-κB decoy oligonucleotides 277, demonstrated reduced 
inflammation in models of colitis.   
Furthermore, activated NF-κB is found in human IBD.  A significant increase in p65 
protein in lamina propria macrophages and IECs from CD patients was correlated with increased 
production of the inflammatory cytokines IL-1β, IL-6, and TNF 106.  In vitro treatment of lamina 
propria macrophages from CD patients with p65 antisense oligonucleotides was effective in 
down-regulating inflammatory cytokine production, suggesting a key role for NF-κB p65 in 
inflammatory cytokine expression in CD 
106
.  Activated NF-κB has been reported in 
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macrophages and IECs from inflamed mucosa of patients with IBD in situ using a specific p65 
antibody that exclusively detects the activated form of NF-κB 267.  No significant differences 
were found between sections of inflamed mucosa from patients with CD, UC, or diverticulitis 
267
.  This study indicated that activation of NF-κB is not necessarily specific for the 
pathophysiology of IBD: NF-κB activation could represent an important step in mucosal 
inflammation regardless of the etiology. 
Accordingly, selective IKK inhibition represents a potential therapeutic strategy in IBD.  
A concern about the use of inhibitors that completely suppress IKK activity is that they may also 
inhibit the ability of basally active NF-κB to act as a physiologic survival factor, thereby raising 
the possibility of toxicity.  Activation of the IKK complex in response to inflammatory mediators 
depends critically on the presence of the NEMO subunit of the IKK complex.  For example, 
NEMO-deficient cells lack detectable NF-κB binding activity in response to TNF, IL-1β, and 
LPS 
278
.  Furthermore, recent studies have shown that continuous administration of the NBD 
peptide effectively ameliorates inflammatory responses in animal models of inflammation 
without overt side effects such as liver or kidney toxicity 
76, 279
.  Additionally, the NBD peptide 
preserves the alternative pathway of NF-κB activation, necessary for B cell development and 
lymphoid organogenesis, again minimizing potential toxicity concerns. In our studies, while 
there was an inhibition of activated NF-κB the levels of basal NF-κB translocation stayed 
constant (Figure 9&11).  Significantly, in vivo, 8K-NBD inhibited activated NF-κB in the ileal 
lamina propria, but basal NF-κB appeared to be preserved in the Peyer’s patches. This feature 
theoretically allows for dampened inflammatory responses, without altering other roles of NF-κB 
within the cell.   
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 Specific inhibition of IKK activity by NBD peptides may have pleiotropic mechanistic 
and durable immunologic effects in inflammatory diseases. In mouse models of chronic 
inflammation, including collagen induced arthritis (CIA) 
71, 76
 and experimental allergic 
encephalomyelitis (EAE) 
75
, in vivo treatment with NBD peptides blocked disease activity, pro-
inflammatory cytokine expression, and homing of cells to inflammatory sites due to inhibition of 
expression of cellular adhesion molecules. In EAE, clinical recovery was correlated with a 
durable alteration of the T cell phenotype, as NBD-treated mice demonstrated Th2 cytokine 
production rather than disease-associated Th1 cytokine production 
75
. Furthermore, mice treated 
systemically with an NBD peptide for five days after induction of CIA maintained clinical and 
histological improvement for nearly three weeks following termination of peptide administration 
76
. In our study, the 8K PTD was detected in important immune inductive sites (spleen and 
mesenteric lymph nodes) following intraperitoneal administration; however we could not 
identify the peptide in the intestinal lamina propria or epithelia (data not shown). This finding 
suggests that the mechanism of action of 8K-NBD in IBD is likely to be more complicated than 
can be explained by direct inhibition of activated NF-κB in the inflamed intestine. Future 
mechanistic studies in IBD models will be necessary to characterize functional and phenotypic 
alterations in immune cell populations and durability of clinical responses with the 8K-NBD. 
While PTD-NBD has demonstrated efficacy in other inflammatory models, important and 
distinguishing features of colitis in IL-10
-/-
 mice compared to these other experimental systems 
are that it is a chronic, “spontaneously” occurring model of inflammation, and 8K-NBD was an 
effective therapeutic intervention when administered after the onset of disease 
109
.  Furthermore, 
CIA and EAE induced inflammatory models are specifically T cell mediated diseases, however, 
IL-10
-/-
 mice have pathologic innate and adaptive immune responses 
75
.   
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To further characterize the effects of inhibition of NF-κB in IBD, it will be critical to 
dissect protective from detrimental properties of NF-κB activation in mucosal inflammation. 
Although increased activation of NF-κB is implicated in the pathogenesis of numerous chronic 
disorders, NF-κB activation pathways may be protective and serve to maintain homeostasis in 
the intestine 
280, 281
.  For example, the toll-like receptor (TLR) family recognizes extracellular 
microbial constituents resulting in the downstream activation of NF-κB.  TLR-deficient mice or 
strains with deletions in signaling intermediates such as MyD88 demonstrate a decrease in 
survival compared to wild-type mice when colitis is induced with dextran sodium sulfate (DSS) 
281
. Intestinal epithelial proliferation was shown to be markedly decreased in TLR/MyD88
-/-
 
animals. This study suggested that TLRs, expressed on IECs, may recognize luminal microbial 
constituents and mediate a protective response through NF-κB activation. Furthermore, mice 
with a targeted deletion of IKKβ in intestinal epithelial cells demonstrate increased epithelial 
apoptosis 
282
 and are susceptible to radiation induced injury 
283
.  Most relevant to this study, mice 
with a targeted deletion of NEMO in intestinal epithelial cells (IEC) develop severe spontaneous 
intestinal inflammation through TNF and MyD88 dependent pathways, further suggesting that 
IKK activation in intestinal epithelium mediates homeostatic pathways
112
. Interestingly, a slight 
increase in TNFα levels were observed in the 10mg/kg NBD-treated IL-10-/- mice compared to 
those treated with 2mg/kg NBD.  This could be potential due more cell types being tranduced by 
the NBD peptide secondary to higher dose.  Thus, if IEC were affected at higher rather than 
lower doses of this could lead to barrier breakdown similar to the NEMO deletion in IEC, and a 
slight increase in TNFα.  While still much lower than mNBD-treated miceIn summary, NF-κB 
inhibition, particularly in the intestinal epithelium, may lead to abrogation of mucosal protective 
effects. 
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Conversely, the preponderance of evidence suggests that inhibiting NF-κB in lamina 
propria macrophages and DC may be of therapeutic benefit in IBD.  A recent study demonstrated 
that the development of colitis in IL-10
-/-
 mice is completely dependent on TLR signaling 
pathways
284
. In IL-10
-/-
 × MyD88
-/-
 mice, colitis is abrogated and intestinal IL-12 p40 levels are 
markedly decreased. Furthermore, bone marrow chimera experiments reveal that bone marrow 
derived cells are responsible for recognition of commensal microbial signals and mucosal innate 
immune activation.  
Taken as a whole, the spectrum of NF-κB biology in the gut is complex. Our results and 
those of others suggest that inhibition of activated NF-κB in mucosal macrophages and DC may 
ameliorate innate immune responses that underlie chronic IBD; however, NF-κB may play a 
protective role in the epithelium. Thus, in contemplating therapeutic strategies that target NF-κB, 
many interrelated factors may be important to determine ultimate clinical applicability, including 
inhibition of activated versus basal NF-κB, targeting specific cell types (macrophages versus gut 
epithelium), and route of delivery (systemic versus local).  
This study supports the concept that selective inhibition of IKK by 8K-NBD is an 
effective strategy for suppressing intestinal inflammatory responses.  Compared to other NF-κB 
inhibitors tested in chronic inflammatory diseases, 8K-NBD has the theoretic advantages of 
inhibiting activation of NF-κB, a hallmark of chronic inflammation, while not inhibiting basal 
NF-κB activity, which may be involved in fundamental cellular homeostatic processes.   
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3.0  EVALUATION THE ROLE OF NF-ΚB ACTIVITY IN AGING 
3.1 ABSTRACT 
NF-κB is a family of transcription factors that play a pivotal role in determining cell fate 
in response to stress, including inflammatory, oxidative and genotoxic stress. NF-κB is 
implicated in numerous chronic inflammatory and degenerative diseases, many of which are 
associated with aging. To test the hypothesis that NF-κB plays a causal role in driving the 
degenerative changes associated with aging, we tested whether genetic depletion or 
pharmacologic inhibition of NF-κB delays the onset of degenerative diseases in a mouse model 
of accelerated aging (Ercc1
-/∆
 mice). Like naturally aged mice, Ercc1
-/-
 mice exhibit increased 
NF-κB activity as they reach their maximum lifespan. Ercc1-/∆ mice haploinsufficient for the 
p65/RelA subunit of NF-κB had a modest delay in the onset of age-related symptoms. This was 
recapitulated in mice chronically treated with a peptide inhibitor of NF-κB activation, which 
exhibited a significant delay in overall aging score and improved histopathological alterations. 
These findings implicate NF-κB as a major driver of degenerative changes associated with aging 
and set a precedent for therapeutic intervention.  
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3.2 INTRODUCTION 
Aging is characterized by the progressive erosion of the ability of a tissue to maintain 
homeostasis, resulting in increased risk of morbidity and mortality
121
. Increasing chronologic age 
is the top predictive risk factor for a variety of diseases including cancer, heart disease, arthritis, 
and dementia is increased chronologic age
285
.    There is an exponential increase in the ag-at-
onset of these disease compared with a linear increase in chronologic age
120
 suggesting specific 
mechanisms are contributing to this change. With the US population over the age of 65 
increasing
122
, and the fact that 27% of the 327 billion dollar Medicare budget in 2008 was spent 
on care for patients in their last year of life
123
, society has begun to realize the burden that 
treating age related diseases can have on our healthcare system and our national economy.  
Therefore, identifying strategies to reduce this burden and understand the mechanisms of aging is 
of critical importance.   
One such mechanism may be the gene expression changes mediated by NF-κB, which 
acts as a dimer and promotes transcription of immune, anti-apoptotic, and cell cycle regulating 
genes.
5
  Transcription by NF-κB is mediated by cell stress stimuli, including inflammatory 
cytokines and pathogens but also endogenous stressors such as DNA damage
12
, hyperglycemia
286
 
and reactive oxygen species (ROS) formation
13
.  Stress stimuli signal via the Inhibitor of κB 
Kinase (IKK) complex, which is is composed of two catalytic subunits, IKKα and IKKβ and a 
regulatory subunit, IKKγ or NEMO. Once activated by IKKγ, IKKα and β phosphorylate the 
cytoplasmic inhibitor of NF-κB, IκBα, which is subsiquently poly-ubiquitinated and undergoes 
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proteosomal degradation
287
.  This allows NF-κB to trasnlocate to the nucleus and activate target 
genes.     
Upregulation of NF-κB has been observed in numerous studies associated with aging.  
Tissues derived from aged rodents including skin, liver, kidney, cerebellum, cardiac muscle and 
gastric mucosa exhibit increase in DNA binding of NF-κB subunits158-163.  Analysis using motif 
mapping of gene expression data from both human and murine tissues suggest that NF-κB is the 
transcription factor most associated with normative mammalian aging
151
.  Furthermore, human 
cells derived from aged patients (age 72-93) and those with Hutchinson-Gilford progeria, also 
exhibited increased NF-κB signaling compared to controls151, 157.   In addition, numerous 
pathologies associated with aging including, atherosclerosis
168
, osteoarthritis
169
, dementia
170
, 
osteoporosis
171
, diabetes, cancer
288
 and cardiovascular disease
172
 all have reported increases in 
NF-κB activity.  These previous studies have elucidated a novel pathway by which age-
associated diseases and overall aging may be propagated. Two recent studies by Adler et al and 
Kawahara et al. observed that  age-associated pathology was reversed via suppression of NF-κB 
signaling
151, 164
. Thus, we hypothesize that by inhibiting the NF-κB signaling pathway, age-
related degenerative phenotypes and histologic changes associated with mammalian aging will 
be limited. 
Various mechanisms are used to block NF-κB transcriptional activation, including both 
genetic and pharmacologic suppression.  In this study we will evaluate mice heterozygous 
p65/RelA, as in Kawahara et al.
164
 as this NF-κB subunit is a documented transcriptional 
activator
5
 and is known to play a role in age-related changes and cellular senesence
151, 155
.  Due 
to the embryonic lethality of germ-line homozygous deletion of this gene only mice 
haploinsufficient for p65 can be used
289
.  There are vast number of NF-κB inhibitory 
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compounds
4
, the majority of which have off-target effects or poor in vivo bioavailability.  
Therefore, the NEMO binding domain (NBD), an 11 amino acid peptide derived from the 
domain of IKKβ that is critical for its interaction with IKKγ was used in this study14. NBD is 
linked to a protein transduction domain (PTD) consisting of eight lysine residues (8K) that 
promotes internalization of the inhibitor into cells.  It has been shown that chronic administration 
of NBD is efficacious in the treatment of numerous murine models of degenerative disease 
including arthritis
71
, diabetes
67
, and Parkinson’s disease72, and the efficacy of 8K-NBD was 
shown in Dave et al
78
. 
We hypothesize that suppression of NF-κB trascriptional activation will delay or 
ameliorate age-related phenotypic changes in mammalian aging.  To study aging-related changes 
we have chosen a progeroid-like or accelerated aging model, the ERCC1 deficient mouse.  This 
model allows for the assement of age-related changes in a model which recapitulates the 
transcriptional changes associated with the accumulation of DNA damage and oxidative stress 
known to occur in normative agings 
125, 126, 216
. ERCC1 progeria is described previously in 
Niedernhofer et al.
130
 and Robinson et al
290
, and develops secondary to a defect in DNA repair. 
Ercc1
-/-  
and Ercc1
-/∆
 mice have 0% and 10% ERCC1-XPF expression respectively, and age over 
a period of 28 days and 28 weeks respectively, with phenotypic changes similar to those 
observed in normative aging mice.   
In Kawahara et al., Sirt6
-/-
 mice haploinsufficient for p65/RelA, an NF-κB subunit, had 
improved lifespan and reduced degenerative changes
164
. However, it was observed that these 
mice have a colitis like phenotype and associated with gross inflammation which may have 
contributed to this effect
165
.  The ERCC1 deficient mous model is an accurate predictor of aging 
on the transcriptional level with the exception of innate and complement responses that are only 
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upregulated in normative aging mice level
130, 291
.  Therefore, the ERCC1 deficient mice will 
allow for evaluation of the role of NF-κB signaling independent of inflammation. Due to the 
predictable order of symptom development, healthspan of these animals can be evaluated by 
determining delay in age-at-onset of symptoms and examining degenerative histologic changes, 
thus allowing for a proper analysis of the effects of NF-κB suppression on age-associated decline 
3.3 MATERIALS AND METHODS: 
3.3.1 Mice: 
Both Ercc1
-/- 
and Ercc1
-/∆ 
mice were generated in an f1 hybrid background by 
intercrossing Ercc1
+/-
 and Ercc1
+/∆ 
mice in a C57Bl/6J or FVB/n inbred background.   Genomic 
DNA was isolated from an ear punch using a Machery-Nagel vacuum manifold according to 
instructions.  PCR amplification of the null allele was achieved with primers specific for exon 7 
and intron 7 of Ercc1 and neo
r (5’GAAAAGCTGGAGCAGAACTT, 5’-
AGATTTCACGGTGGTCAGAC, and 5’-GAAGAGCTTGGCGGCGAATG, respectively), 
while 3'-UTR reverse 5'-CTAGGTGGCAGCAGGTCATC is needed in addition to the other 
primers to detect the deletion mutation in exon 10. 
Ercc1
-/- 
eGFP
NF-κB 
mice were generated by crossing Ercc1
+/-
 C57Bl/6J mice with eGFP
NF-
κB 
mice, a generous gift from Christian Jobin (UNC Chapel Hill)
107
.  These mice were then bred 
with Ercc1
+/- 
FVB/n to create Ercc1
-/- 
eGFP
NF-κB
. Genotyping procedure used as described in 
107
. 
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3.3.2 Fluorescent Microscopy:   
Ercc1
-/- 
eGFP
NF-κB 
mice and a wild type eGFP
NF-kB 
littermate were sacrificed at 21 days of 
age.  Tissues were placed in 10% formalin for 6 hr, then transferred to 30% sucrose in phosphate 
buffered saline (PBS) overnight at 4°C.  The tissues were then frozen in 2-methylbutane and 
embedded in optimal temperature cutting at -30°C. Six micron sections were cut using cryostat.  
Tissues were stained using HOESCT stain (Sigma) and coverslipped using gelvatol, as desribed 
in 
292
.  Samples were allowed to sit overnight at 4°C and were subsequently analyzed using 
Axiovert200 Microscope and Axiovision software (Zeiss).  To quantify eGFP expression in 
tissues Metamorph software (MDC) was used.  Five 20x images were taken for each tissue 
analyzed in each mouse (n=6 per group), the percent eGFP expression was quantified based on 
tissue area.  The amount of eGFP was normalized within litters to (normative aging littermate) to 
determine baseline levels of eGFP within the litter.  These normalized eGFP expression levels 
were then analyzed between groups using Wilcoxon rank methods using SPSS (SPSS Inc).  
3.3.3 Isolation and Treatment of Mouse Embryonic Fibroblasts: 
Pregnant mice were bred to produce WT, Ercc1
-/
,
-
 and Ercc1
-/-
p65
-/-
 pups were prepared 
as in 
130
.  Briefly, mice were sacrificed at E13.5 by CO2 inhalation. Individual embryos were 
dissected and plated on 10 cm cell culture dishes. Cells were genotyped as described above. The 
cells were then grown at 3% O2, which is considered physiologic
149
 and grown in MEF media 
(DMEM 44% ml Ham’s F10 44%, 10% FBS, 1%, P/S, 1% NEAA).  
To stress the cells with oxidative insult, MEFs were grown at 20% O2
149
. Proliferation 
rates were determined as in 
215
.  Briefly, cells were passaged in 10 cm plates, and counted at each 
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passage (determined by the first plate to reach confluency) to evaluate their proliferation rates.  
Cells were then reseeded at 25,000 cells per plate and returned to either 3% or 20% O2.   
3.3.4 NF-κB Luciferase assay   
HEK293 cells stably transfected with a multimerized NF-κB DNA binding element-
luciferase reporter (DMEM/10% FBS/1% Pen/Strep) were left untreated or pretreated for one 
hour with 10μM NF-κB inhibitor Compound A (Calbiochem), 10μM ATM inhibitor (2-
Morpholin-4-yl-6-thianthren-1-yl-pyran-4-one (KU-55933, Calbiochem) or 25μM p53 inhibitor 
(pifithrin-α, Calbiochem).  Cells were then γ-irradiated from a 137Cs source. The cells were lysed 
in reporter lysis buffer and luciferase activity was measured with a luciferase assay system 
(Promega) using a AutoLumat Luminometer (Berthold Technologies). 
3.3.5 Nuclear extracts and Western blotting   
Nuclear extracts from treated MEFs were isolated following manufacturer’s protocol 
(NE/PER Reagents, Pierce).  Protein concentration was determined using the Bradford assay 
(Pierce).  Western blot analyses were performed on nuclear and cytoplasmic extracts as 
described previously 
274
.  Anti-p-p65, p-IκBα, and IκBα antibodies were purchased from (Cell 
Signaling, Danvers MA) Lamin A/C (Santa Cruz Biotechnology) and β-actin (Abcam).  All 
primary antibodies were used at 1:1000 antibody dilutions and allowed to incubate overnight at 
4°C.  Secondary antibodies goat α-rabbit, and rabbit-α-mouse (Cell Signal) were used at 1:1000 
dilutions.    
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3.3.6 Peptides:  
The peptides 8K-NBD (NBD) (acetyl-KKKKKKKKGGTALDWSWLQTE-amide), and 
inactive
 
8K-mutant NBD (mNBD) (acetyl-KKKKKKKKGGTALDASALQTE-amide, where
 
the 
underlined amino acids represent tryptophan to alanine mutations),
 
were synthesized
 
by the 
peptide synthesis facility at the University of Pittsburgh,
 
Pittsburgh, PA.  
3.3.7 Treatment of Animals:  
Sibling pairs of Ercc1
-/∆ 
mice housed in a single cage were evaluated in this study.  
Treatments were given in a blinded fashion, mice were identified by ear clips prior to initiation 
of the study, and these mice were denoted as 1 or 2 for each group.  Mice were then assigned a 
treatment for 1 or 2 by a third party.  One syringe was then filled with NBD while the other with 
mNBD.  These were then labeled by the third party with a 1 or 2 label.   Paired mice were 
injected with NBD or mNBD three times per week.  Treatments with the peptides were initiated 
at 5 weeks of age.  The peptide were given intraperitoneally (i.p.) at a dose of 10 mg/kg in 100μl 
of phosphate buffered saline (PBS).  Treatment was administered 3 times per week through the 
entire lifespan of the animal.  Mice were euthanized via CO2 inhalation at points 18-20 weeks of 
age or until end of life and tissues were collected for analysis. 
3.3.8 Phenotype and Weighing:  
Weight and the age-at-onset of spontaneous age-related symptoms (dystonia, trembling, 
kyphosis, ataxia, sarcopenia, priapism, urinary incontinence, and lethargy) were assessed bi-
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weekly by an investigator blinded to the treatment of the mutant animals. The onset of each 
symptom was recorded, averaged within a treatment group and reported in tabular form.  The 
difference in the age at onset of symptoms between groups was analyzed using a paired 
Student’s t-test.  This cumulative aging score is calculated by assigning animals within each 
littermate pair a + if a symptom is delayed or a – if the onset is earlier or equivalent in both 
groups.  The + scores are then added and normalized to the total number of symptoms evaluated 
within that group and analyzed using a Student’s t-test. The aging score provides an overall 
evaluation of quality of life. 
3.3.9 Tissue Sections/ IHC: 
Dissected tissues were fixed in 10% formalin overnight, embedded in paraffin and 
sectioned using a microtome.  p16 staining was completed as follows anti-p16 
(CDKN2A/p16INK4a Abcam) according to standard immunohistochemical protocols.  Insulin 
staining was completed as follows, anti-insulin (Biogenex) with secondary biotin-horse-α-mouse 
(Vector).  Staining was resolved using ABC-Elite (Vector) and AEC substrate (Scytek).  Percent 
insulin positive cells were quantified using Metamorph software (Molecular Devices) and data 
was evaluated using Student’s t-test 
3.3.10 MicroCT:  
Micro-computed tomography of the spines isolated from 20 wk-old Ercc1
-/∆
 mice and wt 
littermates mice were acquired using a VivaCT 40 (Scanco Medical) using 15-µm isotropic 
voxel size resolution, 55 kVp of energy, and 145 µA of current. After the acquisition of 
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transverse two-dimensional image slices, three-dimensional reconstruction of the lumbar 
vertebrae was performed using a constant threshold value of 235 which was selected manually 
for the bone voxels by visually matching the threshold areas to the gray-scale images.  NBD 
treated and control treated Ercc1
-/∆
 mouse data were compared using Student’s t-test.   
3.3.11 Microarray:  
To measure genome-wide changes in transcription in mice treated with NBD or mNBD, 
microarray analysis was performed as described
130
. Briefly, RNA was isolated from the liver of 
Ercc1
-/∆
 mice (n=3 treated with NBD and mNBD at 12 weeks of age and 18 weeks of age, each) 
using an RNA isolation kit (Qiagen) according to the manufacturer’s instructions. Synthesis of 
double-stranded cDNA and biotin-labeled cRNA, hybridization to Affymetrix GeneChip® 
Mouse Genome 430 2.0 Arrays were completed using Affymetrix protocols Microarray 
(Affymetrix).  Analysis was completed using GeneGo (GeneGo bioinformatics software) and 
IPA (Ingenuity Systems).  GeneGo was used to analyze both gene ontology categories as well as 
transcriptional regulation analysis (via its network building tool).  IPA was used to analyze gene 
ontology categories.    
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3.4 RESULTS: 
3.4.1 Ercc1-/- cell lines have over-active NF-κB signaling which contributes to 
proliferation defects:  
To evaluate NF-κB activity, levels of activated or phosphorylated-p65 (p-p65) 
translocation to the nucleus in Ercc1
-/-
 and WT mouse embryonic fibroblasts (MEFs) generated 
from littermates were defined by immunodection (Figure 16A).  Quantification shows 
approximately 2.5±0.5 fold increase in p-p65 levels in the nuclei of Ercc1
-/-
 cells compared with 
control cells (Figure 18A).  Previous data suggests that Ercc1
-/-
 MEFs have proliferation defects 
and senesce more rapidly than WT cells
130
.  This is confirmed in Figure 16B, Ercc1
-/-
 MEFs 
exhibit proliferation defects which are exacerbated in high oxygen or stress environment (20% 
O2)
149
.  After 3 passages at 20% oxygen, Ercc1
-/-
 MEFs show increased NF-κB translocation to 
the nucleus compared with identical cell lines grown at 3% oxygen over the same period of time 
(Figure 16C).  This suggests that the Ercc1
-/-
 MEFs experiencing growth or proliferation defects 
secondary to DNA damage or oxidative stress exhibit concomitant increases in NF-κB signaling.     
To evaluate whether NF-κB suppression had a positive impact on cell growth, 
proliferation profiles were completed for WT, Ercc1
-/-
, and Ercc1
-/-
 MEFs with a homozygous 
deletion of p65 (Ercc1
-/-
p65
-/-
) (Figure 16D).  Ercc1
-/-
p65
-/- 
MEFs proliferated at a rate between 
the Ercc1
-/-
 and WT MEFs at 3% oxygen conditions; however, in oxidative  conditions of 20% 
oxygen the Ercc1
-/-
p65
-/-
 MEFs grew similar to WT MEFs for the initial passages and then 
exhibited a reduction in cell growth, while the Ercc1
-/-
 cells had far slower cell proliferation. 
Thus, p65 homozygous deletion in Ercc1
-/-
 MEFs partially restored early stage proliferation 
rates, when compared with WT MEFs 
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Figure 16: NF-κB is activated in Ercc1-/- cells and limits proliferation under conditions of oxidative stress. 
(A)Immuodetection of markers of NF-κB activation in fractionated MEFs: nuclear phosphor-p65 and 
cytoplasmic IκB and phosphor-IκB. Lamin A/C and actin were used as loading controls for nuclear and 
cytoplasmic fractions, respectively. (B) Proliferation of WT and Ercc1
-/-
 cells grown at 3 or 20% oxygen 
(normative or oxidative environment) (C) Immunodetection of p-p65 subunits of NF-κB  in WCEs from 
primary Ercc1
-/- 
mouse embryonic fibroblasts, grown for 4 passages at 3% or 20% O2, to induce oxidative 
stress . (D)Proliferation of WT, Ercc1
-/-
, and Ercc1
-/- 
p65
-/-
 primary MEFs grown 3% oxygen (Top panel) and 
at 20% O2 to induce oxidative stress (Bottom Panel). 
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3.4.2 NF-κB is activated by gamma irradiation in an ATM dependent manner and 
NF—κB suppression promotes cellular survival. 
Genetic suppression of NF-κB improved the growth profile for Ercc1-/- MEFs, suggesting 
that reduced NF-κB signaling improves growth and/or survival under stress conditions such as 
DNA damage and oxidative stress, both of which are increased in the Ercc1
-/-
 cells.  ERCC1 
deficient mice by their nature have an abnormal accumulation of bulky adducts, interstrand 
crosslinks and double strand breaks. This DNA damage mediates the accelerated aging 
phenotype in these mice.  To evaluate the effects of DNA damage on NF-κB activation, HEK293 
cells stably expressing a mutimerized NF-κB DNA binding element-luficerase reporter (293NF-
κB
) were exposed to 0, 10 and 20Gy of irradiation and NF-κB transcriptional activity was 
analyzed at varying time points (Figure 17A).  NF-κB activity was shown to increase by 6 hours 
and began to dissipate at 12 hours.  When cells were pretreated with a potent IKKβ specific 
inhibitor, Compound A
293
, NF-κB induced luciferase activity secondary to γ-irradiation was 
reduced to basal levels (Figure 17B).  NF-κB luciferase activity was reduced equally with 
pretreatment of 10μM of KU55933, an ATM specific inhibitor, suggesting that NF-κB is 
activated in an ATM dependent manner after γ-irradiation.  This further promotes the idea that 
NF-κB is activated by DNA damage alone after γ-irradiation.  Protein analysis evaluating p-p65 
shows increased NF-κB translocation to the nucleus of MEFs three hours after exposure to 10G 
of γ-irradiation (Figure 17C).  Further analysis in a 5 day survival time course revealed that 
transient inhibition of NF-κB using Compound A, prior to γ-irradiation, increased cellular 
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survival of γ-irradiated MEFs p=0.009(Figure 17D).  This effect was likely due to increased 
  
 
Figure 17: NF-κB is activated by γ-irradiation in an ATM dependent manner: (A) Luciferase levels were 
quantified from HEK293 cells stably transfected with a mulimerized NF-κB DNA binding element luciferase 
reporter (293
NF-κB) were treated with 0, 10, or 20Gy of γ-irradiation and evaluated at 6, 9, and 12 hours post 
irradiation. (B) Luciferase levels were determined from 293
NF-κB
 cells pretreated with 10μM Compound A 
(NF-κB inhibitor), 10μM KU55933 (ATM inhibitor), 25μM pifithrin-α (p53 inhibitor) or left untreated.  After 
1 hour cells underwent 10G of irradiation. (C) Immunodetection of p-p65 from Ercc1
-/- 
MEFs treated with 0 
or 10Gy of γ-irradiation.  (D) MTT assay was used to determine five day survival levels for MEF undergoing 
0 or 10Gy of irradiation with or without the treatment of 10μM Compound A. 
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survival, as non-irradiated control MEFs treated with Compound A exhibited reduced 
proliferation compared to those left untreated.   
3.4.3 Progeroid-like ERCC1-deficient mice exhibit overactive NF-κB signaling:  
As NF-κB activity was increased in vivo in ERCC1 deficiency, it was pertinent to 
determine if progeroid-like ERCC1-deficient mouse model exhibits increased NF-κB signaling 
as well. Ercc1
-/-
 were bred with mice expressed eGFP under an NF-κB regulatory element (NF-
κBeGFP)275.  Mice were analyzed at 21 days of age, or 75% of maximum lifespan.  Figure 18 
compares the eGFP expression in both progeroid-like Ercc1
-/-
eGFP
NF-κB
 and their normative 
aging (Ercc1
+/+
NF-κBeGFP or Ercc1+/-NF-κBeGFP) littermates.  eGFP mRNA isolated from the 
kidney is increased in the accelerated aging Ercc1
-/-
 mice compared to their littermate controls 
(Figure 18A).  This upregulation is confirmed using fluorescent microscopy, examining eGFP 
fluorescence in numerous tissues including kidney, muscle, pancreas, and liver with the 
exception of the spleen (Figure 18B/C).  Fluorescent intensity was quantified and differences 
between the two groups were found to be statistically upregulated in the kidney, liver, pancreas 
and muscle of Ercc1
-/-
NF-κBeGFP (Figure 18D).  The liver exhibited a 3.58 fold increase 
(p<0.012) in NF-κB activity, while the kidney and pancreas had approximately a 2.5 fold 
increase (p<0.001 and p<0.021 respectively) and the muscle had a 1.7 fold increase (p<0.032).  
Interestingly, this over-expression in the tissues examined is nearly equivalent to the over-
activation of NF-κB determined using Ercc1-/- MEFs analyzed in Figure 16A/19A.  These data 
confirm that, as with normative aging mice, ERCC1-deficient mice have increased NF-κB 
signaling as the animals near their maximum lifespan.  
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Figure 18: NF-κB is activated in progeroid Ercc1-/- mice. Ercc1-/- mice were bred to express an NF-ΚB -eGFP 
reporter transgene. (A) mRNA was isolated from the kidney of Ercc1
-/-
NF-κBeGFP mice and littermate 
eGFP
NF-κB
 controls and NF-κB activity measured by RT-PCR of eGFP mRNA using β-actin as a control. 
(B/C) Kidney and additional tissue sections from Ercc1
-/-
NF-κBeGFP and NF-κBeGFP mice. Imaged by 
fluorescent microscopy to detect eGFP expression (green); Dapi (blue). (D) eGFP levels were quantified as 
relative to tissue are. Five random fields (20X) were analyzed per mouse (n=6 per group).  Green dots 
represent individual NF-κBeGFP control mice and yellow indicate Ercc1-/-NF-κBeGFP mice  Each mouse is 
correlated to eGFP expression in the tissues of NF-κBeGFP littermates within that group.  The black bar 
indicates the average eGFP levels within for each genotype.  
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3.4.4 Ercc1-/∆ mice with genetically suppressed IKK/NF-κB signaling have delayed 
onset of phenotypic changes:  
Despite increased NF-κB activity in ERCC1-deficient accelerated aging mouse tissues as 
well as in normative aged tissues, it is unknown whether NF-κB has a protective or detrimental 
effect.  Complete deficiency in p65 results in embryonic lethality
289
, thus Ercc1
-/∆
 mice were 
bred to have a heterozygous deletion of p65 (Ercc1
-/∆
p65
+/-
).  Mice were assessed biweekly for 
onset of symptoms listed in Figure 19A including dystonia, kyphosis, ataxia, sarcopenia, 
lethargy, incontinence, and priapism.  Interestingly, the Ercc1
-/∆
p65
+/- 
mice experienced a delay 
in the time of onset for the majority of symptoms compared to Ercc1
-/∆
 controls.  For dystonia, 
trembling, ataxia, and sarcopenia the changes were negligible (≤ 0.3 weeks), However, for 
kyphosis and priapism, and incontinence the delay in onset was 1.2, 2.5 and 6.0 weeks 
respectively, or 4%, 8%, and 20% of lifespan.  
Interestingly, the visual appearance of these mice was even more dramatically improved 
than this delay in age-at-onset of symptoms would suggest. The differences between the Ercc1
-
/∆
p65
+/-
 and Ercc1
-/∆
 mice can be appreciated in Figure 19C/D, where Ercc1
-/∆
 mice exhibit 
earlier and more severe phenotype changes than Ercc1
-/∆
p65
+/- 
littermates, such as incontinence, 
blindness, and priapism, as well as greater severity of disease/degeneration, exhibited by extreme 
kyphosis, sarcopenia and cachexia observed in representative images taken at 15 and 19 weeks 
(Figure 19C and 19D).  One explanation for the disparity between minimal change in time of 
onset of symptoms and vast differences in overall appearance, is while age-at-onset of many 
symptoms only improved slightly, perhaps the progression of these symptoms was slowed and 
thus the severity of disease was diminished, which can be observed visually but is difficult to 
quantitate.  Ercc1
-/∆
p65
+/-
 had increased weight gain compared to their Ercc1
-/∆ 
controls
 
(Figure 
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17B).  
Figure 19: Haploinsufficiency of p65 NF-κB  subunit delays the onset of aging symptoms. (A) Ercc1-/∆ and 
Ercc1
-/∆
p65
+/-
 were evauated biweekly spontaneous symptoms associated with aging. Reported are the average 
age at onset of each symptom for each group and the difference between the averages between groups. (B)  
Ercc1
-/∆
 and Ercc1
-/∆
p65
+/-
 weights were measured biweekly, and change from initial weight recorded at 5 
weeks of age was recorded (C) Representative images of Ercc1
-/∆
 and Ercc1
-/∆
p65
+/-
 sex-matched littermates at 
15.5 weeks of age.  The Ercc1-/∆ mouse has ocular changes, signs of neurodegeneration (broad-based stance, 
urinary incontinence, dystonia) muscle wasting, kyphosis and aged appearance. (D) Representative images of 
Ercc1
-/∆
 and Ercc1
-/∆
p65
+/-
 sex-matched littermates at 19 weeks of age.  The Ercc1
-/∆
p65
+/-
 exhibits some 
changes such as dystonia, kyphosis, and mild sacropenia.  The Ercc1
-/∆
 mouse has signs of neurodegeneration 
(abnormal stance, priapism, dystonia) muscle wasting, kyphosis and worsened/aged appearance. 
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19B).  However, this was due primarily to a reduced starting weight of nearly 2g.  This may be 
indicative of suppressed developmental process in the presence of reduced NF-κB signaling 
before sexual maturity. Therefore, we chose to further explore NF-κB suppression using 
pharmacologic inhibition of the NF-κB pathway, using the NBD peptide inhibitor starting at 5 
weeks of age, when gross developmental processes are less likely to be affected.   
3.4.5 NBD peptide inhibitor suppresses upregulation of NF-kB signaling:  
Ercc1
-/-
 cells were treated with the NBD peptide to determine if increased translocation of 
p-p65 could be reversed.  NBD peptide (200uM) reduced levels of p-p65 in the nucleus to 51% 
of Ercc1
-/-
 levels three hours after treatment, which is nearly equivalent to WT MEF p-p65 levels 
(Figure 20A).  Thus, we determined that the NF-κB activity seen in the Ercc1-/- mice can be 
inhibited by NBD at the level of the IKK complex. 
Based on this finding NBD was evaluated in vivo in the Ercc1
-/∆ 
mice .  The NBD peptide 
provides numerous advantages over the genetic manipulation of p65.  First, due to the embryonic 
lethality of p65 deletion, heterozygous deletion of p65 was used and Ercc1
-/∆
p65
+/-
 mice have a 
maximum of 50% suppression of p65.  Furthermore, other NF-κB subunits remain intact and 
may compensate for the loss of p65, for example other studies have shown a role for c-rel in the 
aging process
154
.  Second, the NBD peptide has therapeutic potential to treat age-associated 
disease while genetic deletion is not a feasible approach, but can confirm the importance of 
biologic pathways.  Third,  NBD inhibits at the level of the IKK complex and in Chapter 2 of this 
thesis we show that activated but not basal NF-κB is inhibited.  Finally, because p65 is integral 
in embryonic development, the reduction of this transcriptional subunit in embryonic and early 
life development may have detrimental effects on the animals.   
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3.4.6 Ercc1-/∆ mice with suppressed IKK/NF-κB signaling have delayed onset of 
phenotypic changes:  
To evaluate whether NF-κB suppression using the NBD peptide was as or more effective 
than genetic suppression of p65, a similar phenotypic study to assess the age-at-onset of 
numerous age-associated symptoms was conducted.  It is of relevance to note that this study was 
completed as a blinded, sex matched, twin study, where mice were treated triweekly with NBD 
peptide or the inactive mutant form mNBD as described in the Materials and Methods.  
Mice treated with NBD experienced a delay in the age-at-onset of all symptoms 
evaluated with the exception of trembling (Figure 20B); however, the only symptom exhibiting a 
significant delay in age-at-onset was sarcopenia (p=0.024).  When analyzing the impact of the 
delay in age-at-onset of the symptoms it is important to take into account the animal’s limited 
lifespan.  For two of the symptoms associated with aging, sarcopenia and incontinence, the time 
to onset was delayed on average 3 and 3.3 weeks respectively which is 10.7 and 11.7% of 
maximum lifespan.  When correlated to a human lifespan of 80 years this equals a delay of 8.6 
and 9.3 years respectively.  The cumulative aging score, an optimal method for analyzing quality 
of life, showed significant improvement in the NF-κB suppressed animal compared with their 
littermate controls with a p-value of 0.005 (Figure 20B).  Images of mice treated with either 
NBD or their littermate controls, offer visual confirmation of the phenotypic changes, striking 
differences seen between NF-κB suppressed and littermate controls can be appreciated in these 
images (Figure 20C/D), which were evaluated in Fig. 20B.  Additionally, female but not male 
mice treated with NBD exhibited increased weight gain compared to littermate controls, which is 
of relevance because both sarcopenia and cachexia correlate with a loss of body mass (data not 
shown).   
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Figure 20: NBD peptide suppression of the IKK/NF-κB activation delays the onset of aging symptoms. 
(A)Immunodetection of phosphor-p65 in nuclear extracts of Ercc1
-/-
 primary MEFs grown at 20% O2 and 
treated with 200 M NBD peptide for 3 hours. (B) Quantitation of nuclear p-p65 in blot (A) relative to WT 
MEFs derived from littermate controls.  Values obtained are averages and standard deviation from three 
independent experiments. (C) Sibling pairs of Ercc1
-/∆ 
mice were
 
treated with NBD peptide
 
or an inactive 
mutant control peptide, 10 mg/kg, i.p., 3X per week, beginning at 5 wks of age and continuing throughout 
their lifespan. The mice were evaluated biweekly for spontaneous symptoms associated with aging by an 
investigator blinded to treatment.  Reported are the average age at onset of each symptom for the two 
treatment groups and the difference between the group averages. Those symptoms marked with an asterisk 
were significantly delayed in mice treated with NBD relative to mice treated with the mutant peptide. The 
Aging Score reflects the overall quality of life (see Materials and Methods). (D) Representative images of 
Ercc1
-/∆ 
littermates treated with NBD or mutNBD peptide, at 15 weeks of age.  The mouse treated with the 
inactive peptide shows premature onset of signs associated with neurodegeneration (dystonia, broad-based 
stance) early stages of kyphosis and muscle wasting.  (E) Representative images of Ercc1
-/∆ 
littermates treated 
with NBD or mutNBD peptide, at 19 weeks of age.  The mouse treated with the inactive peptide shows 
premature onset of signs associated with neurodegeneration (dystonia, broad-based stance, urinary 
incontinence), visual impairment, cachexia, and muscle wasting, While the NBD treated littermate shows 
dystonia and early stages of kyphosis and muscle wasting. 
 
 
 
Recent examination of NBD and mNBD peptides, as well as, vehicle control in a murine 
model of arthritis and cell culture experiments has raised concerns that the mNBD peptide may 
not be completely inactive.  Thus, using ANOVA analysis the age-at-onset for the various 
symptoms were analyzed compareing NBD-treated mice, mNBD-treated mice, and vehicle 
control treated mice.  Interestingly using this analysis we found that three symptoms, trembling,  
 111 
 
Figure 21: NBD peptide improves symptoms of Ercc1
-/∆ 
compared with untreated Ercc1
-/∆ 
controls: Ercc1
-/∆ 
mice were
 
treated with NBD peptide
 
10 mg/kg, i.p., 3X per week, beginning at 5 wks of age and continuing 
throughout their lifespan. The mice were evaluated biweekly for spontaneous symptoms associated with aging 
by an investigator blinded to treatment.  Reported are the average age at onset of each symptom for the NBD 
treated mice were compared with Ercc1
-/∆ 
 untreated mice.   Cell marked in yellow are those with delayed age-
at-onset in NBD treated mice 
 
 
 
 
ataxia, and sarcopenia, were significantly delayed p ≤ 0.05 in the NBD treated mice compared 
with the vehicle control mice; and further both dystonia and kyphosis showed trends p ≤ 0.10 of 
being delayed  (supplementary Fig 21).  Thus, the efficacy of NBD may be greater than 
littermate-controlled data suggested. 
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3.4.7 IKK/NF-κB suppression attenuates histologic changes associated with aging:   
Due to the significant alterations in phenotypic findings observed in NBD-treated mice, 
even greater than those observed in the genetic suppression of p65, histologic changes in NBD 
and control-treated animals were evaluated. Ercc1
-/∆
 mice eventually die from severe liver 
dysfunction.  When analyzing liver histology it is apparent that these mice have an increasing 
number of senescent cells defined by expression of p16, recently defined as the first biomarker of 
aging
294
.  As expected, p16
 
protein levels were reduced in Ercc1
-/∆
 mice treated with NBD 
(Figure 22A).  These reduced levels of p16 correlated with a 1.7 fold decrease in p16 gene 
expression as determined by qRT-PCR (data not shown). 
Numerous tissues exhibit age-associated changes.  Bone marrow develops fatty 
deposits
295
, vertebral bone becomes osteoporotic
205
, and pancreatic islet cells have reduced 
insulin secretion
296
.  As with the reduction in senescent changes in the liver, there was a similar 
delay in fatty replacement of the bone marrow in Ercc1
-/∆
 mice receiving NBD peptide, 
compared with those receiving mNBD peptide (Figure 22A).  Vertebral degeneration evaluated 
by μCT, was reduced by NBD-treatment as represented by fewer osteoporotic holes and 
improved trabecular structure when compared to control Ercc1
-/∆
 control mice (Figure 22A).  
Bone densities were compared using control WT, control Ercc1
-/∆
 (injected with vehicle, n=5) 
and NBD treated Ercc1
-/∆
 mice (n=3).  Control Ercc1
-/∆
 mice had reduced bone density of 31.5 ± 
2.5 % while the reduction in bone density in NBD-treated mice was limited to 21.6 ± 5 % 
compared to normative aging controls (p=0.003) (Figure 22B).  As expected, porosity, a marker 
of bone degeneration, was increased in the Ercc1
-/∆
 control mice by 25.1 ± 2%; however 
treatment with NBD reduced this increase to 16.7 ± 3% (p = 0.0009) (Figure 22C).  Ercc1
-/∆
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treatment with NBD reduced this increase to 16.7 ± 3% (p = 0.0009) (Figure 20C).  Ercc1
-/∆
 
  
Figure 22: NBD peptide suppression of the IKK/NF-κB activation delays histolopathological changes 
associated with aging. (A) Immunodetection of senescence marker p16 in liver of Ercc1
-/∆ 
mice treated with 
NBD peptide or an inactive mutant peptide as described in Fig. 4 and Material and Methods. Nuclear p16 
staining is more frequent and intense in hepatocytes of mice treated with the mutant peptide. (Red arrows 
indicate p16 positive nuclei, while green arrows indicate p16 negative nuclei) Cross-section of the femur 
stained with haematoxylin and eosin. Mice treated with the mutant peptide have early onset of fatty 
replacement (yellow arrows) of the bone marrow. MicroCT of the vertebra of Ercc1
-/∆ 
mice. Mice treated with 
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NBD have improved appearance of bone density. Immunodetection of insulin in pancreatic sections from 
treated Ercc1
-/∆ 
mice. NBD peptide delayed the loss of insulin-producing islet cells.  Islets are indicated by 
yellow islets and brown stain indicates insulin positivity. (B) Analysis of microCT images in percent bone 
density (normalized to WT littermate controls) (top panel) as well as  quantification of bone porosity, 1-
BV(bone volume) /TV (total volume) (bottom panel). Values for the treated Ercc1
-/∆ 
mice were compared to 
normal littermates. (C) The percent of insulin producing cells in Ercc1
-/∆ 
mice treated with NBD or the 
inactive mNBD compared to normal littermate controls. 
 
 
 
mice demonstrate degeneration of pancreatic islets between 12 and 18 weeks of age (unpublished 
data).  While NBD treated Ercc1
-/∆
 mice had nearly the same number of insulin producing cells 
in their islets (72.8 ± 4.5%) as WT control mice at 18-19 weeks of age, mNBD treated mice had 
lost greater than 50% of their insulin positive islet mass (28.8 ± 25.7%) (Figure 22C).  This 
improvement in islets can be appreciated in the bottom panels of Figure 22A.  This data suggests, 
NBD treatment either blocks or allows for regeneration resulting in improved pathologies in 
numerous tissues undergoing age-related changes observed in this model of accelerated aging. 
3.4.8 NBD treatment led to global as well as NF-κB specific gene expression 
changes:   
As NBD-treatment improved phenotypic and histologic changes associated aging, micro-
array analysis was completed to determine if these changes were mediated by a limited number 
of gene expression changes.  In the liver (n=3 per group), expression of approximately 5% of all 
genes showed significant changes in expression levels between the NBD and mNBD-treated 
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groups, demonstrating that NBD had a functional effect in vivo.  Grouping genes to their known 
or predicted biologic function using gene ontology (GO), allowed for characterization of 
pathways which were preferentially altered by NBD treatment.   
The most significantly affected processes altered between NBD and mNBD treated 
animals were those listed in Figure 23A.  Two different analysis programs defined processes 
involving cell and tissue development, cell signaling and proliferation, cell death and regulation 
of apoptosis, as well as regulation of infectious diseases and metabolic pathways as those that 
were most significantly altered.  This further confirms our findings in Figure 16, that p65 
expression can alter cell growth and proliferation in Ercc1
-/-
 MEFs.   
To further assess whether the NF-κB pathway was a factor in the gene expression 
changes, a transcriptional regulation analysis was completed.  This analysis determined that NF-
κB subunits accounted for the 7th, 14th, 24th, and 25th most effected transcription factors (Figure 
23B).  However, taken as one transcriptional element, they account for 243 nodes, compared to 
the most significant transcription factors which had 112 effected nodes.  Further analysis shows 
that NF-κB is one of the central factors involved in the top 5 networks as defined by Ingenuity, 
which is denoted by the red circle in Figure 24. The other central mediator is HNF4α denoted by 
the blue circle (a protein directly regulated by NF-κB). Additionally, of approximately 400 genes 
examined with known NF-κB regulatory elements, 8% showed significant expression differences 
between the two groups of mice (Figure 23C). Expression of 89% (27/30) of these genes was 
significantly down-regulated in mice treated with NBD, as expected with chronic IKK inhibition.  
A number of these NF-κB regulated genes are involved in cell cycle control, specifically, 
Gadd45β, Cyclin D2 and D3, Bcl-2, and protein kinase C.  Thus, it is likely that treatment with 
NBD could act through several mediators to alter and delay age-associated changes. 
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Figure 23: NBD peptide suppresses expression of NF-κB regulated genes. Ercc1-/∆ mice were treated 
chronically with NBD peptide or inactive mutant peptide as described in Fig. 4 and Materials and Methods. 
At 18-19 weeks mice were euthanized, tissues isolated, mRNA purified and analyzed by Affymetrix 
microarray. (A) Top networks and Top Processes affected in NBD treated Ercc1
-/∆ 
mice relative to those 
treated with mutant peptide defined by Ingenuity and Metacorps GeneGo, respectively. (B) Ranking of the 
transcription factor networks most affected by NBD treatment as defined by GeneGo Network Builder 
Transcription Regulation.  NF-κB  family members are highlighted in dark grey.  (C) Genes with significantly 
altered expression in Ercc1
-/∆
 mice treated with NBD relative to Ercc1
-/∆ 
mice treated with inactive peptide 
that have a known NF-κB  regulatory element. Eighty-nine percent of these were down-regulated as expected 
if NBD is inhibiting activation of NF-κB .  Genes highlighted in grey are known to have a role in cell survival 
and cell cycle control. 
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Figure 24: NF-κB is a central mediator of top affected networks (A) Network map of the top affected 
networks defined by Ingenuity in Figure 23A.  Central mediators are NF-κB (red circle) and HNF4A (blue 
circle) 
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3.5 DISCUSSION: 
In this study, we evaluated the effects of NF-κB suppression on age-associated 
degeneration in a mammalian model of accelerated aging.  Figures 16 and 17 suggest that as with 
normative aging animals, the ERCC1-deficient mouse model of accelerated aging has elevated 
levels of NF-κB activity.   As hypothesized, chronic inhibition of the NF-κB pathway using both 
genetic suppression and the NF-κB inhibitory peptide led to delays in age-at-onset of phenotypic 
changes associated with aging.  The overall aging score, which takes into account the age at 
onset of numerous symptoms and is an overall measurement of quality of life, showed a 
significant improvement (p<0.005) in NBD treated mice compared to those treated with mNBD 
peptide.  While these changes were recorded in a blinded fashion, their true significance can be 
seen by the images included in figure 18C/D & 19C/D, which portray the vivid differences 
between Ercc1
-/∆
p65
+/-
 and Ercc1
-/∆
 and between NBD and mNBD treated Ercc1
-/∆
 mice.    
Furthermore, when comparing age-at-onset of phenotypic changes in NBD-treated mice 
compared with mice treated with vehicle alone, rather than mNBD-treated mice (a potentially 
partially active control) there are significant (p<0.05) and trending (p<0.1) delays in five of the 
phenotypic symptoms assessed (Figure 20).  Importantly, these phenotypic delays are 
accompanied by amelioration of degenerative pathologic changes associated with aging in 
general.  NBD-treated Ercc1
-/∆
 mice exhibited reduced markers of cellular senescence in the 
liver, a delay in fatty replacement of bone marrow, and reduced osteoporotic changes.  Further, 
NBD treatment resulted in reduced degeneration of pancreatic islet cells.  These data suggest that 
NF-κB up-regulation is not an organ or cell specific event, but rather NF-κB signaling has an 
impact on the aging process as a whole. 
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Additionally, mice treated with NBD peptide differ dramatically in gene expression 
compared to their Ercc1
-/∆
 control littermates.  When evaluating top networks and processes 
altered by NBD as compared to mNBD-treated mice, cell death/apoptosis, cell and organ 
development, organism survival, and stress response were the processes that were most highly 
altered.  It is not surprising, that an improvement in these pathways would be altered with 
treatments that prolong healthspan and delay age-associated changes. Furthermore, these affected 
pathways confirm findings that alterations in p53 signaling, a major controller of cell cycle 
regulation and apoptosis, and leads to extended lifespan in progeroid-like models of aging
290, 297
.   
Our analysis of gene expression changes revealed a 5% genomic shift (nearly 2000 
genes) between NBD and mNBD treated animals. These changes in gene expression may be 
highly relevant in determining which, if any, genes are specifically relevant to the aging process.  
A recent study by Schumacher et al. suggests that rapidly aging, long-lived, and normative aging 
mice have similar alterations in gene expression when compared with young wt mice
216
.  
However, evaluating gene expression data in our NBD treated mice with previously examined 
aging cohorts may elucidate genes that are biomarkers of aging.  The goal of identifying these 
biomarkers can be completed by comparing gene expression data from numerous anti-aging 
compounds/genetic manipulations including SIRT1, p53, p38, and caloric restrinction to find 
overlapping or commonly altered genes.   
Gene expression analysis also confirms the efficacy of NBD, by showing decreased 
expression of numerous genes with known NF-κB promoter sequences.  Further analysis of 
transcriptional regulation confirms that NF-κB subunits are integral in the expression changes 
observed with NBD treatment.  Independently, NF-κB transcriptional elements account for 4 of 
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the top 25 altered transcription factors, however, as a group they become the single most 
important transcription factored altered by NBD treatment.   
Figure 17, shows decreased NF-κB activity in the spleen despite overall increases in NF-
κB activity in other organs.  These data, along with the observation of no major inflammatory 
cell infiltrate into the organs examined, leads us to believe that the role of overactive NF-κB 
signaling is not secondary to a gross inflammatory response as was speculated in Kawahara et al. 
evaluation of Sirt6
-/-
 mice and NF-κB.  Further support of this lack of inflammation is that Ercc1-
/- 
gene expression was highly correlative with that of natural aging mice with the exception that 
Ercc1
-/-
 mice did not exhibit an increase in inflammatory and immune related gene
130
.  Thus it is 
likely that the alteration in NF-κB activity and the positive affects of NF-κB inhibition via the 
NBD peptide most likely results from an involvement in cell cycle and survival transcriptional 
regulation.  From our analysis, altered genes with known NF-κB promoter sequences involved in 
cell cycle/cell survival include Gadd45β, Cyclin D2 and D3, Bcl-2, apolipoprotein D, and protein 
kinase C
4
.  Interestingly the two most highly suppressed NF-κB regulated genes, apolipoprotein 
D and Gadd45β have been shown to have roles in cellular senescence298, 299 and age-related 
disease
300
. 
Our in vitro data further support a role for NF-κB in cell cycle regulation and 
proliferation.  In agreement with previously published data, the Ercc1
-/- 
MEFs exhibit reduced 
proliferation rates compared with wild type MEFs.  These slow rates of proliferation are further 
exacerbated by oxidative stress and gamma irradiation
149, 215
.  In each of these cases NF-κB 
activity is increased.  However, when evaluating Ercc1
-/-
p65
-/-
 MEFs there was a rescue of cell 
proliferation rate compared with Ercc1
-/-
.  Thus, confirming that NF-κB is acts in an non-
inflammatory role to contribute to the aging process and that NBD blocks this change.   
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It is important to note that existing progeroid models are not identical to normative aging, 
although recent gene expression and characterization studies suggest that these mice mimic 
normative aging to a high degree.  The previous study, which evaluated NF-κB inhibition on 
aged skin pathology, hypothesized that aging is an active process whereby genes must be 
continually expressed at altered levels to sustain the aged phenotype
151
.  Therefore, inhibition of 
pathways controlling gene expression could reverse the aging phenotype.  In this study, with 
chronic inhibition of NF-κB was observed to delay the age-at-onset of numerous aging 
parameters, but no reversal or complete block of aging changes, either histologic or phenotypic, 
were observed.  This lack of disease state reversal can be explained in at least two different 
ways.  First, age-related pathology development may not necessitate constant gene expression 
changes, and once initial gene alterations occur they may be irreversible.  However, an alternate 
explanation is possible. The accumulation of DNA and cellular damage in the ERCC1 deficient 
models is far greater and more rapid than that observed in normative aging.  Thus, even with 
chronic treatment of NBD, the cells are continually bombarded with damage that they cannot 
repair.  Therefore, NF-κB suppression may result in only a delay in the age-at-onset of age-
associated changes; however, if damage and repair cycles were to occur as in normative aging 
animals, the NBD therapeutic intervention has even greater potential. This theory can only be 
confirmed by long term studies in normative aging mice. 
This compilation of phenotypic, histologic, and gene expression data demonstrates that 
therapeutic intervention via inhibition of the NF-κB signaling pathway alters numerous aspects 
of the aging process in the Ercc1
-/∆ 
mice.  While it is premature to suggest that global NF-κB 
suppression is a viable method to treat aging, this study gives new insight to the treatment of 
many age-assocaited disease.  Specifically, targeted NF-κB suppression may be efficacious for 
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treating osteoporosis, diabetes, Alzheimer’s, Parkinson’s or other age-related diseases.  This 
approach could avoid potential side effects, which are a concern when inhibiting inflammatory 
pathways.  It is important to note that no adverse side effects were observed in this 20 week 
study of NBD treatment, a finding consistent with previous NBD studies.  However, additional 
studies will have to be completed to determine the efficacy of other NF-κB inhibitors.  
Furthermore, additional studies using IKK or p65 tissue conditional knockouts as well as other 
genetic knockdown modles are necessary to evaluate to determine the mechanism, or likely 
multiple mechanisms, by which NF-κB contributes to the overall aging process.  Additionally, as 
natural aging has even greater up-regulation of immune and inflammatory responses at the gene 
expression level than the ERCC1 deficient models
130
, NF-κB suppression may have more 
beneficial effects in controlling the normative aging process. 
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4.0  PHARMACOLOGIC NF-ΚB INHIBITION CAUSES ANTIGEN PRESENTING 
CELLS TO UNDERGO ROS-DEPENDENT PROGRAMMED CELL DEATH . 
4.1 ABSTRACT: 
Monocyte derived professional antigen presenting cells (APC) are innate immune 
mediators of inflammatory and age-associated degenerative changes.  Differentiation, activation, 
and functional processes of APC are regulated in different degrees by the NF-κB family of 
transcription factors.  In this study, we evaluated the role of pharmacologic inhibition of NF-κB 
APC.  Macrophages and monocyte derived DC cells underwent programmed cell death (PCD) in 
the presence of pharmacologic NF-κB inhibition.  Unlike previous studies which implicated the 
TNFα/JNK/Caspase8 signaling in this cell death pathway, the mechanism initiating PCD in our 
hands is induction of ROS formation, which subsequently causes a loss of mitochondrial 
membrane potential and activation of caspase signaling.  This observed macrophage NF-κB-
inhibition-induced PCD may be one of the mechanisms by which inflammatory and age-
associated disease pathologies are reduced in response to NF-κB suppressive treatment. 
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4.2 INTRODUCTION   
NF-κB/IKK suppression is a therapeutic approach currently being examined in models of 
human disease including, muscular dystrophy
73
, diabetes mellitus
273, Parkinson’s72, 
inflammatory bowel disease
78
, rheumatoid arthritis
71
, heart disease, aging
151
, and cancer
31
.  It is 
commonly assumed that the beneficial effects of NF-κB suppression in mammalian diseases are 
due to reduced cytokine signaling in innate immune cells, as well as a reduction in subsequent T-
cell activation and signaling.  Specifically in diseases with known inflammatory components, 
researchers have consistently evaluated cytokine profiles, including innate immune cytokines, 
TNFα, IL-1β, and IL-12, as well as secondary T-cell cytokines IFNγ, IL-2, and IL-17.    
Study of these cytokines and T-cell activation is appropriate due to the role of NF-κB as a 
central mediator of immune activation. NF- B transcriptionally regulates numerous cytokines 
(IL-2, IL-12, IL-23, IL-17, IFN-γ, TNFα), chemokines (MIP-1, KC, RANTES) and adhesion 
molecules (I-CAM, VCAM, p-selectin)
4
.  Furthermore, NF-κB plays an important role in cellular 
survival specifically in cases of infection and increased inflammation
301
.  NF-κB transcriptional 
regulation is mediated through a series of cellular signaling pathways, including Toll-receptors, 
IL-1R, TNF receptors, TCR and BCR signaling apparatus, as well as ATM and other damage 
sensors.  Each of these inflammatory signaling pathways coalesce at the IKK complex, which is 
considered the central regulator in the canonical or activated NF-κB signaling cascade5.  The 
IKK complex consists of a regulatory subunit, IKKγ (NEMO), and two catalytic subunits, IKKα 
and IKKβ.  Once IKKα/β are activated they phosphorylate the cytoplasmic inhibitor of NF-κB, 
IκBα, thus targeting it for ubiquitination and subsequent degradation.  The degradation of IκBα 
leads to the release of NF-κB subunits by revealing a nuclear localization sequence, thereby 
allowing NF-κB to translocate to the nucleus where it can then act as a transcription factor5.  
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Due to the importance of NF-κB signaling in the inflammatory response and the 
reduction in innate immune cytokines observed after NF-κB inhibitory treatment of disease, it 
was pertinent to explore the role of NF-κB/IKK inhibition in innate immune cells, specifically 
macrophages and dendritic cells (DC).  We hypothesized that NF-κB suppression would result in 
a reduction in cytokine signaling and antigen presentation, as well as a subsequent reduction in 
T-cell activation, and reduced trafficking of innate immune cells to sites of inflammation in vivo.  
However, what we observed was that antigen presenting cells (APC), which constitute both 
macrophages and DC, underwent a programmed cell death phenomenon (PCD) in the presence 
of NF-κB inhibition. 
There are numerous reports of NF-κB involvement in cell death.  The vast majority of 
which implicate TNFα induced JNK and caspase 8 apoptotic cell death.  The role of NF-κB in 
PCD was recognized early due to the embryonic lethality of p65(RelA)
-/-
 mice
289
, IKKγ-/-278, and 
IKKβ-/-302 mice, a condition which is reversed in all cases by TNFR-/- crossbreeding303.  The 
TNFα-induced cell death phenomenon has been confirmed in numerous studies304, 305, and is 
thought to be due to NF-κB transcriptional control of several anti-apoptotic genes including 
XIAP, Bcl-xL, A1-bfl2, c-FLIP, A20, and GADD45β.  One theory suggests that both the pro-cell 
death JNK and caspase 8 pathways and the anti-apoptotic NF-κB pathways are activated by TNF 
as described in Papa et al
306
.  By inhibiting only the NF-κB pathway, the PCD cascade prevails, 
leading to apoptosis. Interestingly, two previous reports observed macrophage cell death using a 
non-specific NF-κB inhibitor, PTDC, without exogenous stimulation.  We suggest here that this 
cell death response seen in primary APC is independent of the well documented 
TNF/JNK/Caspase 8 PCD signaling pathway. 
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In this current study, numerous specific NF-κB inhibitors, which block either signaling at 
the IKK complex, IKKβ, proteosomal degradation of IκBα or translocation of the p65 subunit to 
the nucleus were evaluated.  This NF-κB-suppression-induced PCD was found to be dependent 
on reactive oxygen species (ROS).  This accumulation of ROS leads to subsequent loss of 
mitochondrial membrane potential (MMP) and activation of the caspase 9/3 pathway, resulting 
in apoptotic cell death.  Overall, our data suggest that APC death, in of both macrophages and 
monocyte derived DC, contributes to the anti-inflammatory phenotype seen in murine models 
after treatment with NF-κB inhibitors.   
4.3 MATERIAL AND METHODS: 
4.3.1 Materials:   
NF-κB inhibitors used include: Compound A (gift from Bayer), IKK inhibitor VII 
(Calbiochem), IKK2 inhibitor IV (Calbiochem), JSH-23 (Calbiochem), Wedelolactone 
(Calbiochem), MG-132 (Calbiochem), caspase activation was inhibited by zVAD-fmk 
(Calbiochem),  ROS production and apoptosis was inhibited by butylated hydroxyanisole (BHA) 
(Sigma).  Iron chelator and anti-oxidant, Desferrioxamine Mesylate (DFO) (Calbiochem). All 
compounds were diluted as suggested by manufacturers in DMSO and then diluted in desired 
media.  MTT (Sigma) diluted to 5mg/ml in optimem media.  Etanercept from Wyeth 
Pharmaceuticals.   
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4.3.2 Peptides  
The peptides TAT-NEMO Binding Domain (NBD; (YGRKKRRQRRRGGTALDWS 
WLQTE-amide), inactive (mutant) TAT-NBD (mNBD; YGRKKRRQRRRGGTALDAS 
ALQTE-amide), were synthesized
 
by the peptide synthesis facility at the University of 
Pittsburgh,
 
Pittsburgh, PA. Underlined amino acids represent tryptophan to alanine mutations. 
Peptides were purified
 
and characterized by reversed-phase high performance liquid
 
chromatography and mass spectrometry.  For in vitro experiments, TAT-NBD and TAT-mNBD 
peptides were used, while in vivo 8K-NBD and 8K-mNBD peptides were used due to differing 
transduction rates.
 
 
4.3.3 Murine macrophages, DC and other cell lines:   
Bone marrow
 
(BM)-derived macrophages were isolated from the femurs
 
of mice. BM 
was flushed with washing medium (RPMI 1640
 
with 1% penicillin/streptomycin), passed 
through a 70-µm
 
nylon cell strainer into a 50-ml conical tube, and spun down
 
at 1500 rpm for 5 
min. RBC were lysed using ACK lysis buffer for 15 min, and
 
resuspended in complete medium 
(washing medium with 10% FBS).
 
BM cells were seeded in conditioned L-cell media (consisting 
of 20% precondition L-cell media, 60% DMEM, 20% FBS) additional 1% L-glut, 1% sodium 
pyruvate, and 1% penicillin/streptomycin (P/S) were then added to the media.   Cells were 
seeded in 10cm dishes and media was replaced after 3 days and cells were collected on day 7.  
Cells were passaged every 3-4 days and were discarded after one month.   
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Bone marrow derived dendritic cells (BMDC) were isolated from mice as were BMDM.  
Bone marrow cells were seeded at 5e6 cells per well in 6 well plates in complete RPMI 
supplemented with 10ng/ml of GM-CSF (Cell Sciences) and 20g/ml IL-4 (Cell Sciences).  2ml 
of media was replaced on Day 3 (supplemented with GM-CSF and IL-4) and cells were collected 
on Day 7.  Cells were then isolated using MACs columns (Miltenyi Biotech) with positive 
selection using CD11c beads.  Isolated cell were then seeded and used for experiments seeded in 
complete RPMI media.   
 
Other cell lines used included Fetal Skin Dendritic Cells (FSDC) and immortalized 
murine DC cell line (maintained in RPMI with 10% FBS and 1% P/S), RAW264.7, a murine 
macrophage cell line (maintained in RPMI with 10% FBS and 1% P/S),  a prostate tumor cell 
line DU145 (maintained in maintained in DMEM 10%FBS, 1%P/S, 1% HEPES), an 
immortalized T-cell line D10 (maintained in RPMI 10% FBS, 1% NEAA, 1% Pen/strep, 1% 
Hepes,  1% Sodium Pyruvate 0.1% beta-ME supplemented with 1:2000 50,000U IL-2), and 
primary mouse embryonic fibroblasts (MEFs) derived as described in Niedernhofer et al.
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(maintained in DMEM 44% ml Ham’s F10 44%, 10% FBS, 1%, P/S, 1% NEAA). 
4.3.4 NF- B luciferase assay    
HEK293 cells stably transfected with a multimerized NF- B DNA
 
binding element-
luciferase reporter (DMEM with 10% FBS and 1%
 
penicillin/streptomycin) were pretreated for 1 
hour with varying NF-κB inhibitory compounds (in Materials) were activated for 3 h with 10 
ng/ml TNF (R&D Systems). The
 
cells were lysed in reporter lysis buffer and luciferase activity
 
was measured with a luciferase assay system (Promega) using
 
AutoLumat Luminometer 
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(Berthold Technologies,).  Due to the high binding affinity of the PTD fragments of the peptides 
(peptides were treated in Optimem prior to addition of TNF) all other NF-κB inhibitors were 
treated in maintenance media. 
 
4.3.5 MTT Assay: 
Cells were seeded in 96 well plates at a concentration of 40,000 cells per well for FSDC, 
30,000 cells/well DU145, 10,000 cells/well for MEFs, 30,000 for D10, 30,000cells per well for 
BMDM and BMDC and 30,000cells/well for HEK293-NF-κBlufiferase.   Cells were treated with 
listed doses of the NF-κB inhibitors and allowed to grow for 24 hours or as described.  10ul of 
MTT working solution (5mg/ml) was added to each well and incubated for 2 hours.  Excess 
media was removed and crystals were dissolved in 20ul of DMSO and then diluted in dH20.  
Absorbance was measured at 530nm on MRX revelation microplate reader (Dynex 
Technologies).  Values were then normalized to untreated controls and blank wells. 
4.3.6 Western blotting  
Cells were treated over a reverse time course with varying NF-κB inhibitors as described 
in the results.  Cells were collected by scraping, then pelleted and lysed using Reporter Lysis 
Solution (Promega).  Protein concentration was determined using Bradford assay (Pierce).  
Western blots were performed and analysis was performed with the following antibodies: 
Caspase 3 (Cell Signal), Cleaved Caspase-9 (Cell Signal), Cleaved Caspase 8 (Cell Signal) β-
actin (Abcam), A1/bfl-1 (Cell Signal).  
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4.3.7 Mitochondrial Membrane Potential and Cellular ROS production:   
Cells were treated with desired compounds as listed in individual experiments.  At 
desired timepoints, cells were treated with 40nM DiOC6(3) (Invitrogen), which was made from a 
40mM stock in DMSO, and 5mM MitoSOX (Invitrogen) used according to manufacturers 
instructions.  Cells were incubated in these solutions diluted in complete IMDM media for 30min 
at 37°C protected from light. Cells were then washed two times in complete IMDM media and 
were subsequently imaged using fluorescent microscopy using Axiovert200 Microscope and 
Axiovision software (Zeiss).  To remove background fluorescence, all images had equally altered 
red and green channel levels for imaging but not quantification.  After 30min incubation with 
fluorophores and washing, cells were then collected and evaluated by on LSR2 flow cytometer 
(BD Bioscience).  FACS analysis using cells stained with DiOC6(3) and MitoSox were 
evaluated on Axiovert200 Microscope.  Further FACs analysis was completed using FlowJo 
(TreeStar Inc) 
 
4.3.8 Immunofluorescence. 
Cells were grown on poly-L-lysine-coated coverslips.  Poly-L-lysine coverslips were 
prepared as follows coverslips were washed for 10 minutes in boiling 1M HCl.  Slides were 
rinsed completely in dH2O.  Coverlsips were then incubated in 0.1% poly-L-lysine hyrdro 
bromide (Sigma) for 10 min.  Coverlsips were then washed and dried in oven at 60°C.Cells were 
fixed for 15 minutes using 2% paraformaldehyde (Sigma) and then washed with PBS.  The cells 
were then permeabilized with 0.1% Triton X (USB) in PBS and then washed and blocked with 
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2%BSA for 45 minutes.  Cells were treated with primary antibodies (as listed) for 1 hour and 
then secondary antibodies conjugated to fluorophore either Cy3 (1:1000) or SA488 (1:500) 
(Jackson) for 1 hour.  DAPI stain was then added to cells for 30 seconds and cells were fixed to 
glass slides using gelvatol solution.  Confocal microscopy was completed using Olympus 
Flowview 1000.   
4.3.9 mRNA analysis: 
FSDC and BMDM were collected from 6 well plates as defined in the experiments 
below.  mRNA was isolated from cell pellets using RNAqueous Kit (Ambion).  mRNA was then 
quantified using NanoDrop (Thermo Scientific).  Samples were then were analyzed for A1/bfl-1 
(Fwd:5’AATTCC AACAGC CTCCAG ATATG3’ Rev:5’GAACAA AATAT CTGCAA 
CTCTGG3’) Bcl2 (Fwd 5’TACCGT CGTGAC TTCGCA GAG3’ Rev5’GGCAGG CTGAGC 
AGGGT CTT3’) BclXL (Fwd 5’AGGCA GGCGA TGAGT TTGAA C3’ Rev GAACC ACACC 
AGCCA CAGTC A3’) FHC (Fwd5’AGACC GTGATG ACTGG GAGAG3’  Rev 5’AGCTT 
AGCTCT CATCAC CGTG TC3’) and β-actin (Fwd 5’TAAAA CGCAG CTCAG TAACA 
GTCCG3’ Rev 5’TGGAA TCCTG TGGCA TCCAT GAAAC3’) Samples were run for 30 
cycles using PCR machine Techgene (Techne). 
4.3.10 Statistical analysis:  
Experiments shown are representative of 3 independent experiments.  P-values were 
determined using the student T-test.   
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4.4 RESULTS:   
 
4.4.1 NF-κB suppression results in APC death: 
 Previously, our laboratory evaluated the efficacy of the Nemo Binding Domain peptide 
(NBD), an inhibitor of the IKK complex, in a murine model of IBD
78
, where it ameliorated 
disease with  good in vivo efficacy.  The efficacy of NBD is supported by numerous other in vivo 
studies
67, 72, 73
. It was observed that levels of inflammatory cytokines derived from innate cells 
including IL-12p40 and TNFα were reduced in the NBD treated animals compared with control 
treated animals
78
.   Initially, a decrease in cytokine secretion was observed in macrophages 
pretreated with NBD for one hour before stimulation with LPS or TNF (data not shown).  Under 
visual observation, however, the majority of the macrophages in culture exhibited characteristics 
of apoptosis cell death, including fragmentation or blebbing, nuclear condensation, cell 
shrinkage, and loss of symmetry (Figure 25A).   
TAT-NBD (NBD) but not TAT-mNBD (mNBD), an inactive control peptide, treatment 
was shown to cause cell death in a dose-dependent manner (data not shown).  Cells treated with 
200μM of NBD peptide underwent rapid cell death, with 100% cell death occuring within 4 
hours (Figure 25B).  This cell death response was confirmed visually using trypan blue exclusion 
analysis (Figure 25A), in which all NBD-treated cells, but not the mNBD-treated cells failed to 
exclude the trypan blue stain.  Annexin V and PI staining confirmed that the NBD induced 
programmed cell death (PCD) was indeed apoptotic (Figure 25C).  In the NBD treated sample 
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71.5±1.2% of cells were double positive for Annexin V and PI, while in the mNBD treaded 
sample 11.8±5.4% were double positive.   
While the data comparing NBD with mNBD suggest that the cell death was due to the 
NF-κB inhibitory domain of the peptide, it was necessary to confirm whether this was a NF-κB 
specific phenomenon or a by-product of this particular inhibitor.  To evaluate this more closely, 
seven NF-κB inhibitory compounds were used, each of which targeted different aspects of the 
NF-κB inhibitory cascade (Table 3).   
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Figure 25: NBD peptide induces apoptotic PCD in APC.  (A) RAW264.7 cells were treated with NBD or 
mNBD peptide for 12 hours, cells were then stained with trypan blue and then images were obtained.  The 
left image indicates a high number of trypan blue stained (dead) cells following NBD treatment.  In the image 
on the right, phase-contrast microscopy was utilized in order to visualize mNBD treated cells, which remain 
alive and capable of excluding trypan blue. (B) RAW264.7 murine macrophages cell line was treated with 
NBD or mNBD (200uM) for varying time-points and cell death was determined by trypan blue exclusion. (C) 
RAW264.7 cells were treated for 4 hours with NBD or mNBD peptide and analyzed for expression of Annexin 
V (apoptotic marker) and PI (cell death marker)  NBD treated cells expressed an upregulation in both 
Annexin V and PI compared with inactive control peptide.   
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Table 3: Selected NF-κB inhibitory compounds 
Inhibitor Chemical Composition Target Citation 
NBD TALDWSWLQTE IKK complex 
formation 
14, 73, 78
 
Compound A 
(Cmp A) 
2-Amino-6-(2-
(cyclopropylmethoxy)-6-
hydroxyphenyl)-4-(4-
piperidinyl)-3-
pyridinecarbonitrile 
IKKβ specific 
inhibitor 
293, 307
 
MG-132 Carbobenzoxy-L-leucyl-L-
leucyl-L-leucinal 
Proteosome 
inhibitor: blocks 
IκBα degradation 
308, 309
 
IKKiVII 2-benzamido-pyrimidine-
derivative 
IKKα and β inhibitor 97, 310 
Wedelolactone 7-Methoxy-5,11,12-
trihydroxy-coumestan 
IKKα and β inhibitor 311 
TPCA-1 5-(p-Fluorophenyl)-2-
ureido]thiophene-3-
carboxamide 
I(KK2 inhibitor IV) 
IKKβ specific 
inhibitor 
312, 313
 
JSH-23 4-Methyl-N
1
-(3-
phenylpropyl)benzene-1,2-
diamine 
p65 nuclear 
translocation 
inhibitor 
314
 
  
Each of these seven inhibitors were evaluated for induction of APC death using the fetal 
skin dendritic cell line (FSDC), and for their NF-κB inhibitory properties using a stably 
transfected NF-κB-luciferase reporter HEK293 cell line (293NF-κB) (Figure 26).  The cell death 
profile FSDC was proportional to that of the NF-κB inhibition profile with each inhibitor used, 
confirming that NF-κB suppression was indeed the inducer of PCD.  JSH-23, which inhibits p65 
nuclear translocation alone, did not induce complete PCD even at elevated doses, however, this 
could be due to compensation by other NF-κB subunits.   
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Figure 26: Decreased cell survival is directly correlated with decreased NF- B activity following treatment 
with a panel of NF-κB and IKK inhibitors.  The 239NF-κB reporter cell line was utilized to measure relative 
levels of NF-κB activation secondary to TNFα stimulation after 3 hour incubation at varying concentrations 
of the respective inhibitors (black lines).  The inhibitors were also evaluated in the FSDC APC cell line (grey 
line) where the percent survival was determined by MTT assay after 24hr incubation with varying doses of 
the inhibitors (FSDC cells, unlike the 293
NF-κB
, were not stimulated exogenously). 
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Due to the high concentrations of NBD (200-400μM) that were needed to induce cell 
death compared to the more controlled profile provided by Compound A (Cmp A), TPCA-1, 
IKKiVII, and MG-132, these other NF-κB inhibitory compound were used for the majority of in 
vitro experiments in the remainder of this manuscript.  
4.4.2 NF-κB induced cell death is specific to APC populations:  
Two previous reports suggesting the phenomenon of NF-κB-inhibition-induced 
macrophage cell death
35, 315
, these reports did not evaluated DC nor other cell lines to determine 
whether this was an APC specific response.  Using four of the NF-κB inhibitors, cell death 
profiles using an MTT assay were evaluated in HEK293, immortalized D10, and primary MEFs 
cell lines compared with the FSDC cell line.  Cell death induction in the FSDC cell line occurred 
at far lower concentrations as compared with the other three non-APC cell lines.  Compound A 
and TPCA-1, two IKKβ selective inhibitors, showed very little toxicity in non-APC cell lines 
(Fig 25A/B), while the two IKK complex inhibitors, IKKiVII and Wedelolactone, had greater 
affinity for producing PCD in the FSDC over other cell lines, but did exhibit some toxicity at 
higher concentrations (Figure 27C/D).  When analyzing the non-APC cells in culture, it was 
apparent that the decrease in MTT activity observed at eleveated concentrations was secondary 
to necrosis-like morphologic changes or reduced cell growth rather than apoptotic morphologic 
changes (data not shown).    
Using Compound A , the specificity of cell death to APC cell lines was further confirmed 
by evaluating survival profiles for an increased number of cell lines including both primary bone 
marrow derived DC (BMDC) and macrophages (BMDM), RAW264.7 macrophage cell line, as 
well as DU145, along with the previous evaluated cell lines. Figure 27E indicates LD50 values 
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for each cell line.  Here the high level of specificity of NF-κB-inhibition-induced APC death is 
apparent.  The HEK293 cells had LD50 ± SE of 199.5 ± 32.6, DU145 were 175 ± 23.9, MEFs had 
improved growth trends with NF-κB inhibition (so no calculable LD50), while the APC had LD50 
ranging from 2.7 ± 0.2 for FSDC to 8.9 ± 0.4 for RAW264.7, with wtBMDM, and wtBMDC at 
3.2 ± 3.0 and 6.3 ± 0.1 respectively.  One can see that the four APC cell lines had significantly 
lower LD50 compared with the other cell lines (p<0.002 for D10 to 0.000001 for MEFs).  This 
data confirms that this effect is a specific pan-monocyte derived APC phenomenon.   
4.4.3 NF-κB activates caspases response in APC:   
NBD treatment increased annexin V and PI positivity in APC by 4 hours, suggesting 
apoptotic cell death (Figure 25C); however the exact mechanism of this PCD is unknown. 
Several mechanisms have been hypothesized to explain similar PCD phenomenon.  TNFα 
induced PCD occurs via activation of JNK and caspase 8, which is described for varying cell 
types in the literature.  The more recently described mechanism is PCD secondary to increased 
ROS production followed by capsase 9/3 activation.  Each pathway individually or collectively 
may play a role in this APC specific PCD pathway, and will be explored further herein.   
Therefore, caspase activation was analyzed after treatment with the NF-κB inhibitors.  
Time-courses performed using three NF-κB inhibitors, Compound A, IKKiVII and MG-132, 
showed an increase in caspase 8, caspase 9 and caspase 3 cleavage over a 7 hour time-course 
(Figure 28A).  This caspase activation was confirmed using immunofluorescence for cleaved 
caspase 3 (Figure 28B) and the specific caspase inhibitor zVAD-fmk was able to inhibit NF-κB 
induced PCD in FSDC after treatment with CmpA, IKKiVII and MG-312 (Figure 28A).  
Interestingly, while primary BMDM also underwent caspase 3 and 9 cleavage, as determined by  
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Figure 27: IKK induced cell death is APC specific.  (A-D) Four cell lines, D10, wtMEF, HEK293, and 
wtFSDC, were evaluated for percent survival in the presence of increasing doses of several IKK inhibitors. 
Each point was determine by averaging at least 3 measurements at the indicated concentrations of IKKβ 
specific inhibitors, Compound A and TPCA-1 (A-B), or IKK complex inhibitors, Wedelolactone and IKKiVII 
(B-D), respectively.  (E) LD50 values were determined for 4 APC and 4 non-APC cell lines in the presence of 
Compound A.  Values were completed by regression analysis and determination of the 50% death point on a 
minimum of 3 survival curves for each cell line.  p-values were determined by comparing each non-APC cell 
line with the most resistant APC cell line (RAW264.7) 
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Figure 28: NF-κB suppression activates Caspases 8, 9 and 3 in a time-dependent manner.  (A) Levels of 
caspase-8, -9, and -3 activation were determined via Western blot analysis at the indicated time-points 
following treatment with three different NF-κB inhibitors.  β-actin was used as a positive control. (B) 
Immunoflourencnce shows an increase in the levels of cleaved caspase 3 (red) after 5 hour treatment with 
10μM Compound A. 
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WB, zVAD pretreatment led to only minimal or no increase in cell survival, a feature also 
observed in RAW264.7 cells (data not shown).  However, there have been several reports of 
macrophages undergoing cell death after treatment with zVAD
316, 317
, thus preventing a clear 
understanding of caspase dependency in these other cell lines.   
The activation of caspase 9 suggests a mitochondrial induced apoptosis response, as was 
described previously
35
.  In most instances, a loss in mitochondrial MMP induces cytochrome C 
release, which then activates caspase 9 and then caspase 3.  Two major mediators of capsase 9 
cleavage and activation are upstream caspase 8 activation or ROS production, both of which may 
result in loss of MMP
318
. However, there are reported cases of direct caspase 9 activation by 
ROS prior to loss of MMP
13, 319
.  Caspase 8 is known to be a downstream signaling component 
of the death domain signaling pathways, and is often secondary to TNFR activation.  Thus, the 
roles of ROS and TNF signaling were explored. 
 
4.4.4 APC NF-κB-inhibition-induced death is dependent on ROS production 
To determine if NF- B-inhibition-induced PCD is associated with increased ROS 
production, DiOC6(3) and mitoSOX were used to evaluate mitochondrial membrane potential 
(MMP) and ROS production, respectively.  FSDC were treated with 10μM of Compound A and 
stained for FACS analysis at 0, 3, 7, 15, and 24 hours. During this time-course, there was a 
progressive increase in ROS and a concomitant loss in MMP (Figure 29A).  These findings were 
confirmed by immunofluoresence, which shows a vast increase in ROS production (red staining) 
after incubation with Compound A.  In addition, cells with apoptotic morphology (marked with 
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arrows), specifically at 4 and 9 hours, are those cells which have increased ROS levels and 
decreased MMP suggesting a role for this pathway in cell death (Figure 29B).   
A ROS scavenger, BHA, which has been shown to reduce O2
-
 production
320
, was used to 
evaluate the role of ROS.  While there is an initial increase in ROS production in FSDC treated 
with BHA and Compound A at 3 hours, the amount of ROS stabilizes and does not increase 
during the 7 and 15 hour time-points.  Furthermore, the treatment of CmpA with the addition of 
BHA prevents the loss of mitochondrial membrane potential seen with CmpA alone (Figure 29C 
and 27A respectively).  This suggests that loss of MMP is secondary to ROS formation.  The 
ROS formation in Compound A in the presence or absence of BHA or in FSDC left untreated 
was further examined at the 3 and 15 hour time-points (Figure 29D, left panels).  The reduced 
ROS production in BHA treated samples led to a maintenance of mitochondrial membrane 
potential (Figure 29D, right panels).  In addition to leading to reduced ROS and rescue of the 
MMP, BHA treatment of cells results in rescue of cell death secondary to three NF-κB inhibitors, 
CmpA, IKKiVII, and MG-132 (Figure 30B), as well as a rescue of PCD in BMDM, BMDC and 
FSDC treated with Compound A (Figure 30C).  Taken together, these data suggest that caspase 9 
activation may be secondary to ROS formation or loss of MMP, but that ROS formation is likely 
the initiating event. 
4.4.5 NF-κB-inhibitor-induced cell death is stimulation dependent but independent 
of the TNFα/JNK/Caspase pathway:   
The activation of caspase 8 (Figure 28A) suggests a TNF dependent cell death pathway, 
which is the most commonly observed NF-κB induced PCD pathway described in the 
literature
301
 and will be abbreviated here as the TNF/JNK/Caspase 8 PCD pathway.   NF-κB 
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condary 
to liver apoptosis
301
 and has, subsequently, been observed in numerous cell mice  
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Figure 29: IKK suppression results in increased ROS production and secondary loss of MMP.  (A) FSDC 
were treated with 10μM compound At time-points listed, MitoSOX (red fluorescent marker which increases 
with increased ROS formation) and DiOC6(3) (green fluorescence indicator of MMP, reduced fluorescence 
indicates loss of MMP), markers for ROS and MMP, respectively, were analyzed via flow cytometry. (B 
FSDCs were treated with 10uM Compound A and at the indicated time-points, MitoSOX (Red) and 
DiOC6(3) (Green) were analyzed by fluorescent microscopy, apoptotic cells are marked with yellow arrows. 
(C) FSDC were treated with 10μM CmpA and 200μM of BHA and analyzed for ROS production and MMP 
using flow cytometry.  (D) FSDC ROS and MMP were evaluated via flow cytometry after 3 and 15 hours 
after 10μM CmpA ± treatment with 200μM BHA. 
 
induced PCD was observed initially with the embryonic lethality of p65
-/-
 mice secondary to 
liver apoptosis
301
 and has, subsequently, been observed in numerous cell lines
301
.  In each case, 
the NF-κB induced cell death was dependent on TNF signaling, and acted through caspase 8, a 
common mechanism for mitochondrial induced cell death.   As caspase 8 is activated one hour 
after caspase 3/9 in both the MG-132 and IKKiVII treated samples, this may not be the initiating 
event. However, because this apparent delay in activation could be due to differences in 
exporure, TNFα-/- and WT primary macrophages were used to evaluate whether this APC death 
was TNF/JNK/Caspase 8 dependent.   
Primary macrophages, WT or TNFα-/-, were evaluated with Compound A, MG-132, and 
IKKiVII.  The TNFα-/- cells were highly resistant to IKKβ inhibition-induced cell death, 
evaluated using Compound A and TPCA-1 treatment (Figure 31A top two panels).  In addition, 
TNFα-/- macrophages were less susceptible to IKKiVII (pan-IKK) and MG-132-induced death 
than WT macrophages.  In the case of IKKiVII-treatment, the TNFα-/- macrophages did undergo 
PCD at highertconcentrations (Figure 31A).  Thus, it appears that NF-κB-suppressionNFα PCD 
at highertconcentrations (Figure 31A).  Thus, it appears that NF-κB-suppression-induced PCD is 
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PCD at highertconcentrations (Figure 29A).  Thus, it appears that NF-κB-suppressionNFα PCD 
at  hightNFα  -/- m 
Figure 30: APC death is dependent on Caspase and ROS signaling.  (A) MTT assays were used to 
measure survival of FSDC that were untreated or treated with the listed doses of CmpA, MG-132, or 
IKKiVII (NF-κB inhibitors) in the presence of 75μM zVAD or 200μM BHA.  (B) Cells were further analyzed 
by microscopy to evaluate changes in morphology.  Untreated cells show apoptotic morphologic changes 
including reduced size, blebbing and the loss of reflected light. Treatment with  zVAD prevented morphologic 
changes induced by all NF- B inhibitors, while treatment with BHA prevented apoptosis in CmpA and 
IKKiVII treated samples.  (C) FSDC, BMDM, and BMDC were treated with CmpA ± 200μM BHA and 
analyzed for survival via MTT assay. 
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dependent on the activation state of macrophages, secondary to the inhibitors.  
To evaluate if the TNFα-/- macrophage resistance to the IKKβ inhibition-induced PCD 
was truly a TNFα dependent phenomenon, TNFα-/- macrophages were treated with TNFα 
(10ng/ml), LPS (100ng/ml), or left untreated in the presence of CmpA.  Addition of exogenous 
TNFα caused TNFα-/- BMDM to become more sensitive to CmpA-induced cell death than WT 
cells treated with CmpA alone.  However, this same sensitivity was achieved with the addition of 
exogenous LPS (100ng/ml), suggesting that this is not a TNF/JNK/Caspase 8 dependent event 
but rather a stimulation or activation dependent event (Figure 31A top panel).  This same 
phenomenon was observed with the other NF-κB inhibitors (TCPA-1, IKKiVII, and MG-132).  
It is likely that the endogenous TNFα produced by WT macrophages led to the minimal 
activation state required for the APC death response.  Therefore, TNF was depleted from WT 
macrophages 1 hour prior to CmpA treatment using 50 or 25ug of etanercept (anti-TNF 
antibody) resulting in blocked cell. However, NF-κB-inhibitor induced PCD was induced upon 
the addition of exogenous LPS in the presence of  etanercept (Figure 31B).  Further supporting 
the claim that TNF is not necessary to induce cell death, and also suggesting that the level of 
simtulation contributes to PCD induction in the presence of NF-κB inhibition.  
As NF-κB-inhibitor induced PCD was observed after LPS stimulation in TNFα-/- 
macrophages, the role of stimulation in primary APC death was further examined.  Only very 
low levels of exogenous stimuli were necessary for Compound A induced cell death to occur.  
While TNFα and LPS are normally used at levels of 10ng/ml or 100ng/ml respectively in culture, 
amounts as low as 0.05ng/ml of TNF and 0.01ng/ml of LPS were sufficient to induce significant 
cell death in Compound A treated TNFα-/- macrophages, suggesting that only minor activation of 
these cells is necessary for induction of the NF-κB inhibition-induced PCD (Figure 31C).  
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Figure 31: NF-κB-inhibition induced APC death is dependent upon stimulation.  Cellular survival was 
measured after 24 hours using MTT assays in the following experiments: (A)  TNFα-/- (darker colors) and 
WT (lighter colors) primary macrophages were evaluated for survival in the presence of NF-κB inhibitors, as 
well as in the presence of 10ng/ml of TNFα (green) or 100ng/ml of LPS (red) or left untreated (blue). (B) WT 
macrophages were  either left untreated, or treated with CmpA (10μM), or CmpA (10μM) + Embrel 
(50ng/ml) ± 100ng/ml LPS and survival was measured by MTT assay.  (D) WT macrophage survival in the 
presence 10μM Compound A and decreasing concentrations of TNF (top) or LPS (bottom).    
 
 
4.4.6 NF-κB-inhibitor-induced PCD is independent of Death Domain Signaling 
through JNK and caspase 8 
APC apoptotic response was induced without TNFα signaling suggesting a novel 
mechanism of NF-κB induced cell death. However, it is possible that this cell death could be 
secondary to another death domain receptor acting via JNK and caspase 8.  Thus, SP600125 a 
potent inhibitor of JNKI and JNKII signaling, was evaluated in FSDC and BMDM. In FSDC, 
inhibition of Jnk reduces NO signaling (data not shown), but has no effect on NF-κB induced 
FSDC death at doses of 10μM or 25μM (Figure 32A) or in BMDM (data not shown).  Therefore 
APC death in response to NF-κB inhibition is likely independent of JNK signaling.  To further 
confirm that this was a novel TNF/death domain independent pathway, caspase 8 activation was 
evaluated.  Caspase 8 is also activated secondary to death domain- and Jnk-induced cell death.  
Caspase 8 activation was observed secondary to Compound A, MG-132, and IKKiVII (Figure 
28A). However, caspase 8 cleavage can occur either before mitochondrial membrane disruption 
or secondary to caspase 9/3 activation.  Immunoblot analysis of FSDC pretreated with BHA or 
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left untreated revealed that caspase 8 activation was seen only in Cmp A treated samples, but not 
those treated with BHA and CmpA (Figure 32B), suggesting that caspase 8 activation, in this 
system, is activated after ROS and mitochondrial membrane dysfunction and is not the proximal 
mechanism of cell death 
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Figure 32: NF-κB suppression-induced APC PCD is independent of Jnk and Death Domain receptors.  (A) 
FSDC were pretreated with either 10 or 25μM of specific Jnk inhibitor (SP600125) and varying 
concentrations of NF-κB inhibitors, and cell survival was evaluated by MTT assays.  (B) FSDC samples were 
collected at 4, 5, 6, and 7 hours in the presence of CmpA (10μM) ± BHA (200μM), and caspase 8 and caspase 
3 activation were evaluated via immunoblot.  β-actin used as a loading control. 
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4.5 DISCUSSION: 
This chapter describes a novel NF-κB-inhibtior-induced cell death response in APC.  The 
widely accepted and previously reported NF-κB-inhibitor-induced PCD response occurs via the 
TNFα/JNK/caspase 8 signaling pathway. However, in APC we observe that NF-κB inhibition 
results in increased ROS formation, which leads to a subsequent loss of MMP (Figure 29) and 
activation of caspase9/3/8 (Figure 28).  Using TNFα-/- primary macrophages, it was observed 
that a minimal level of NF-κB activation must be present for IKK inhibition induced cell death to 
occur.  However, these levels are similar to basal levels of TNFα (0.05ng/ml) produced by WT 
macrophages in cell culture
321
.  Further evidence that this is a TNFα/JNK/Caspase 8 and death 
receptor independent include, LPS signaling induces cell death equivalent to the addition of 
TNFα in TNFα-/- BMDM (Figure 31), lack of effects of JNK inhibition on the cell death 
response, and caspase 8 is activated downstream of ROS production(Figure 32).  Therefore, the 
observed APC death is likely a novel NF-κB induced cell death pathway. 
Our data reinforce and elaborate on the findings of two previous studies, which evaluated 
the roles of NF-κB-inhibition-induced cell death in macrophages.   Mannick et al, observed that a 
non-specific NF-κB inhibitor, PTDC, caused RAW264.7 macrophages to undergo cell death in 
culture
315
.  This finding was expanded upon by Pagliari et al who also used PTDC, but 
additionally examined NF-κB suppression using an adenovirus expressing IκBα DN.  They 
showed a clear collapse of MMP using the Ad-IκBα-DN.  However, when using PTDC, it was 
observed that the cells were not rescued from apoptosis using caspase inhibitors, possibly due to 
zVAD toxicity in RAW264.7 cells.  In addition, they did not observe caspase 3 degradation, and 
in fact they suggested a caspase 3-independent pathway, and did not address the role of ROS 
production in this apoptotic response
35
.  Furthermore, as these studies used PTDC, which can 
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also act an anti-oxidant
322
, some of the true mechanisms of the NF-κB cell death pathway may 
have been overlooked.  In exploring this phenomenon, we noted that A1/bfl-1 was 
downregulated at the mRNA level in the presence of CmpA although to a lesser extent than 
shown by Pagliari et al (Figure 33A).  However, an increase in A1/bfl-1 protein expression was 
observed after NF-κB suppression (Figure 33B/C).  As A1/bfl-1 acts to protect MMP, but does 
not alter ROS production, it is likely that A1/bfl-1 transcriptional suppression is not a primary 
mechanism controlling APC death after NF-κB inhibition.   
That APC are not reliant on TNFα to undergo NF-κB induced PCD is not entirely 
surprising, as macrophages and DC have higher basal levels of NF-κB activity compared to other 
cell types
35.  Further, while TNFα is a danger marker for the majority of cell types and can often 
lead to cell cycle arrest and stress responses, in APC TNFα acts as a pro-growth, activation 
signal
323
, thus the effects of this cytokine are likely different in APC compared with other cell 
types.  
We demonstrate here that ROS production is a proximal component of NF-κB inhibition-
induced PCD.  ROS formation occurs upstream of both MMP loss (Figure 29) and caspase 
activation (Figure 32). NF-κB is known to transcriptionally regulate several anti-oxidant proteins 
within the cell, inclduing superoxide dismutases (SOD1
324
, SOD2
325
), and ferritin heavy chain 
(FHC)
326
.  Of these anti-oxidant proteins FHC has been previously implicated in 
TNFα/JNK/Caspase 8 induced NF-κB cell death while the other anti-oxidant proteins appear to 
play a lesser role
13, 322
.  However, mRNA analysis showed no downregulation of FHC, despite 
the rescuing effect of DFO, a chelator of free iron, in showed no downregulation of FHC despite 
 153 
the rescuing effect of DFO, a chelator of free iron, in 
 
Figure 33: A1/bfl-1 mRNA, but not protein, is reduced in NF-κB suppressed APC. (A)  mRNA was isolated 
and evaluated for expression at 0 and 5 hours post-treatment with Cmp A, as well as 3hr post treatment with 
LPS.  Expression of Bcl-2 family members A1/Bfl-1, Bcl-2, Bcl-XL were analyzed via Western blot. -actin 
was used as the loading control. (B) IF of A1/bfl-1 was completed in control cells or at 5 hours post-CmpA 
treatment. (C) Immunoblot of A1/bfl-1 expression during a timecourse of NF-κB suppression-induced PCD. 
 
 
rescuing IKKβ specific cell death (Figure 34).  Thus, further studies must be completed to 
determine the downstream effectors of increased ROS in our NF-κB inhibited macrophages.   
Possibly more important than the exact mechanism of increased ROS production is the 
likelihood that these findings may help to explain human physiologic and therapeutic responses 
to NF-κB inhibition. PCD secondary to NF-κB inhibition in APC may explain response observed 
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in specific pathogen infections.  There are a few well known pathogens that cause macrophage 
and DC apoptosis, and in a number of these cases, it has been determined that these bacteria 
produce NF-κB inhibitory compounds.  Two specific examples are the Yersinia bacteria and 
Vaccinia Virus.  Numerous articles suggest that APC death is induced secondary to one of two 
NF-κB inhibitors produced by Y. pestis, YopP and YopJ, as a loss of these molecules leads to 
improved survival 
327, 328
 Furthermore, this NF-κB inhibition-induced PCD is enhanced by LPS 
signaling
327
.  Vaccinia virus inhibits NF-κB signaling via two proteins, N1L329 and B14330. 
Furthermore, it has been reported that Vaccinia causes macrophage and DC apoptotic cell 
death
331, 332
.  Interestingly, one of the differences between attenuated Vaccinia, which does not 
induce APC, and the non-attenuated apoptosis inducing Vaccinia is the expression of N1L
333
.  
Therefore APC death induced by NF-κB inhibition may further explain macrophage cell death 
responses secondary to other pathogen infections.  
This NF-κB apoptic response is biologically important not only with regards to APC 
response or protection against infection, but also in evaluating therapeutics for cancer and 
inflammatory/auto-immune diseases.  Recently, several groups have begun to examine the 
efficacy of NF-κB inhibition in treating myeloid leukemias such as acute and chronic myeloid 
leukemia (AML and CML).  AML and CML derive from myeloid progenitors, which give rise to 
non-lymphocyte white blood cells including macrophages and DC
334
.  In Imatinib resistant CML 
cell lines, NF-κB/IKK was activated30, 31, 335, and as expected these cells underwent caspase 
dependent cell death in response to NF-κB/IKK suppression.  Furthermore, mice injected with 
CML cell lines showed reduced tumor burdens when treated with an IKKβ inhibitor30. 
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Figure 34: NF-κB suppression does not suppress FHC gene expression, but iron chelation reduces NF-κB 
induced cell death in FSDC.  (A) mRNA expression of FHC is not altered after treatment with 10μM 
Compound A over a timecourse of 12 horus. (B) MTT survival assay after treatment with NF-κB inhibitors in 
BMDM pretreated with 500μM DFO, 50ng/ml of etanercept, or left untreated. (C) MTT survival assay in 
BMDM treated with a combination of 100ng/ml LPS, 10μM Compound A, or 500μM DFO. 
 
 
 
The NF-κB initiated inflammatory response is an obvious pharmacologic target for the 
treatment of auto-immune and inflammatory diseases.  Not surprisingly, numerous NF-κB 
inhibitory compounds have been evaluated in the treatment of inflammatory disease states, such 
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as inflammatory bowel disease, rheumatoid arthritis, muscular dystrophy, diabetes, as well as 
Parkinson’s and osteoporosis.   In each case, APC play a potent role in disease initiation or 
progression, therefore, activation induced APC death is a possible mechanism that could explain 
the ameliorating effects of NF-κB inhibitor treatment. In two studies evaluating the NBD 
peptide, NF-κB inhibition resulted in decreased APC number.  CD11b microglial cells (central 
nervous system APC), are reduced in number after such treatment in a model of Parkinson’s 
disease
72
.  In addition, this same phenomenon was observed when using NBD in a muscular 
dystrophy model
73
.  In this latter article the reduced APC number was attributed to decreased 
infiltration; however, this decreased infiltration may be the result of increased APC death.  Even 
in mice with floxed IKKβ promoters in macrophages showed that cells with partial deletion of 
IKKβ were selected for and that cells with complete knockdown of IKKβ were 
counterselected
336
, suggesting that macrophages with complete loss of NF-κB/IKK after 
differentiation are not viable.   
The novel mechanism of NF-κB inhibitor-induced PCD in APC described here offers a 
potential explanation for many of these observations.  Furthermore, NF-κB inhibitors, which 
have extremely short half-lives in vivo, can be injected only a few times per week while still 
maintain their immunosuppressive qualities.  Thus, we believe that this APC death may result in 
a fundamental change in the immune system that prolongs the efficacy of NF-κB/IKK inhibition.  
Furthermore, if there is a specific gene which leads to increased ROS production this may be a 
potential therapeutic target for treating inflammatory and autoimmune disease.  Our data and that 
of others support the model that cells with high basal levels of NF-κB activity are most sensitive 
to NF-κB induced PCD.  In addition, our observations that minimal stimulation is required for 
cell death to occur would potentially mean that only activated APC would undergo apoptosis 
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with this therapy, further reducing side effects, and improving the therapeutic potential of NF-κB 
inhibitors. 
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5.0  DISCUSSION AND SIGNIFICANCE 
NF-κB is one of the most studied transcription factors, and has been implicated in a wide 
variety of disease models and cellular processes.  In this thesis, I have explored two very 
different disease models and in each case observed that suppression of NF-κB transcriptional 
activation ameliorates degenerative changes associated with these diseases.  Furthermore, the 
data suggest that NF-κB may regulate several different pathways that possibly act independently 
or synergistically to affect the varying disease phenotypes. 
Initially, I observed NF-κB inhibition using the NBD peptide ameliorates disease in a 
murine model of IBD.  This was not surprising due to the evidence implicating NF-κB and 
immune activation in IBD pathogenesis, specifically increased inflammatory infiltrates in the 
intestines of human and murine disease sufferers.  NF-κB is upregulated in tissue sections from 
both species as well as in lamina propria macrophages residing in the intestine.  Interestingly, 
during the publishing process of our manuscript describing the amelioration of murine colitis via 
inhibition of NF-κB78, another manuscript described that genetic deletion of NEMO and IKKβ in 
intestinal epithelial cells led to a colitis phenotype
112
.  While surprising at first, these differential 
effects of NF-κB suppression are not unexpected when one considers the diverse roles of NF-κB 
in varying cell types.   
As described in the introduction, the intestine is one of the few organs in which the 
primary goal of the resident immune cells is to suppress an overt immune response.  This 
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knowledge can explain both our findings, and the fact that IKK suppression in IEC leads to 
colitis.  NEMO deletion in IEC led to a reduction in antimicrobial peptides which allowed for 
bacterial invasion and subsequent apoptosis of the IEC themselves.  The apoptosis of IEC is 
likely perpetuated by increased TNFα and the lack of NF-κB survival signal, a well document 
PCD pathway
301
.  This in turn leads to a vicious cycle in which chronic intestinal infection leads 
to a colitis phenotype.  With regards to our findings, this suggests that NF-κB inhibition via 
NBD does not target all cells e.g. intestinal epithelium, but perhaps has more a more eslective 
impact on specific cell populations such as macrophages and DC.  This is further supported by 
the reduction in the inflammatory cytokines TNFα, IL-12, and INFγ seen in the treated mice 
compared with control treated mice.  In addition, I found that peptides trafficked toward the 
mesenteric lymph node and spleen 30 minutes after injection. Overall, the data derived in the 
IBD model using NBD as well as another NF-κB inhibitory compound, ethyl pyruvate, 337  
provide strong evidence that NF-κB inhibition is a viable therapeutic approach for IBD.   
In fact, current therapies for the treatment of IBD have NF-κB suppressive qualities as 
discussed in Section 1.2.4; however, many of these therapies have off-target effects.  Even 
current state-of-the-art biologic therapies, such as infliximab have drawbacks such as 
susceptibility to infections, increase cancer risk, and a 30% failure rate
84
.  Even with the 
improvement of therapies for the treatment of IBD and other inflammatory and auto-immune 
disorders, many of which share significant mechanisms such as macrophage, T-cell and NF-κB 
involvement, there is still a vast need to improve therapeutic strategies. I believe that targeting 
NF-κB signaling in a cell specific manner may help to achieve these goals.    
As innate immune cells are major mediators of IBD and other inflammatory diseases, I 
chose to explore the role of NF-κB signaling in monocyte derived APC cell lines.  Initially, I 
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wanted to examine the effects of NF-κB inhibition on macrophage and DC cytokine profiles.  
What I observed, however, was a PCD phenomenon. This cell death is independent of exogenous 
stimulation, and in fact occurred via a novel mechanism, dependent on increased ROS 
production, with secondary loss of MMP and caspase activation.  The other important finding, 
from a therapeutic perspective, is that APC need to have a minimal level of stimulation to 
undergo cell death in the presence of these NF-κB inhibitors.  This likely means that NF-κB 
inhibition would not cause massive induced apoptosis of APC, but it would enable targeting of 
this PCD to areas of inflammation, potentially reducing the number of side effects.    
Unfortunately, I have yet to convincingly show that there is increased APC cell death in 
vivo.  However, our in vitro findings suggest that this APC cell death is a possible mechanism by 
which NF-κB suppression may reduce the inflammatory disease phenotype in the IL-10-/- mouse 
model.  This is supported by other groups, who showed a reduced number of macrophages in 
MDX mice treated with NF-κB inhibitors73 as well as reduced number of CD11b+ microglia in a 
murine model of Parkinson’s after NF-κB inhibitor treatment72.  Thus, I believe that the 
macrophage cell death pathway described here is a possible link between NF-κB suppression and 
reduced IL-12 and TNFα cytokine signaling, reduced inflammation, and amelioration of colitis.  
APC may take up higher concentrations of the NF-κB inhibitors over intestinal epithelial cells, or 
because these inhibitors have short half-lives in vivo, only the PCD response would provide a 
long term effect seen in macrophages over other cell types.  Each of these hypotheses may 
explain the reduction in disease pathology with the subsequent maintenance of intestinal barrier 
function.  The idea that macrophage apoptosis may reduce inflammatory disease is not new and 
was reviewed by Pope
338
 in 2002.  However, there have been few mechanisms by which to target 
apoptosis to specific cell types.  Therefore it will be pertinent to determine if NF-κB treatment in 
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vivo does cause specific activated APC cell death, and whether increased ROS production in 
macrophages secondary to other therapeutics a similar effect, leading to possible new 
therapeutics with potentially high efficacy and low off target and side effects.   
One link between APC and the leukemia and lymphoma cell lines that undergo NF-κB 
induced cell death is upregulation of basal NF-κB signaling.  Therefore, the PCD pathway, 
described in chapter 4, may occur in other cell types with high basal level of NF-κB activation, 
such as neutrophils or tumor cells.  Our findings may contribute to our understanding of how 
NF-κB suppression may be used to treat cancer.  It is know that cancers secrete factors which 
induce resident monocyte derived APC to become regulatory or suppressive in phenotype
339
.  
Thus, treating cancers with NF-κB inhibitory compounds as an adjuvant therapy may have a 
two-pronged effect.  First, NF-κB suppression of the tumor cells themselves may allow for 
decreased survival, as overactive NF-κB signaling is often a survival mechanism used by tumor 
cells
340, 341
.  Second, NF-κB suppression may allow these suppressive APC to undergo PCD and 
then be replaced by more immunogenic cells.  While this would be a highly complex treatment 
strategy, understanding the differential role of NF-κB in varying cell lines is highly important 
when designing cancer therapies.     
While the role of NF-κB upregulation in inflammatory and auto-immune diseases is an 
expected scenario, recent evidence has also shown that NF-κB plays a role in numerous other 
diseases not defined as “inflammatory” in nature.  A wide variety of diseases in which NF-κB 
has been implicated occur with increased chronologic age.  Additionally, there have been several 
papers published within the last few years which have shown increasing amounts of NF-κB 
signaling in tissues of aged animals.  While there is increasing correlative evidence that NF-κB 
plays a role in aging and age-related disease, it was unknown whether NF-κB was a protective or 
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causative agent with regard to these changes.  I first showed that NF-κB is upregulated under 
conditions of increased stress whether it be genotoxic or oxidative, both of which are known to 
induce age-related changes (Figure 16-18).  This NF-κB activation was confirmed in vivo using 
the ERCC1 deficient model of accelerated aging. I then determined using both genetic and 
pharmacologic suppression that indeed NF-κB signaling contributed to phenotypic and histologic 
changes associated with aging.   
As NF-κB is known to respond to cell stress events such as DNA damage, it may initially 
be a protective mechanism; however, in the case of increasing damage over a period of time, this 
initially protective feature may become pathologic.  For instance, increased NF-κB activity may 
promote cellular senescence. On an individual cell basis, this may result in positive outcomes, by 
preventing tumor growth and ending the proliferation of a damaged cell.   However, on a gross 
scale if the vast majority of cells undergo senescence the whole organism will age.  As NF-κB is 
a regulator of numerous cell cycle control genes such as Gadd45, Lamin B, ApoD, and Cyclin D 
these may mediate changes associated with aging.  However, it is likely that NF-κB mediates 
age-associated changes in numerous ways, which may in fact vary from tissue to tissue or cell to 
cell.   
NF-κB is known to play a role in osteoclastogenesis, as well as to negatively regulate 
osteoblasts
342
.  As osteoclasts are macrophage-like cells, NF-κB inhibition may reduce 
osteoclasts by inhibiting their differentiation and proliferation, or by causing osteoclast PCD, 
while at the same time increasing osteoblast activity.  With regards to neurodegenerative 
changes, NF-κB inhibition may reduce inflammatory mediators, which can reduce neuronal cell 
viability, as discussed in the 1.3.4.  In other tissues, such as liver, NF-κB may play a role in 
cellular senescence and reducing proliferation.  Furthermore, in collaboration with other groups, 
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we have preliminary evidence which suggests that stem cells and progenitor cells 
haploinsufficient for p65 have improved stress response, and proliferation capacity.  We can 
therefore theorize that NF-κB suppression may improve the viability and regenerative capacity of 
endogenous stem cells, thereby enhancing tissue function and body homeostasis.  Thus, it is 
likely that NF-κB suppression acts through numerous mechanisms to mediate its beneficial 
effects.   
It is theorized that aging occurs secondary to the accumulation of random damage.  Our 
research is one of the earliest studies to implicate NF-κB signaling as a damage response signal 
in aging, using a model of accelerated aging.  A possible schematic of how NF-κB is integrated 
into the damage induced aging process is shown in Figure 35.  The role of a common signaling 
mechanism in age-associated disease is of importance because it provides a link between 
Alzheimer’s, Parkinson’s, osteoporosis, atherosclerosis, diabetes, and sarcopenia, which 
scientists and clinicians have thought had little in common except their increased incidence with 
advanced chronologic age.  Thus, our research has offered a mechanistic avenue by which these 
diseases are related and secondarily provides a potential therapeutic target to address pathologic 
changes that occur with aging.  In concert with this, I have also studied the role of a 
mitochondrial targeted ROS scavenger XJB and its ability to ameliorate and delay pathology 
associated with aging.  As ROS are known to activate and be controlled by NF-κB signaling, this 
may be one mechanism by which NF-κB transcriptional activation contributes to aging 
pathology.  
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Figure 35: Schematic of NF-κB central role in the aging process. Genotoxic stress activates NF-κB signaling12, 
153, 343-345
 B. Oxidative stress activates NF-κB signaling 346-349 C. NF-κB stimulates expression of  
proinflammatory cytokines
5, 157, 350
 and causes chronic inflammation 
5, 351, 352
 D. Chronic inflammation causes 
age related diseases
353, 354
, including: atherosclerosis
355
 sarcopenia
201, Alzheimer’s disease356, diabetes357 and 
cancer
358
 E. Non-inflammatory mechanisms of tissue dysfunction, including cell cycle dysregulation
359,360
, 
cellular senescence
135, 136, 167, 361-363
, DNA damage
364
,  differentiation
365
 or failure to differentiate
366
) F. 
Accumulation of DNA damage promotes aging
125-130
.  G. Oxidative stress promotes aging
135, 136, 362, 363
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Overall, this research has exemplified the pleotropic effects of NF-κB signaling from its 
role in inflammatory disease, to diseases associated with aging.  NF-κB activations regulates a 
wide range of processes, including dampening of cytokine secretion, alteration of stem cell 
physiology, effects on proliferation, cell cycle control, and organism development, as well as its 
role in controlling cell death and survival responses.  It is important to recognize the pleiotropic 
nature of NF-κB when evaluating its role in pathogenesis as well as the effects of suppressing 
this signaling as a possible therapeutic mechanism.  However, I believe that targeted suppression 
of specific NF-κB induced pathways may have beneficial effects in treating a wide variety of 
diseases.    
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